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Recent research suggests that amino acids can significantly increase skeletal 
muscle glucose uptake.  However, the mechanism(s) have not been fully elucidated and it 
is also not clear if the beneficial impact amino acids have on healthy tissue translates to 
insulin resistant skeletal muscle.  Therefore, in this series of studies, the effects of an 
amino acid mixture on glucose tolerance and insulin resistance were investigated.  Study 
1 Experiment-1 (Exp-1) demonstrated that an amino acid mixture significantly reduced 
the blood glucose response to an oral glucose challenge in Sprague Dawley rats.  In Study 
1 Exp-2, it was found that the improved glucose tolerance was due to an increase in 
skeletal muscle glucose uptake.  The enhanced amino acid induced muscle glucose 
uptake was associated with improved cellular signaling.  In Study 1 we could not 
determine the combined and/or individual effects of insulin and amino acids on glucose 
uptake, so in Study 2, the hindlimb of Sprague Dawley rats were perfused with glucose 
with or without amino acids in the presence and absence of insulin.  Study 2, confirmed 
 vii
our previous findings that an amino acid mixture increased skeletal muscle glucose 
uptake compared to a carbohydrate supplement in the presence of insulin.  The enhanced 
amino acid-stimulated glucose uptake was not due to increased phosphatidylinositol 3-
kinase (PI 3-kinase) activity, although it was related to an increase in Akt substrate of 160 
kDa (AS160) phosphorylation and a greater number of glucose transporters at the plasma 
membrane.  In the final experiment, Study 3 investigated whether amino acids could 
improve glucose tolerance in an insulin resistant model.  Study 3 Exp-1, demonstrated 
that an amino acid mixture significantly lowered the blood glucose response to an oral 
glucose challenge in obese Zucker rats.  Study 3 Exp-2 showed that the improved glucose 
tolerance was due to enhanced amino acid induced skeletal muscle glucose uptake.  
Taken together, the results of this research suggests that adding an amino acid mixture to 
a carbohydrate supplement improves the blood glucose response to an oral glucose 
challenge, acutely lowers insulin resistance and this appears due to increased skeletal 
muscle glucose clearance and enhanced cellular signaling.        
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Chapter I: General Introduction 
 
Under normal conditions, the acute ingestion of carbohydrate elevates blood 
glucose levels, which stimulates pancreatic insulin secretion.  The hormone insulin 
returns blood glucose back to fasting levels by stimulating peripheral tissue uptake and 
limiting its release from the liver.  Thus, for proper blood glucose homeostasis, there 
must be a balance between the entry of glucose into the blood, its removal by peripheral 
tissues and its output from the liver.  Of the insulin sensitive tissues, skeletal muscle 
serves as the primary site of whole body glucose disposal.  An estimated 80% of all 
insulin-stimulated glucose uptake can be attributed to skeletal muscle, with the majority 
of this glucose at rest being converted and stored as glycogen for later energy use (2).  
Despite the fact that glucose is the primary fuel for many of the body’s functions, low 
levels can be fatal and high blood glucose levels, when left unmanaged for an extended 
time, can lead to morbid obesity, blindness, cardiovascular disease and peripheral 
neuropathy.  Therefore, blood glucose homeostasis is a highly regulated process.  
Although this is a very effective process in many people there is a rapidly growing 
segment of the population in which this process begins to fail, resulting in dangerously 
high glucose and insulin levels.   
Insulin resistance is a condition in which the cells of the body do not respond 
appropriately, or are resistant to the effects of insulin.  While the rise in blood glucose is 
quickly returned to baseline by insulin in healthy individuals, the same amount of insulin 
has little effect in lowering blood glucose in insulin resistant people.  Thus, normal 
amounts of insulin secreted from the pancreas are unable to produce a normal blood 
glucose response.  As a compensation mechanism, the pancreas is forced to release more 
 2
insulin in order to return blood glucose to baseline levels.  The inability to properly 
remove blood glucose can be attributed to reduced skeletal muscle glucose transport (1).  
Glucose transport is defined as the penetration of glucose across the plasma membrane.  
This is a reversible process and the net flux of glucose depends on both the concentration 
gradient and the number of glucose transporters at the plasma membrane (5).  In contrast, 
the irreversible removal of glucose from the extracellular space and into the cell is 
defined as glucose uptake.    
Recent studies suggest that amino acids may aid in the regulation of blood 
glucose.  Of these, both isoleucine and leucine are the amino acids in which much of the 
research has focused on.  Although these amino acids have been shown to reduce blood 
glucose, many questions regarding their mechanism(s) of action have not been answered.  
Studies have reported that amino acids increase both in vitro (3, 7, 8) and in vivo (3, 4, 6) 
skeletal muscle glucose uptake.  Nishitani et al. (8) demonstrated using an isolated soleus 
muscle preparation that both phosphatidylinositol 3-kinase (PI 3-kinase) and protein 
kinase C (PKC), but not mammalian target of rapamycin (mTOR), was directly involved 
with leucine-stimulated glucose uptake.   In agreement with these findings, Doi et al. (3) 
reported that isoleucine-stimulated glucose uptake in C2C12 myotubes was inhibited in the 
presence of a specific inhibitor for PI 3-kinase but not in the presence of an inhibitor of 
mTOR.  Although there is strong evidence suggesting amino acids can increase glucose 
uptake in healthy skeletal muscle, it is not clear whether these same amino acids have an 
affect in insulin resistant tissue.  
Therefore, this series of studies aimed to investigate the effects of a novel amino 
acid mixture on glucose tolerance and insulin resistance.  In doing so, these studies will 
assess differences in blood glucose, plasma insulin, skeletal muscle glucose uptake and 
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signaling proteins between a supplement containing only carbohydrate and a 
carbohydrate plus amino acid mixture.   
OBJECTIVES 
Study 1:  Study 1 consists of 2 separate experiments. The purpose of experiment-
1 (Exp-1) is to evaluate the ability of an amino acid supplement containing a mixture of 
branched-chain and essential amino acids to improve glucose tolerance in Sprague 
Dawley rats during an oral glucose tolerance test (OGTT).  This experiment is designed 
to determine 1) if orally consuming a carbohydrate supplement with an amino acid 
mixture improves glucose tolerance, 2) if adding amino acids to a carbohydrate load 
alters circulating insulin levels and 3) how increasing the leucine concentration of the 
amino acid mixture will affect glucose tolerance.  The purpose of experiment-2 (Exp-2) is 
to determine if differences in glucose tolerance observed in Exp-1 are associated with 
changes in skeletal muscle glucose clearance.  This experiment is designed to determine 
1) if the amino acid mixture improves the glucose response during an OGTT via an 
increase in skeletal muscle glucose uptake and 2) the effect of the amino acid mixture on 
components of the PI 3-kinase and mTOR signaling pathways. 
Study 2:  The purpose of study 2 is to investigate the effects of an amino acid 
supplement containing a mixture of branched-chain and essential amino acids on glucose 
uptake via the hindlimb perfusion technique in Sprague Dawley rats.  This study is 
designed to determine 1) if perfusing the amino acid mixture increases skeletal muscle 
insulin-stimulated and non-insulin-stimulate glucose uptake, 2) if amino acids activate PI 
3-kinase and 3) if the amino acid mixture enhances cellular signaling.  
Study 3:  Study 3 consists of 2 separate experiments.  The purpose of experiment-
1 (Exp-1) is to investigate the effects of an amino acid supplement containing a mixture 
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of branched-chain and essential amino acids on glucose tolerance and insulin resistance 
in obese Zucker rats.  This experiment is designed to determine 1) if orally consuming a 
carbohydrate supplement with an amino acid mixture improves glucose tolerance in an 
insulin resistant model, 2) if adding amino acids to a carbohydrate load alters circulating 
insulin levels and 3) how increasing the leucine concentration of the amino acid mixture 
will affect glucose tolerance and insulin resistance.  The purpose of experiment-2 (Exp-2) 
is to determine if differences in glucose tolerance observed in Exp-1 are associated with 
changes in skeletal muscle glucose clearance.  This experiment is designed to determine 
1) if the amino acid mixture improves the glucose response during an OGTT via an 
increase in skeletal muscle glucose uptake and 2) the effect of the amino acid mixture on 
components of the PI 3-kinase and mTOR signaling pathways. 
HYPOTHESIS 
Study 1:  
1. In comparison with a carbohydrate supplement, addition of the amino acid 
mixture will increase insulin secretion and decrease the blood glucose response 
during an oral glucose challenge.   
2. Increasing the leucine concentration of the amino acid mixture will further 
enhance the affects of the supplement.   
3. In comparison with a carbohydrate supplement, addition of the amino acid 
mixture will increase skeletal muscle glucose uptake and this will be associated 
with increased activation of signaling proteins.   
Study 2:  
1. In comparison with a perfusate including carbohydrate, adding the amino acid 
mixture will increase insulin and non-insulin-stimulated glucose uptake.  
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2. In comparison with a perfuste with carbohydrate, adding the amino acid mixture 
will increase PI 3-kinase activity.   
3. The increase in glucose uptake will be associated with an increase in Akt 
substrate of 160 kDa (AS160) phosphorylation and plasma membrane glucose 
transporter 4 (GLUT4) protein concentration.   
Study 3:  
1. In comparison with a carbohydrate supplement, addition of the amino acid 
mixture will increase insulin secretion and decrease the blood glucose response 
during an oral glucose challenge in an insulin resistant model.   
2. Increasing the leucine concentration of the amino acid mixture will further 
enhance the affects of the supplement.   
3. In comparison with a carbohydrate supplement, addition of the amino acid 
mixture will increase skeletal muscle glucose uptake in an insulin resistant model 
and this will be associated with increased activation of signaling proteins. 
SIGNIFICANCE  
The prevalence of obesity, insulin resistance and type 2 diabetes mellitus (T2D) 
has reached epidemic proportions.  For example, the percentage of Americans who are 
classified as obese has doubled since 1980, and similar trends have been reported for 
insulin resistance and T2D.  Particularly startling is that T2D, generally viewed as a 
disease that primarily affects adults, is now being diagnosed in children and teens at an 
alarming rate.  We cannot ignore the fact that genetics are an underlying factor in insulin 
resistance and T2D in some individuals, but for many people, poor dietary habits and lack 
of physical activity are the two major components in the development of this disease.  
Moderating one’s diet and prescribing an exercise regime have both been shown to 
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prevent and/or reverse the effects of insulin resistance by heightening the sensitivity of 
skeletal muscle to insulin.  However, the mechanism(s) for this improvement is unclear.  
Thus, novel means to improve the regulation of blood glucose is an important area of 
research because future efforts will increase our understanding of the disease and help 
identify potential protein targets for intervention.   
A single bout of exercise has been shown to improve insulin sensitivity in insulin 
resistant and T2D subjects.  Exercise training offers even greater benefits, with the 
positive affects being sustained for a much longer period of time.  However, those with 
impaired glucose tolerance may be unable, or unwilling, to engage in regular physical 
activity.  Therefore, dietary factors become even more critical.   With the recent 
movement towards non-pharmacological approaches to medicine, many people have 
turned toward natural alternatives, such as dietary supplements to improve one’s general 
well being.  It is often touted as a more natural, and safer alternative to pharmaceuticals, 
were there is tradeoff between benefits and side effects.  Diabetics are often prescribed a 
list of medications to help them properly regulate their blood glucose levels.  Therefore, 
those with insulin resistance and diabetes could benefit greatly from a dietary supplement 
regime that could possibly replace their medications.   
It has been known for many years that amino acids are integral in many 
physiological processes, most notably protein synthesis.  However, it has only been 
recently that amino acids have been demonstrated to play a role in blood glucose 
homeostasis.  Much of the literature regarding the effects of amino acids on blood 
glucose levels have focused on single amino acids.  As a result of these studies, it has 
been shown that not all amino acids have the same affect on blood glucose levels.  For 
example, isoleucine has been shown to increase glucose uptake.  Leucine has also been 
shown to increase glucose uptake, but this amino acid also increases insulin secretion and 
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glycogen synthesis.  Nevertheless, this raises an intriguing possibility that a mixture 
containing amino acids with different affects on glucose metabolism could be designed 
with the goal of improving blood glucose levels. 
Therefore, the goal of these studies were to demonstrate that a mixture of amino 
acids consisting of leucine, isoleucne, valine, methionine and cysteine could lower the 
blood glucose response to an oral glucose challenge, reduce insulin resistance and 
provide a mechanism for these improvements.  Ideally, the results of these studies could 
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Chapter II: Review of the Literature 
 
It is well known that amino acids are essential for protein synthesis.  However, 
recent research suggests that amino acids may also reduce the blood glucose response to 
an oral glucose challenge.  Several investigators have reported that amino acids improve 
glucose tolerance using both in vitro (17, 35, 36) and in vivo (17, 18, 28) models.  
Therefore, this review will discuss the relevant literature regarding insulin signaling, 
protein/amino acid supplementation and insulin resistance in skeletal muscle.     
THE PHOSPHATIDYLINOSITOL 3-KINASE SIGNALING PATHWAY 
A rise in blood glucose levels stimulates the release of insulin from the pancreatic 
β-cells.  Because insulin is a peptide hormone it requires a specialized receptor on the 
cell’s surface to exert is actions.  The insulin receptor consists of two alpha- and two 
beta-subunits.  The alpha-subunits are located on the extracellular portion of the plasma 
membrane while the beta subunits span the membrane with both extracellular and 
intracellular portions.  The binding of insulin to the extracellular alpha-subunit causes a 
conformational change that initiates the autophosphorylation of the beta-subunits.  Next, 
the activated beta-subunits phosphorylates the downstream insulin receptor substrate-1 
(IRS-1).  In skeletal muscle, both insulin receptor substrates 1 and 2 (IRS-1 and IRS-2) 
are expressed (51).  However, IRS-1 is the primary isoform responsible for insulin-
stimulated glucose transport.  Once phosphorylated IRS-1 acts a docking protein for 
molecules containing Src homology 2 (SH2), such as the p85 regulatory subunit of 
phosphatidylinositol 3-kinase (PI 3-kinase).  The docking and binding of IRS-1 to the p85 
subunit activates the p110 catalytic subunit of PI 3-kinase.  The PI 3-kinase subunit, 
p110, can then disassociates from p85 and translocate to the plasma membrane, where it 
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catalyses the conversion of phosphatidylinositol (3,4)-biphosate (PIP2) to 
phosphatidylinositol (3,4,5)-triphosate (PIP3).  The activation of PI 3-kinase is a 
necessary step in insulin-stimulated glucose transport as has been demonstrated by 
blocking its actions with an inhibitor.  Wortmannin, a specific inhibitor of PI 3-kinase, 
blocks its kinase activity by binding to the lysine 833 residue of PI 3-kinase causing a 
conformational change of the protein.  Following the administration of wortmannin, 
Wojtaszewski et al. (52) observed a dose dependent reduction in insulin-stimulated 
glucose uptake and transport, but the binding of insulin to its receptor, IR-β subunit 
autophosphorylation and tyrosine phosphorylation of IRS-1 were unaltered.  
Furthermore, Kanai et al. (29) observed dose dependent inhibition of PI 3-kinase activity 
and glucose transporter 4 (GLUT4) translocation in response to wortmannin.  The author 
also reported no change in the proximal signaling proteins.  Collectively, these findings 
suggest that PI 3-kinase is required for insulin-stimulated GLUT4 translocation and 
glucose transport and that the effects of wortmannin were elicited on PI 3-kinase alone.   
As discussed above, the activation of PI 3-kinase generates the phosphoinositide 
lipid PIP3 at the plasma membrane.  These membraneous lipids are required for the 
activation of proteins containing pleckstrin homology domains, including 
phosphoinositide dependent kinases 1 and 2 (PDK-1 and PDK-2).  PDK-1 and PDK-2 
activate the downstream serine/threonine kinases protein kinase B (Akt/PKB) and 
atypical protein kinase C (aPKC).  PDK-1 phosphorylates Akt on threonine 308 while 
serine 473 is phosphorylated by PDK-2, which has recently been identified as mTOR-
RICTOR complex (39).  Skeletal muscle expresses three forms of Akt/PKB isoforms; 1, 
2 and 3.  However, it appears that Akt/PKB 2 is the primary isoform involved in skeletal 
muscle insulin-stimulated glucose uptake.  In addition, there are two aPKC isoforms 
expressed in skeletal muscle, of which PDK-2 phosphorylates aPKC-zeta (aPKC-ζ) on 
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threonine 410 and aPKC- lambda (aPKC-λ) on threonine residue 403.  Both Akt/PKB 
and aPKC-ζ/λ have been observed to be involved for insulin-stimulated glucose transport 
in skeletal muscle. 
Recently, AS160 has been identified as a potential substrate for Akt/PKB 
signaling.  AS160 contains several Akt/PKB phoshporylaiton sites in addition to a Rab 
GTPase activating protein (GAP) domain (50).  It is believed that under basal conditions 
the GAP activity of AS160 could maintain a Rab protein in an inactive GDP-bound state.  
However, insulin could trigger signaling through Akt/PKB for AS160 phosphorylation 
and inhibition of its GAP domain, converting the Rab protein to its active GTP-bound 
form, thereby allowing GLUT4 translocation (50).   
GLUCOSE TRANSPORT   
Evidence suggesting that insulin increased glucose uptake by increasing the 
translocation of glucose transporters from an intracellular pool to the plasma membrane 
was first demonstrated in adipocytes (15).  Shortly after, the results in adipocytes were 
confirmed in isolated diaphragm muscles (49) and then in rodent skeletal muscle (31).  
Utilizing the hindlimb perfusion technique, Klip et al. (31) found that insulin increased 
the number of plasma membrane associated glucose transporters 2-fold, while the 
intracellular glucose transporter concentration was reduced by 70%.  Furthermore, the 
strong relationship between the number of GLUT4 transporters translocated to the plasma 
membrane and glucose transport was demonstrated using a labeled cell surface GLUT4 
protein (20).  Collectively, these studies suggested that insulin increases glucose uptake 
by increasing the number of plasma membrane associated glucose transporters.   
Because the lipid bilayer of the plasma membrane is impermeable to glucose, a 
glucose transport system is required to move glucose by facilitated diffusion down its 
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concentration gradient from the extracellular to intracellular space.  There are twelve 
homologous transmembrane glucose transport proteins (GLUT1-GLUT12) that have 
been identified (53).  Each of which displays characteristically substrate specificity, 
kinetic properties and tissue distribution.  For example, skeletal muscle expresses both 
GLUT1 and GLUT4.  GLUT1, a ubiquitous glucose transporter, allows a constant influx 
of very low amounts of glucose under basal, or non-insulin-stimulated conditions.  In 
contrast, in the absence of insulin GLUT4 is stored within the cytosol by specialized 
recycling endosomes known as vesicular tubular clusters (11, 50).  However, in the 
presence of insulin GLUT4 is translocated from these intracellular pools to the plasma 
membrane.     
Insulin-stimulation results in the remodeling of the actin cytoskeleton in which 
GLUT4 can be translocated from the cytosol to the plasma membrane. This process 
appears to be mediated by both the classical, or PI 3-kinae, and novel, or c-Cbl associated 
protein (CAP)/c-Cbl insulin signaling pathways.  The convergence between these two 
pathways occurs at aPKC.  aPKC activates its downstream target TC10, which is a distal 
components of the novel cascade.  It has been demonstrated that TC10 is associated with 
Exo 70, an exocyst complex, which translocates to the plasma membrane following TC10 
activation (24).  Because overexpressing a mutated form of Exo 70 attenuated insulin-
stimulated glucose uptake with no affect on GLUT4 translocation it was suggested that 
the exocyst complex may direct GLUT4 to the target-SNARE receptor (t-SNARE) 
complexes for docking and binding at the plasma membrane.  Both cytochalasin D and 
Latrunculin B, pharmaceuticals that alter the actin cytoskeleton, inhibit insulin-stimulated 
glucose uptake and GLUT4 translocation, possibly by inactivating TC10 (24).  The 
translocation of GLUT4 is therefore mediated by the cellular actin filaments.  In addition, 
the Rho family GTPase Cdc42 are also thought to mediate actin remodeling.  Cdc42 
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binds and activates the Wiskott-Aldrich Syndrome Protein (WASP).  It has been 
suggested that WASP plays a role in altering the actin cytoskeleton as patients with 
WASP mutations exhibit defects in cell morphology (24).  In addition, microtublule 
motor proteins kinesin KIF5b and KIF3 have been shown to facilitate GLUT4 
translocation to the plasma membrane.  Thus, it is possible that molecular motors move 
GLUT4 along tracks of actin, which under go a significant remodeling process under 
insulin-stimulated conditions (11).    
In the presence of insulin GLUT4 exocytosis is increased while endocytosis is 
decreased. GLUT4 is recycled between vesicles and the cell surface via endosomal 
compartments (32) and localized to the trans-golgi network, clathrin-coated vesicles, and 
endosomes of the recycling pathway.  Insulin-stimulated GLUT4 exocytosis is described 
by the SNARE model of GLUT4 trafficking in which GLUT4 is localized to 
tubulovesicular compartments enriched with the vesicle-SNAP receptor (v-SNARE) and 
the vesicle associated membrane protein-2 (VAMP2).  The v-SNARE proteins VAMP2 
and VAMP3/cellubrevin encompass part of the GLUT4 containing vesicles in skeletal 
muscle (11).  Contact between GLUT4 containing vesicles and the plasma membrane is 
facilitated by the v-SNARE synaptobrevin and the target-SNAP receptor (t-SNAREs) 
syntaxin-4. According to this model, GLUT4 containing vesicles fuse with the plasma 
membrane via the complex interaction between VAMP2 with the t-SNARE complex 
which is composed of syntaxin 4 and the soluble NSF attachment protein-23 (SNAP23).  
It is the SNAP proteins then that regulate the association between the v-SNAREs and t-
SNAREs (50).   
However, tubulovesicular elements in the cytoplasm appear to contain the 
majority of GLUT4 (32).  Thus, following insulin-stimulated translocation, GLUT4 
accumulates in clathrin-coated portions of the plasma membrane via the AP2 adaptor 
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complex, which facilitates internalization through clathrin mediated endocytosis (32).  
The GTPase dynamin is a protein involved in GLUT4 endocytosis.  Upon insulin 
stimulation dynamin translocates to the plasma membrane where it interacts with Grb2.  
The dynamin-Grb2 complex increases the GTPase activity of dynamin for the formation 
of clathrin-coated vesicles.  Clathrin-coated GLUT4 containing vesicles are then moved 
through the endosomal recycling system where they loose their clathrin coat and can then 
be stored in specialized perinuclear reticular compartments (32). 
THE MAMMALIAN TARGET OF RAPAMYCIN SIGNALING PATHWAY 
Mammalian target of rapamycin (mTOR) is a serine/threonine kinase and a 
member of the PI 3-kinase related family (21).  The mTOR signaling pathway is 
activated by insulin, amino acids, growth factors and impaired by deficient nutrients and 
energy (48).  The activity of mTOR is regulated by multiple phosphorylation sites.  As 
suchm, ser-2481 is a site for autophosphorylation whereas ser-2448 and thr-2446, when 
phosphorylated, increase the activity of mTOR toward its downstream targets (21).   
The best know inhibitor of mTOR is rapamycin.  Rapamycin inhibits mTOR 
through FKBP12.  Specifically, the rapamycin-FKBP12 complex inhibits the activity of 
the complex, raptor-mTOR-GβL, which regulates the kinase activity of mTOR (39).  In 
the rapamycin insensitive complex raptor is replaced by rictor to form the rictor-mTOR 
complex (39).  Thus, the primary binding partners of mTOR are raptor and rictor.  These 
complexes are also referred to as mTORC1 and mTORC2  (48).  
Insulin activates mTOR signaling, possibly through PI 3-kinase.  Insulin activates 
PI 3-kinase, leading to the phosphorylation and activation of Akt/PKB.  Akt/PKB in turn 
phosphorylates tuberous sclerosis complex 2 (TSC2), a small G-protein Rheb.  The GAP 
activity is inhibited by phosphorylated TSC2, allowing Rheb to accumulate in its active 
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GTP-bound form (48).  The accumulation of GTP-Rheb stimulates the kinase activity of 
mTOR. Furthermore, mTOR-RICTOR has been shown to phosphorylate Akt/PKB at Ser-
473 in response to insulin.  In contrast, the rapamycin sensitive mTOR/RAPTOR 
complex is a downstream target of Akt/PKB, placing mTOR both upstream and 
downstream of Akt function depending on its associated interacting partner.   
mTOR signaling is also mediated by amino acids, specifically leucine.  The 
precise mechanism of leucine induced activation of mTOR is unclear, but it does appear 
that it may be independent of TSC2.  Amino acid withdrawal was found to inhibit mTOR 
signaling in TSC2-deficient cells (42).  Recent evidence suggests that the TSC2 
independent signal may act through the PI 3-kinase related protein HVPS34 (10).  
However, more work is needed to determine the involvement HVPS34, as well as 
additional PI 3-kinase related proteins, and their exact interaction with mTOR.       
AMINO ACIDS 
Amino acids are compounds containing both an amine and carboxylic group and a 
side chain that is unique to each amino acid.  In general, amino acids are central to life 
and have many functions including their roles as the building blocks for proteins and as 
intermediates for metabolism.   Of the 22 amino acids, 8 are classified as essential amino 
acids because the human body cannot synthesize them from other compounds.  
Therefore, the essential amino acids must be obtained from one’s diet.  The essential 
amino acids can further be divided into those exhibiting side chains with a branch and 
those with no branching.  Amino acids having an aliphatic side-chain with a branch are 
termed branched-chain amino acids and include leucine, isoleucine and valine.  The 
branched-chain amino acids are of particular importance because they account for a large 
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proportion of the essential amino acids in muscle protein, used clinically for a variety of 
aliments and recently, been shown to impact glucose metabolism.   
Much work has been dedicated to the individual effects of amino acids.  As a 
result of this research, it has become possible to combine amino acids in order to create 
mixtures that can have a far greater affect on, for example, glucose metabolism, than an 
individual amino acid can.  Some amino acids are reported to have either a direct affect 
on glucose uptake or act indirectly through increases in insulin or muscle glycogen levels.  
Leucine (36), isoleucine (17, 18) and cysteine (23) have been shown to increase skeletal 
muscle glucose uptake in the absence of insulin.  Although leucine increases insulin 
secretion, it is noteworthy that the elevated insulin levels do no account for its positive 
impact on glucose uptake.  In addition, methionine also increases insulin secretion (12) 
but its exact role in glucose metabolism is unclear.  Furthermore, both leucine (36) and 
valine have been shown to increase skeletal muscle glycogen synthesis (17) 
Since amino acids must enter muscle cells before exerting their actions they  
require transport proteins, or systems, to move across the plasma membrane.  There are 
several different transport systems located on the sarcolemma, each classified by the type 
of amino acid it transports, its transport mechanism and its regulation.  The majority of 
skeletal muscle amino acid transport occurs through either System A or System L 
transporters.  System A consists of secondary active transport that moves short, neutral 
amino acids across the plasma membrane against their concentration gradient that is both 
pH and insulin sensitive (13).   In contrast, System L transports bulky, neutral amino 
acids as well as the branched-chain amino acids and is not regulated by pH or insulin 
(13).  Because System L acts independent of sodium it uses non-System L amino acids to 
move its substrates across the plasma membrane.  Thus, for each System L amino acid 
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that is transported into the muscle cell, a non-System L amino acid is transporter out of 
the cell (34).          
  EFFECTS OF BRANCHED-CHAIN AMINO ACIDS ON GLUCOSE TRANSPORT 
In addition to insulin, branched-chain amino acids, specifically isoleucine and 
leucine may increase glucose uptake.  It is well documented that branched-chain amino 
acids, especially leucine, are integral to protein synthesis, and this process appears to 
occur through mTOR (2).  But recent studies suggest that both isoleucine and leucine 
may be involved in insulin signaling and glucose homeostasis.  Nishitani et al. (36) 
investigated the effects of leucine on skeletal muscle glucose uptake in the absence of 
insulin.  Using the isolated muscle preparation, soleus muscle incubated in leucine 
showed a significant increase in glucose uptake.  Interestingly, the increase in glucose 
uptake for muscle bathed in leucine showed a 1.5 fold increase in glucose uptake, which 
was similar to that achieved by a physiological amount of insulin (36).  However, the 
effect of leucine was suppressed by the administration of both LY294002, a specific 
inhibitor of PI 3-kinase and GF109203X, a specific inhibitor of PKC.  In contrast, 
glucose uptake was not impaired when the isolated soleus was exposed to rapamycin, a 
specific inhibitor of mTOR, and leucine.  These findings suggest that leucine may 
stimulate glucose transport via PI 3-kinase and PKC, and not mTOR and this appears to 
be independent of insulin.   
Recent evidence suggests that isoleucine, rather than leucine is a stronger effector 
of glucose uptake and whole-body glucose homeostasis.  An oral gavage of isoleucine 
decreased blood glucose levels and increased skeletal muscle glucose uptake (18).  This 
occurred despite no significant increase in the circulating insulin concentration.  
Although the exact mechanism was not determined in this study, the authors did find that 
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hepatic glucose production was reduced in vitro (18).  In addition, 4-hydroxyisoleucine 
(4-OH-ILE), an amino acid extract, has been shown to stimulate insulin secretion and 
improve glucose tolerance in diabetic rats (7, 8).  The improved glucose tolerance may 
have resulted from increased glucose uptake and/or decreased hepatic glucose 
production.  The authors also found that 4-OH-ILE may affect insulin signaling, as PI 3-
kinase activity was increased (7).  Collectively, these findings suggest that the branched-
chain amino acids, specifically isoleucine and leucine may enhance glucose uptake and 
regulate glucose homeostasis.    
COMBINED EFFECTS OF CARBOHYDRATES AND AMINO ACIDS ON GLUCOSE 
TRANSPORT 
Although the individual affects of carbohydrates and specific amino acids have 
been demonstrated on glucose tolerance the combined effects are not as well defined.  
The individual administration of carbohydrate and leucine have been shown to enhance 
PI 3-kinase activity (6).  But leucine has not always been shown to have a positive affect 
on PI 3-kinase activity.  Baum et al. (5) compared the effects of an oral dose of 
carbohydrate, leucine or a combined carbohydrate and leucine supplement on glucose 
homeostasis and PI 3-kinase activity.  Fifteen minutes post supplementation there was no 
difference in PI 3-kinase activity between carbohydrate and carbohydrate plus leucine.  
However, from 30-90 min post supplementation PI 3-kinase activity was higher in rats 
that consumed carbohydrate compared to the combined treatment.  Despite reduced PI 3-
kinase activity there was no difference in glucose uptake between carbohydrate and 
carbohydrate plus leucine treated rats.  According to the study authors the initial 
activation of PI 3-kinase was sufficient to initiate glucose uptake (5).  It is therefore 
possible that leucine and insulin enhance glucose transport via different mechanisms.  As 
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previously stated, leucine may stimulate glucose transport by an unidentified process that 
is independent of the mTOR/PI 3-kinase pathway (36, 43).   
Recent studies have demonstrated that a mixture of branched-chain amino acids 
may decrease blood glucose levels.  Oral administration of a branched-chain amino acids 
mixture has been shown to reduce hyperglycemia in a virus-induced diabetic mouse 
model (44) and reduce blood glucose levels in streptozotocin-induced rats (19).  
However, it was not clear as to whether it was the mixture of branched-chain amino acids 
or an individual amino acid that improved glucose metabolism.  In light of these findings, 
Doi et al. (17) investigated the individual effect of leucine, isoleucine and valine on blood 
glucose levels in rats and glucose uptake in cultured C2C12 myotubes.  Rats were gavaged 
with either leucine, isoleucine or valine 30 min prior an OGTT.  The rats were then 
gavaged with a glucose solution and the blood glucose levels were traced over a 120 min 
time period.  Isoleucine significantly reduced blood glucose levels at 30 min and 60 min 
post glucose administration.  Leucine nor valine appeared to improve glucose tolerance 
under these conditions.  In fact, valine increased blood glucose levels, possibly because 
valine, a glucogenic amino acid, increased gluconeogenesis.  In C2C12 myotubes, 
isoleucine had the greatest affect on glucose uptake, and its effect was independent of 
insulin.  Using specific inhibitors for the insulin signaling cascade the authors found that 
the increased glucose uptake by isoleucine involved both PI 3-kinase and PKC.  
However, these improvements did not appear to involve mTOR as rapamycin enhanced 
glucose uptake in isoleucine treated myotubes.     
GLUCOSE DISPOSAL 
Following the transport of glucose across the plasma membrane and into the 
muscle cell, it is either converted to glucose-6-phosphate (G6P) by hexokinase or 
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counter-transporter back into the blood.  At any given time this is largely controlled by 
the activity level of hexokinase and the glucose concentration gradient.  After glucose is 
phosphorylated, it has two distinct fates; used as an immediate energy source via 
glycolysis or be converted to glycogen, a stored form of energy.  Therefore, once 
phosphorylated by hexokinase, becoming G6P, the glucose molecule can not be 
transported back out of the cell as skeletal muscle lacks glucose-6-phosphatase.  Under 
fasting conditions the majority of blood glucose following the ingestion of a carbohydrate 
load will be removed by skeletal muscle and the primary fate of the cleared glucose will 
be its conversion to glycogen.  After the formation of G6P, it is transformed to glucose-1-
phosphate (G1P) by the enzyme phosphoglucomutase.  G1P and uridine triphosphate 
(UTP) is then synthesized to uridine diphosphate (UDP)-glucose in a reaction catalyzed 
by UDP-glucsoe pyrophosphorylase.  The C-1 carbon of UDP-glucose is considered 
“activated” because its hydroxyl group is esterfied to the diphosphate moiety of UDP.  
New glucose units can now be added to the non-reducing end of glycogen.  The UDP-
glucose is transferred to the hydroxyl group at a C-4 terminus of glycogen forming an α-
1-,4 glycosidic linkage.  While the glycogen macromolecule becomes longer its terminal 
hydroxyl group displaces UDP.  Glycogen synthase (GS) is the enzyme for this 
elongation reaction.  However, GS only catalyzes α-1,4-linkages, thereby synthesizing a 
linear macromolecule.  In order for glycogen to increase its storage capacity, solubility 
and the number of non-reducing ends, a branched polymer is needed.  Thus, a branching 
enzyme breaks the α-1,4 linkages and forming α-1,6-linkages to form branches.   
The rate limiting enzyme for glycogen synthesis is GS (33).  It is regulated by 
multiple phosphorylation sites and by several allosteric effectors (38, 47).  Of these 
potential phosphoryaltion sites, ser-7 (site 2), ser-10 (site 2a), ser-640 (site 3a), ser-644 
(site 3b) appear to be the most important regulating residues on GS (41).  In general, 
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phoshporylation reduces the catalytic activity of GS, causing an increase in the Km for 
the substrate UDP-glucose and an increase in the Ka for G6P (47).  Although there are 
several protein kinases that phosphorylate GS, glycogen synthase kinase-3 (GSK-3) 
appears to have the strongest inhibitory effect (41).  However, the amount of inactivation 
depends not only on the sites phosphorylated but the concentration of allosteric effectors 
such as G6P.   
The molecule G6P is a potent allosteric activator of GS.  Despite GS being 
phosphorylated at multiple sites, G6P can still fully activate GS (47).  It is believed that 
G6P activates GS via dephosphoryaltion of the enzyme (38).  The effect of G6P is 
enhanced by the presence of insulin.  Therefore, dephosphorylation of GS by insulin 
decreases the concentration of G6P needed to activate the enzyme (46).   
In skeletal muscle, GS exists in either the I-form or D-form.  The I-form is active 
in the absence of G6P.  Whereas the D-form is active in the presence of G6P but its 
activity is attenuated when G6P is absent.  When at least three sites of GS are 
phosphorylated, the enzyme is quickly converts back to its less active D-form (25).      
INSULIN RESISTANCE 
Insulin resistance is the condition that occurs when a normal level of insulin 
produces a less than normal biological response (27).  As a result, excess insulin must be 
secreted in order to achieve a normal blood glucose response.  Insulin resistance can be 
further characterized by its level of insulin sensitivity and/or insulin responsiveness.  
Insulin sensitivity is defined by the percent of a maximal biological response, or glucose 
transport, caused by a submaximal insulin concentration.  Therefore, a higher percent of a 
maximal biological response at a given submaximal insulin concentration represents an 
increased insulin sensitivity (27).  In contrast, insulin responsiveness is defined by the 
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maximal biological response, or glucose transport, caused by a maximal insulin 
concentration (27).  Thus, a higher maximal biological response indicates greater insulin 
responsiveness.     
Being able to distinguish between insulin sensitivity and responsiveness is critical 
to identifying potential locale(s) of insulin resistance.  A reduction in insulin sensitivity 
indicates potential impairments to the insulin receptor and/or signals leading to the 
receptor.  For example, reduced insulin sensitivity could be caused by a reduction in the 
number of insulin receptors or by reduced affinity of the receptor towards insulin (27).  In 
contrast, reduced insulin responsiveness indicates a post insulin receptor defect such as 
impaired glucose transport and/or glucose disposal (27).   
THE ZUCKER RAT 
Zucker rats are the most commonly used rodent model for obesity and insulin 
resistance research.  The obese Zucker rat exhibits severe insulin resistance due to both 
decreased insulin sensitivity and insulin responsiveness (16, 40).  The genetically obese 
Zucker rat was first described in 1961 by Zucker and Zucker (54).  This rodent model of 
insulin resistance was the result of a single recessive gene when Merck Stock M and 
Sherman rats were cross bred (3).  The symbol fa/fa is used to denote the obese condition, 
whereas the lean litter mates are symbolized by fa/?.  Upon visual inspection, from the 
time of birth and up to 4 weeks of age homozygous rats are not easily distinguishable 
from their heterozygous litter mates.  However, beyond 4 weeks of age the obese Zuckers 
appear “fatter” compared to their lean litter mates as easily seen by their noticeable 
rounder appearance (3).   
The obese Zucker rat is characterized by insulin resistance, hyperinsulinemia and 
hypertriglyeridemia (3), which is due largely to their rapid onset of obesity.  Both 
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hyperphagia and decreased activity levels are major factors in the Zucker rat becoming 
obese (3, 45).  The hyperphagia is primarily due to a defective leptin receptor (37).  
Leptin is a molecule that binds to specific receptors in the hypothalamus and controls 
satiety.  Under normal conditions, such as in the lean Zucker rat leptin will bind to its 
receptor causing the rat to feel full and stop eating.  In contrast, obese Zucker rats have 
defective leptin receptors which prevent leptin from successively binding.  Since leptin 
can not bind to its receptor the rat continuously eats because it does not feel full.  The 
excess caloric intake leads to the rapid development of obesity and insulin resistance.  
The obesity, or excess fat mass, in obese Zucker rats is due to an increase in both adipose 
cell size and number (3).  The significantly larger adipose cell size can be partially 
explained by increased levels of lipoprotein lipase, an enzyme that stores lipids (45).   
As previously stated, the obese Zucker rat has impaired insulin sensitivity and 
insulin responsiveness.  Insulin must only bind to approximately 20% of the insulin 
receptors to elicit a maximal insulin response. Under physiological conditions, the 
number of insulin receptors on the cell membrane will not decline by more than 50-60% 
below normal, suggesting that decreased insulin responsiveness is due to a post receptor 
defect.  Thus, the reduced insulin responsiveness in obese Zucker rats appears to lie in the 
glucose transport process (20, 26, 40).  While the reduced insulin sensitivity observed in 
obese Zucker rats is due to decreased insulin receptor number (14).   
Surprisingly, skeletal muscle GLUT4 expression of obese Zucker rats does not 
appear to be reduced (20, 22).  Rather, the insulin-stimulated translocation of GLUT4 to 
the plasma membrane is impaired (20, 30).  Sherman et al. (40) reported that the rates of 
insulin-stimulated glucose transport were significantly reduced in obese compared to lean 
Zucker rats.  Although not directly measured in this study, the total cellular concentration 
of GLUT4 could not account for the decline in insulin-stimulated glucose transport (4).  
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A follow up study conducted by Brozinick et al. (9) investigated the translocation of 
GLUT4 from its intracellular compartments to the plasma membrane.  Upon insulin-
stimulation in the lean rats there was an increase in GLUT4 at the plasma membrane with 
a parallel decrease of the intracellular GLUT4.  However, insulin stimulation did not 
increase the number of plasma membrane associated glucose transporters in the obese 
rats suggesting a defective GLUT4 translocation process in the skeletal muscle of obese 
Zucker rats.  This finding was later confirmed by Etgen et al. (20) using ATB-BMPA, a 
precise labeling method for plasma membrane GLUT4.   
It is widely accepted that the defect in skeletal muscle GLUT4 translocation 
observed in obese Zucker rats can be attributed to impairments in insulin signaling.  
Using the hind limb perfusion technique Anai et al. (1) reported that obese Zucker rats 
had reduced IRS-1 protein concentration, IRS-1 tyrosine phosphorylation and IRS-1 
associated PI 3-kinase activity under insulin-stimulated conditions compared to their lean 
litter mates.  Thus, there are marked defects in specific insulin signaling proteins and 









1. Anai M, Funaki T, Ogihara T, Terasaki J, Inukai K, Katagiri H, Fukushima 
Y, Yazaki Y, Kikuchi M, Oka Y and Asano T.  Altered expression levels and 
impaired steps in the pathway to phosphatidylinositol 3-kinase activation via 
insulin receptor substrate 1 and 2 in Zucker fatty rats.  Diabetes 47: 13-23. 1998. 
2. Anthony JC, Yoshizawa F, Anthony TG, Vary TC, Jefferson LS and Kimball 
SR.  Leucine stimulates translation initiation in skeletal muscle of postabsorptive 
rats via a rapamycin-sensitive pathway.  J Nutr 130: 2413-2419, 2000.   
3. Argiles J.  The obese Zucker rat: A choice for fat metabolism. 1969-1988: 
Twenty years of research on the insights of the Zucker mutation.  Prog Lipid Res 
28: 53-66, 1989. 
4. Banks EA, Brozinick JR JT, Yaspelkis III BB, Kang HY and Ivy JL.  Muscle 
glucose transport, GLUT-4 content and degree of exercise training in obese 
Zucker rats.  Am J Physiol 263: E1010-E1015, 1992.  
5. Baum JI, O’Connor JC, Seyler JE, Anthony TG, Freund GG and Layman 
DK.  Leucine reduces the duration of insulin-stimulated PI 3-kinase activity in rat 
skeletal muscle.  Am J Physiol Endocrinol Metab 288: E86-E91, 2005. 
6. Bolster DR, Jeffereson LS and Kimball SR.  Regulaiton of protein synthesis 
associated with skeletal muscle hypertrophy by insulin-amino acid and exercise-
induced signaling.  Proc Nutr Soc  63: 351-356, 2004 
7. Broca, C, Breil V, Guglielmacci CC, Manteghetti M, Rouault C, Derouet M, 
Rizkalla S, Pau B, et al.  Insulinotroic agent ID-1101(4-hydroxyisoleucine) 




8. Broca C, Gross R, Petit P, Sauvaire Y, Manteghetti M, Tournier M, Masiello 
P, Gomis R and Ribes G.  4-hydroxyisoleucine: experimental evidence of its 
insulinotropic and antidiabetic properties.  Am J Physiol 277: E617-623, 1999. 
9. Brozinick JR JT, Etgen JR GJ, Yaspelkis BB 3rd and Ivy JL.  Glucose uptake 
and GLUT-4 protein distribution in skeletal muscle of the obese Zucker rat.  Am J 
Physiol 267: R236-R243, 1994. 
10. Byfield MP, Murray JT and Backer JM.  hVps34 is a nutrient-regulaed lipid 
kinase required for activation of p70 S6 kinase,  J Biol Chem 280: 33076-33082, 
2005. 
11. Chang L, Chiang SH and Saltiel AR.  Insulin signaling and regulation of 
glucose transport.  Mol Med 10: 65-71, 2004, 
12. Cherif H, Reusens B, Ahn MT, Hoet JJ and Remacle C.  Effects of taurine on 
the insulin secretion of rat fetal islets from dams fed a low-protein diet.  J 
Endocrinol 159: 341-348, 1998. 
13. Christensen HN.  Role of amino acid transport and countertransport in nutrition 
and metabolism.  Physiol Rev 70: 43-77, 1990.  
14. Crettaz M, Prentki M, Zaninettie D and Jeanfeneaud B.  Insulin resistance in 
soleus muscle from obese Zucker rats: involvement of several defective sites.  
Biochem J 186: 525-534, 1980. 
15. Cushman SW and Wardzala LJ.  Potential mechanisms of insulin action on 
glucose transport in isolated rat adipose cell: apparent translocation of 




16. Czech MP, Richardson DK, Becjer SG, Walters W, Gitomer W and  
Heinrich J.  Insulin response in skeletal muscle and fat cells of genetically obese 
Zucker rat.  Metabolism  2: 1967-1981, 1978. 
17. Doi M, Yamaoka I, Fukunaga T and Nakayama M.  Isoleucine, a potent 
plasma glucose-lowering amino acid, stimulates glucose uptake in C2C12 
myotubes.  Biochem Biophys Res Commun 312: 1111-1117, 2003. 
18. Doi M, Yamaoka I, Nakayama M, Sugahara K and Yoshizawa F.  
Hypoglycemic effect of isoleucine involves muscle glucose uptake and whole 
body glucose oxidation and decreased hepatic gluconeogenesis.  Am J Endocrinol 
Metab  292: E1683-E1693, 2007. 
19. Eizirik DL, Kettelhut RH and Migliorini RH.  Administration of branched-
chain amino acids reduces the diabetogenic effect of streptozotocin in rats.  
Brazalian J Med Res 20: 137-144, 1987. 
20. Etgen G J Jr, Wilson CM, Jensen J, Cushman SW and Ivy JL.  Glucose 
transport and cell surface GLUT4 protein in skeletal muscle of the obese Zucker 
rat.  Am J Physiol 271: E294-E301, 1996. 
21. Fingar DC and Blenis J.  Target of rapamycin (TOR): an integration of nutrient 
and growth factor signals and coordinator of cell growth and cell cycle 
progression.  Oncogene 23: 3151-3171, 2004. 
22. Friedman JE, Sherman WM, Reed MJ, Elton CW and Dohm GL.  Exercise 
training increases glucose transporter protein GLUT-4 in skeletal muscle of obese 
Zucker (fa/fa) rats, FEBS Lett 268: 13-16, 1990. 
 
 29
23. Gazit V, Ben-Abraham R, Vofsi O and Katz Y.  L-cysteine increases glucose 
uptake in mouse soleus muscle and SH-SY5Y cells.  Metab Brain Dis 18: 221-
231, 2003. 
24. Inoue M, Chang L, Hawang J, Chaing SH and Saltiel AR.  The exocyst 
complex is required for targeting of GLUT4 to the plasma membrane by insulin. 
Nature 422: 629-633, 2003. 
25. Ivy JL.  Glycogen resynthesis after exercise: effect of carbohydrate intake.  Int J 
Sports Med 19 Suppl 2 S142-145, 1988. 
26. Ivy JL, Brozinick JT, Torgan CE, and Kastello GM.  Skeletal muscle glucose 
transport in obese Zucker rats after exercise training.  J Appl Physiol 66: 2635-
2641, 1989. 
27. Kahn RC.  Insulin resistance, insulin sensitivity, and insulin responsiveness: a 
necessary distinction.  Metabolism  27: 1893-1902, 1978. 
28. Kalogeropoulou D, LaFave L. Schweim K, Gannon MC and Nuttal FQ.  
Leucine, when ingested with glucose, synergistically stimulates insulin secretion 
and lowers blood glucose.  Metabolism 57: 1747, 1752, 2008. 
29. Kanai F, Ito K, Todaka M, Hayashi H, Kamohara S, Okada T, Hazeki O, Ui 
M and Ebina Y.  Insulin-stimulated GLUT4 translocation is relevant to the 
phosphorylation of IRS-1 and the activity of PI3-kinase.  Biochem Biophys Res 
Commun 195: 762-768, 1994.   
30. King PA, Horton ED, Hirshman MF and Horton ES.  Insulin resistance in 
obese Zucker rat (fa/fa) is associated with a failure of glucose transporter 
translocation.  J Clin Invest 90: 1568-1575, 1992. 
 
 30
31. Klip A, Ramlal T, Yound DA and Holloszy JO.  Insulin-stimulated glucose 
transporters in rat hindlimb muscles.  FEBS Lett 224: 224-230, 1987. 
32. Litherland GJ, Hajduch E and Hundal HS.  Intracellular signaling mechanisms 
regulating glucose transport in insulin-sensitive tissues (review).  Mol Membr Biol 
18: 195-204, 2001. 
33. Manchester J, Skurat AV, Roach P, Hauschka SD and Lawrence JC Jr.  
Increased glycogen accumulation in transgenic mice overexpressing glycogen 
synthase in skeletal muscle.  Proc Natl Acad Sci USA 93: 10707-1-711, 1996. 
34. Meie C, Ristic Z, Klauser S and Verrey F.  Activaiton of system L heterdimeric 
amino acid exchangers by intracellular substrates.  EMBO J 21: 580-589, 2002. 
35. Morifuji M, Koga J, Kawanaka K and Higuchi M.  Branched-chain amino 
acid-containing dipeptides, identified from whey protein hydrolysates, stimulate 
glucose uptake rate in L6 myotubes and isolated skeletal muscles.  J Nutr Sci 
Vitaminol 55: 81-86, 2009. 
36. Nishitani S, Matsumura T, Fujitani S, Sonaka I, Miura Y and Yagasaki K.  
Leucine promotes glucose uptake in skeletal muscle of rats.  Biochem Biophys 
Res Commun 299: 693-696, 2002. 
37. Phillips M, Liu Q, Hammond HA, Dugan V, Hey PJ, Caskey CJ and Hess JF.  
Leptin receptor missense mutation in the fatty Zucker rat.  Nat Genet 13: 18-19, 
1996. 
38. Roach PJ.  Glycogen and its metabolism.  Curr Mol Med 2: 101-120, 2002. 
39. Sarbassov DD, Guertin DA, Ali SM and Sabatini DM.  Phosphorylation and 




40. Sherman WM, Katz AL, Cutler CL, Withers RT and Ivy JL.  Glucose 
transport: locus of muscle insulin resistance in obese Zucker rats.  Am J Physiol 
255: E374-E382, 1988. 
41. Skuart A, Dietrich AD and Roach PJ.  Glycogen synthase sensitivity to insulin 
and glucose-6-phosphate is mediated by both NH2- and COOH-terminal 
phosphorylation sites.  Diabetes 49: 1096-1100, 2000. 
42. Smith EM, Finn SG, Tee AR, Browne GJ and Proud CG.  The tuberous 
sclerosis protein TSC2 is not required for the regulation of the mammalian target 
of rapamycin by amino acids and certain cellular stresses.  J Biol Chem 280: 
18717-18727, 2005. 
43. Throng FS, Dugani CB and Klip A.  Turing signals on and off: GLUT4 traffic 
in the insulin-signaling highway.  Physiology  20: 271-284. 
44. Utsugi T, Yoshida T, Kanada I, Kobayashi M, Kurabayashi S, Tomono S, 
Kawazu and Tajima Y.  Oral administration of branched-chain amino acids 
improves virus-induced glucose intolerance in mice.  Eur J Pharm 398: 409-414, 
2000. 
45. Vasselli Jr, Fiene JA and Maggio A.  Relationship of adipocyte size to 
hyperphagia in developing male obese Zucker rats.  Am J Physiol 245: R33-R38, 
1992. 
46. Villar-Palasi C.  Substrate specific activation by glucose-6-phosphate of the 
dephosphorylation of muscle glycogen synthase.  Biochem Biophys Acta 1095: 
261-267, 1991. 
47. Villar-Palasi C and Guinovart JJ.  The role of glucose 6-phosphate in the 
control of glycogen synthase.  FASB J 11: 544-558, 1997. 
 
 32
48. Wang X and Proud CG.  The mTOR pathway in control of protein synthesis.  
Physiology (Bethesda) 21: 362-369, 2006. 
49. Wardzala LJ and Jeanrenaud B.  Potential mechanism of insulin action on 
glucose transport in the isolated rat diaphragm.  J Biol Chem 256: 7090-7093, 
1981. 
50. Watson RT and Pessin JE.  Bridging the GAP between insulin signaling and 
GLUT4 translocation.  Trends in Biochem Sci 31: 215-222, 2006. 
51. White M.  IRS proteins and the common path to diabetes.  Am J Physiol 
Endocrinol Metab 283: E413-E422, 2002.  
52. Wojtaszewski JF, Hansen BF, Urso B and Richter EA.  Wortmannin inhibits 
both insulin-and contraction stimulated glucose uptake and transport in rat 
skeletal muscle. J Appl Physiol 81: 1501-1509, 1996. 
53. Wood IS and Trayhurn P.  Glucose transporters (GLUT and SGLT): expanded 
families of sugar transport proteins.  Br J Nutr 89: 3-9, 2003. 


















Chapter III: An amino acid mixture improves glucose tolerance and 
insulin signaling in Sprague Dawley rats 
 
ABSTRACT 
The first aim of this investigation (experiment [Exp]-1) was to evaluate the effect 
of an amino acid supplement on the glucose response to an oral glucose challenge.  The 
second aim of this investigation (experiment [Exp]-2) was to evaluate if differences in 
blood glucose response were associated with increased skeletal muscle glucose uptake.  
Exp-1 rats were gavaged with either glucose (CHO), glucose plus an amino acid mixture 
(CHO-AA-1), glucose plus an amino acid mixture with increased leucine concentration 
(CHO-AA-2) or water (PLA).  CHO-AA-1 and CHO-AA-2 had reduced similar blood 
glucose responses compared to CHO with no difference in insulin among the four 
treatments.  Rats in Exp-2 were gavaged with either CHO or CHO-AA-1.  Fifteen min 
after gavage a bolus containing [3H] 2-deoxyglucose and [U-14C] mannitol was infused 
via a tail vein.  Blood glucose was significantly lower in CHO-AA-1 than CHO, while 
insulin responses were similar.  Muscle glucose uptake was higher in CHO-AA-1 
compared with CHO in both fast-twitch red (8.36 + 1.3 vs 5.27 + 0.7 μmol/g/h) and white 
muscle (1.85 + 0.3 vs 1.11 + 0.2 μmol/g/h).  There was no difference in Akt/PKB 
phosphorylation between treatment groups, however, the amino acid treatment resulted in 
increased AS160 phosphorylation in both muscle fiber types. Glycogen synthase 
phosphorylation was reduced in fast-twitch red muscle of CHO-AA-1 compared to CHO, 
while mTOR phosphorylation was increased.  Phosphorylation of glycogen synthase and 
mTOR in fast-twitch white muscle did not differ between treatments.  These findings 
suggest that an amino acid supplement improves glucose tolerance and that these 
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improvements are associated with an increase in skeletal muscle glucose uptake possibly 
due to improved intracellular signaling.   
INTRODUCTION 
It is well documented that amino acids, specifically the branched-chain amino 
acids, are essential for protein synthesis.  Emerging literature, however, suggests that 
amino acids may also play a role in glucose homeostasis.  Of the branched-chain amino 
acids, isoleucine and leucine appear to be the primary amino acids affecting blood 
glucose levels.  Both of these branched-chain amino acids have demonstrated glucose 
lowering abilities (4, 6, 22).  Yet there remain many questions as to how amino acids 
affect blood glucose levels.  Possible mechanisms that have been previously explored 
include a greater insulin response and/or an increased rate of skeletal muscle glucose 
clearance.   
Insulin is a potent stimulator of skeletal muscle glucose transport.  It has been 
shown that the combined ingestion of carbohydrates with either protein (24, 39) or amino 
acids (11, 25, 35, 36) may synergistically enhance insulin secretion.  The glucose 
lowering effect of these compounds, therefore, has generally been assumed to be the 
result of a greater insulin response (8, 36).  However, separate studies utilizing in vitro 
models have reported that leucine and/or isoleucine enhanced skeletal muscle glucose 
uptake under insulin-free conditions (4, 22), suggesting that insulin alone may not explain 
protein and/or amino acid-induced glucose clearance.  Rather, factors beyond an increase 
in plasma insulin, such as altered muscle cell signaling, could be associated with this 
improved glucose tolerance.   
As previously mentioned, both leucine and isoleucine have been found to increase 
skeletal muscle glucose uptake in the absence of insulin (4, 6, 22).  Nishitani et al. (22) 
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reported that leucine-induced glucose uptake in isolated soleus muscle was negated when 
incubated with specific inhibitors for either phosphatidylinositol 3-kinase (PI 3-kinase) or 
atypical protein kinase C (aPKC).  In contrast, pre-treatment with rapamycin, a specific 
inhibitor of the mammalian target of rapamycin (mTOR) had no effect.  In agreement, 
Doi et al. (4) reported that isoleucine-induced glucose uptake in C2C12 myotubes was 
inhibited in the presence of a specific inhibitor of PI 3-kinase but not in the presence of 
an inhibitor of mTOR.  
Although in vitro results support the involvement of PI 3-kinase in amino acid-
induced muscle glucose uptake under insulin-free conditions, this effect in combination 
with insulin and on blood glucose clearance in vivo is unclear.  Therefore, the primary 
aim of this investigation (experiment [Exp]-1) was to determine if an amino acid mixture 
improves glucose tolerance in Sprague Dawley rats, and if differences in glucose 
tolerance are due to differences in skeletal muscle glucose uptake (experiment [Exp]-2).     
MATERIALS AND METHODS 
Animal care and housing.  Exp-1: Twenty-four male Sprague Dawley rats 
approximately 10 weeks old were obtained from Harlan (Indianapolis, IN).  Rats were 
randomly assigned to one of four groups:  carbohydrate (CHO, n = 6), carbohydrate plus 
a 5-amino acid mixture (CHO-AA-1, n = 6), carbohydrate plus a 5-amino acid mixture 
with increased leucine concentration (CHO-AA-2, n = 6) or placebo (PLA, n = 6).  Rats 
were housed individually and provided standard laboratory chow and water ad libitum. 
The temperature of the animal room was maintained at 21° C, with an artificial 12:12 h 
light-dark cycle.  All experimental procedures were approved by the Institutional Animal 
Care and Use Committee (IACUC) of the University of Texas at Austin and conformed 
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to the guidelines for the use of laboratory animals published by the United States 
Department of Health and Human Resources.   
Exp-2: Twelve male Sprague Dawley rats approximately 12 weeks old were 
obtained from the University of Texas at Austin Animal Resources Center.  The rats were 
then randomly assigned to either carbohydrate (CHO, n = 6) or carbohydrate plus a 5-
amino acid mixture (CHO-AA-1, n = 6).  Rats were housed individually and provided 
standard laboratory chow and water ad libitum. The temperature of the animal room was 
maintained at 21° C and an artificial 12:12 h light-dark cycle was set.  All experimental 
procedures were approved by the IACUC of the University of Texas at Austin and 
conformed to the guidelines for the use of laboratory animals published by the United 
States Department of Health and Human Resources.  
Experimental protocol.  Exp-1: Following 1 week of acclimation, rats were 
orally gavaged with distilled water and wrapped in a towel each day for 6 days prior to 
the testing to familiarize them with the experimental procedures.  After a 12 h fast, each 
rat was wrapped in a towel and the tip of their tail cut and bled.  Rats were orally gavaged 
(8 ml/kg body weight) with 1 of 4 solutions: 1) CHO (22.5% glucose), 2) CHO-AA-1 
(amino acid mixture in 22.5% glucose), 3) CHO-AA-2 (amino acid mixture with 
increased leucine concentration in 22.5% glucose) or 4) PLA (distilled water). The amino 
acid mixture contained 5.28 mg cysteine, 3.36 mg methionine, 6.68 mg valine, 944.8 mg 
isoleucine and 6.68 mg leucine per 50 ml solution.  The leucine concentration was 
increased to 50 mg/50 ml for the CHO-AA-2 treatment.  Blood (0.5 ml) was taken from 
the tail immediately before the gavage and 15, 30, 60 and 120 min after.  Blood was 
collected in one test tube containing EDTA (24 mg/ml, pH 7.4), and 0.1 ml of the EDTA 
blood sample was transferred to another test tube containing 10% perchloric acid (PCA).  
These tubes were stored at -80° C for later analysis.  Immediately after the 120 min blood 
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sample, rats were anesthetized with an intraperitoneal injection of sodium pentobarbital 
(75.0 mg/kg body weight) at which time the red and white gastrocnemius were excised, 
freeze clamped in liquid nitrogen and stored at -80° C for later analysis.  Rats were then 
euthanized by cardiac injection of sodium pentobarbital.          
Exp-2: Following 1 week of acclimation, rats were orally gavaged with distilled 
water and wrapped in a towel each day for 6 days prior to the testing to familiarize them 
with the experimental procedures.  After a 12 h fast the rats were wrapped in a towel and 
the tip of their tail cut for blood sampling as described above.  The rats were then orally 
gavaged (8 ml/kg body weight) with either CHO (22.5% glucose) or CHO-AA-1 (amino 
acid mixture in 22.5% glucose).  The amino acid mixture was described previously in 
Exp-1.  Fifteen min after the gavage, a bolus containing 40 μCi/kg body weight [3H] 2-
deoxyglucose (2-DG) and 20 μCi/kg body weight [U-14C] mannitol was injected by 
syringe via a tail vein.  Blood samples were collected before gavage, and at 2, 10, 20 and 
45 min after the radioactive tracers were infused. Immediately after the 45 min blood 
sample, the rats were anesthetized with an intraperitoneal injection of sodium 
pentobarbital (75.0 mg/kg body weight) at which time the red and white gastrocnemius 
were excised, freeze clamped with tongs cooled in liquid nitrogen and stored at -80° C 
for later analysis.  Rats were then euthanized by cardiac injection of sodium 
pentobarbital.          
Blood analysis.  A drop of blood was used to measure blood glucose with a 
portable glucose analyzer (One Touch Ultra 2; LifeScan Inc., Milpitas, CA).  Before 
using the glucose analyzer several blood samples were measured using the Trinder assay 
(34) to verify its validity and reliability.  The glucose analyzer was calibrated according 
to the manufacturer’s instructions.  EDTA samples were then centrifuged 14,000 x g for 
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10 min at 4° C.  Plasma insulin (Linco, cat. # SRI-13K, St. Charles, MO) was determined 
by a radioimmunoassay kit according to the manufacturer’s instructions.  
Muscle glucose uptake.  Rates of 2-DG uptake were determined in both red and 
white gastrocnemius muscle samples.  Approximately 80-100 mg of muscle were 
dissolved in 1 N potassium hydroxide (KOH) by incubating for 15 min at 65° C, vortexed 
then incubated for an additional 5 min at 65° C.  Next, an equal volume of 1 N 
hydrochloric acid (HCl) was added to the digested samples and vortexed to neutralize the 
samples.  To determine the specific activity of the blood, an aliquot of the PCA extract 
was added to 1 N KOH, then neutralized with an equal volume of 1 N HCL.  A 300 μl 
aliquot of neutralized muscle and blood samples were then added to a vial containing 6 
ml Bio-Safe II counting cocktail (Research Products International, Mount Prospect, IL).  
Duplicate samples were counted in a liquid scintillation counter (Beckman LS 6500, 
Beckman Coulter, Fullerton, CA) preset for simultaneous counting of [3H] and [14C] 
DPM.  Quenching was determined by counting prepared standards.  The accumulation of 
intracellular 2-DG is indicative of muscle glucose uptake.  The specific activity of the 
blood for [3H] and [14C] was determined using the integral of the plasma 2-DG and [U-
14C] mannitol over the 15-60 min per glucose molecule.  The extracellular space was 
calculated using the total muscle 14C DPM and its specific activity.  The intramuscular 
accumulation of 2-DG was calculated by subtracting its extracellular space DPM from its 
total muscle DPM divided by its specific activity.   
Tissue Processing.  Approximately 60 mg of muscle was homogenized (1:9) in 
an ice-cold buffer (pH 7.4) containing 20 mM HEPES, 2 mM EGTA, 50 mM sodium 
fluoride (NaF), 100 mM potassium chloride (KCl), 0.2 mM EDTA, 50 mM 
glycerolphosphate, 1 mM DTT, 0.1 mM PMSF, 1 mM Benzamidine, and 0.5 mM Na 
Vanadate (1 ml/100 mg muscle) with a glass tissue grinder pestle (Corning Life Sciences, 
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Acton, MA). The homogenate was then centrifuged at 14,000 x g for 10 min at 4° C. 
Aliquots of the supernatant were stored at -80° C for later analysis. The protein 
concentration of the homogenate was determined using the Lowry method (18).   
Tissue analysis.  The phosphorylation of protein kinase B (Akt/PKB), mTOR, 
Akt substrate of 160 kDa (AS160) and glycogen synthase (GS) were used as an indirect 
measurement of activity.  Sample protein (100 μg for Akt/PKB, 70 μg mTOR and AS160 
and 60 μg for GS) was combined with an equal amount (1:1) of Laemmli sample buffer 
(125mM tris, 20% glycerol, 2% SDS, 0.008% bromophenol blue, pH 6.8) (16) and boiled 
for 5 min.  Next, sample proteins were subjected to SDS-PAGE and the proteins 
separated on either an 8% (mTOR, AS160) or 12% (Akt/PKB and GS) polyacrylamide 
resolving gel for either 1 h (Akt/PKB) or 1.5 h (mTOR, AS160 and GS).  The resolved 
proteins were then transferred to a polyvinylidene difluoride (PVDF) membrane using a 
semidry transfer unit and blocked in 7% nonfat dry milk in Tris-Tween-buffered saline 
(NFDM/TTTBS) for 1 h at room temperature (RT).  The membranes were then incubated 
with either affinity purified anti-phospho-Akt/PKB (Thr-308) (Cell Signaling 
Technology, Danvers, MA), anti-phospho-mTOR (Ser-2448) (Cell Signaling 
Technology), anti-phospho-AS160 (Thr-642) (Millipore, Billerica, MA) or anti-phospho-
GS (Ser-641) (Cell Signaling Technology) overnight at 4° C.  These phosphorylation 
sites were chosen as an indirect measurement of activity because they represent the 
primary sites of phosphorylation of the respective protein under insulin-stimulated 
conditions.  The primary antibodies were diluted to either 1:500 (phospho-AKT/PKB), 
1:800 (phospho-AS160) or 1:1000 (phospho-mTOR, phospho-GS) in TTBS containing 
1% NFDM.  Following the overnight incubation the membranes were washed for 3, 5-
min washes in TTBS then incubated for either 1 h (Akt/PKB and GS) or 2 h (mTOR, 
AS160) at RT with the species-specific (anti-rabbit) immunoglobulin G (IgG) secondary 
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antibodies (Cell Signaling Technology).  The secondary antibodies were diluted to either 
1:750 (Akt/PKB, AS160), 1:900 (mTOR) or 1;2000 (GS) in TTBS containing 1% 
NFDM.  The membranes were washed with 5, 8-min washes with TTBS and antibody 
binding was visualized by enhanced chemiluminescence in accordance to the 
manufacturer’s instructions (Perkin Elmer, Boston, MA).  Images were captured by using 
a charge-coupled device camera in a ChemiDoc system (BioRad, Hercules, CA) and 
saved to a computer.  Density of the bands were quantified with Quantity One analysis 
software (BioRad) and expressed as a percentage of a standard run on each gel.   
After the phosphorylation status of each protein had been determined, the primary 
phosphorylated-antibody was stripped from the membrane to determine total protein 
concentration.  Membranes were placed in a stripping solution containing 100 mM β-
mercaptoethanol, 2% SDS and 62.5 mM Tris base (pH 6.7) and heated at 60° C for 1 h.  
Membranes were washed for 3, 15-min washes with TTBS to remove the stripping 
solution.  The primary and secondary antibody concentrations, incubation times, washing 
and quantification were the same as those described for the determination of 
phosphorylation status.   
Statistical analysis.  A two-way ANOVA was performed on the blood data 
(treatment x time).  A one-way ANOVA was performed for the muscle tissue analysis.  
When a significant F-ratio was obtained, a Fisher’s Least Significant Difference post hoc 
test was performed to identify statistically significant differences (P < 0.05) between 
means.  All statistical analyses were completed using SPSS software (SPSS Inc., 
Chicago, IL) and all values expressed as means + standard error (SE).   
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RESULTS 
Animal characteristics.  For Exp-1, there were no significant differences in body 
mass among treatment groups (CHO 284.4 + 7.4 g; CHO-AA-1 288 + 3.2 g; CHO-AA-2 
284 + 4.2 g; PLA 286.8 + 5.1 g) on the day of testing.  Likewise, for Exp-2, the body 
mass of the CHO (365.8 + 7.6 g) and CHO-AA-1 (366.3 + 6.6 g) groups were similar on 
the day of testing.    
OGTT glucose and insulin.  For both experiments, glucose and insulin 
concentrations were determined following a 12 h fast and during the OGTT.  For Exp-1, 
there were no significant differences in fasting glucose or insulin levels among treatment 
groups.  There was little change in the blood glucose response for PLA throughout the 
OGTT.  This would indicate no undue stress on the animals.  Blood glucose was 
significantly lower for CHO-AA-1 and CHO-AA-2 compared to CHO at 15, 30 and 60 
min post supplementation (Figure 3.1A).  The glucose area under the curve (AUC) was 
also lower for CHO-AA-1 and CHO-AA-2 compared to CHO (Figure 3.1B).  However, 
there were  no differences in plasma insulin levels between CHO, CHO-AA-1, or CHO-
AA-2 treatment groups at any time point (Figure 3.2A) or for the insulin AUC (Figure 
3.2B).  Both the blood glucose and plasma insulin concentrations were similar for CHO-
AA-1 and CHO-AA-2 at all time points, and for the AUC as well, during Exp-1.  Similar 
to the results of Exp-1, blood glucose levels were significantly reduced for CHO-AA-1 
compared to CHO (Figure 3.3A) with no difference in plasma insulin response (Figure 
3.4A) during Exp-2.  The glucose AUC was lower for CHO-AA-1 compared to CHO 
(Figure 3.3B), but insulin AUC was similar between the two treatments (Figure 3.4B).         
Muscle glucose uptake.  Rates of skeletal muscle 2-DG uptake are shown in 
Figure 3.5.  Glucose uptake in the red gastrocnemius was enhanced for the CHO-AA-1 
compared to the CHO treatment group in Exp-2. A similar response was observed in the 
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white gastrocnemius as glucose uptake was greater for the CHO-AA-1 compared to the 
CHO. 
Protein concentration and phosphorylaiton status of signaling proteins.  The 
phosphorylation status of insulin signaling proteins for Exp-2 was assessed as an indirect 
measurement of their activity level.  Akt/PKB protein concentration and Thr-308 
phosphorylaiton were not different in both the red and white gastrocnemius from CHO 
and CHO-AA-1 treatment groups (Figures 3.6A-B).  Although the protein concentration 
of the red and white gastrocnemius for mTOR did not differ between treatment groups, 
mTOR phosphorylaiton at Ser-2448 was significantly increased for CHO-AA-1 
compared to CHO in the red, but not white muscle (Figures 3.7A-B).  There was no 
difference in GS protein concentration between treatment groups.  Phosphorylation of GS 
at Ser-641 was significantly lower in the red gastrocnemius of CHO-AA-1 compared to 
CHO (Figure 3.8A).  This difference, however, between groups was not noted in the 
white gastrocnemius (Figure 3.8B).  Finally, despite no difference in red and white 
gastrocnemius AS160 protein concentration, AS160 Thr-642 phosphorylation levels were 
significantly greater for CHO-AA-1 than in CHO across the fiber types (Figures 3.9A-B).   
DISCUSSION 
The present study found that the addition of an amino acid mixture to a 
carbohydrate supplement improved glucose tolerance in Sprague Dawley rats.  Using an 
OGTT in Exp-1 we demonstrated that rats co-ingesting a carbohydrate and amino acid 
supplement, compared to receiving carbohydrate alone, lowered the blood glucose 
response to the glucose challenge.  Since insulin is a potent stimulator of blood glucose 
clearance, we measured plasma insulin levels to help explain differences in the blood 
glucose responses.  Although insulin secretion is mainly regulated by the blood glucose 
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level, protein and some amino acids stimulate pancreatic insulin secretion (7, 30, 35).  
Furthermore, the addition of protein or amino acids to a carbohydrate supplement has 
been found to result in a greater insulin response than when either is consumed alone (11, 
24, 35, 36, 39). However, in the present study, the co-ingestion of carbohydrate plus an 
amino mixture did not result in a greater insulin response compared to carbohydrate 
consumed alone.  This may be due to the relatively low amino acid concentration of our 
mixture, or possibly the rate of amino acid entry into the gut.  Regardless, it is unlikely 
that the lower glucose response with the cabohydrate/amino acid mixture was due to 
greater insulin availability. 
In an attempt to elicit a more pronounced effect of the amino acid mixture on 
plasma insulin and blood glucose in the current investigation, we increased the leucine 
concentration of the amino acid mixture.  Leucine is known to stimulate insulin secretion 
in vivo (7).  Moreover, leucine has been shown to increase glucose uptake in C2C12 
myotubes and in isolated soleus muscle (4, 22).  Because these studies demonstrated 
amino acid-stimulated glucose uptake in the absence of insulin, we investigated the 
possibility that a further increase in leucine content within our amino acid mixture could 
initiate a greater blood glucose clearance in vivo.  However, our results show that 
increasing the leucine concentration of the amino acid mixture from 0.13 mg/ml (CHO-
AA-1) to 1 mg/ml (CHO-AA-2) had no further affect on either plasma insulin secretion 
or blood glucose response.  Nishitani et al. (22) incubated isolated soleus muscle in 
medium with a leucine concentration between 0 – 4.0 mM.  The authors reported that 2 
mM leucine concentration was optimal for in vitro muscle glucose uptake, with minimal 
glucose uptake with leucine concentrations less than 2 mM and reduced uptake when 
leucine of more than 2 mM was added to the medium.  The present investigation did not 
test a range of leucine concentrations in vivo in Exp-1.  Rather, we assessed blood 
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glucose response to ingesting an amino acid mixture containing either 1.0 or 7.6 mM 
leucine.  It is difficult to make direct comparisons between in vitro and in vivo results and 
when using a mixture of amino acids as opposed to assessing the effects of just one 
amino acid.  However, it appears that increasing the concentration of leucine in our 
amino acid mixture had no additional affect on the blood glucose or insulin responses to a 
glucose challenge.   
There are several possible explanations for the lower blood glucose response 
during the CHO-AA trial compared to the CHO trial.  During an oral glucose tolerance 
test, the rate of glucose appearance is, in part, controlled by the rate of gastric emptying 
of the glucose, and in this regard, protein has been found to reduce the rate of gastric 
emptying (17).  Therefore one possibility for the lower glucose response during the CHO-
AA trials is a slowed rate of gastric emptying. However, considering the amount of 
protein required to limit gastric emptying, it is highly unlikely that the small amount of 
amino acids provided in our carbohydrate/amino acid supplement would have such an 
effect (19).   
The second possibility for an improved glucose tolerance following ingestion of 
our amino acid mixture is that the amino acids suppressed hepatic glucose output thereby 
lowering the rate of glucose appearance.  Doi et al. (6) demonstrated reduced 
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) 
mRNA expression in isolated hepatocytes incubated with isoleucine under insulin-free 
conditions.  The activity of G6Pase was also reduced under these conditions. This raises 
the possibility that reduced hepatic gluconeogenesis may partially explain why blood 
glucose was lower when our rats were treated with our amino acid mixtures.  Conversely, 
insulin is a strong inhibitor of hepatic glycogenolysis and gluconeogenesis (28) with 
relatively small increases in blood insulin levels capable of completely suppressing 
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hepatic glucose output.  In the present study, plasma insulin reached levels in excess of 
350 pmol/L, and were not significantly different among treatments.  These levels of 
insulin should completely suppress hepatic glucose output and negate any effect our 
amino acid mixtures might have had on limiting hepatic glucose output.  Therefore, it is 
highly unlikely that the differences in blood glucose response for our CHO-AA and CHO 
trials were due to differences in hepatic glucose output.  
A third possibility for the lower blood glucose response during the CHO-AA trials 
is an increase in peripheral glucose uptake.  Skeletal muscle is the predominant peripheral 
tissue for blood glucose clearance (3, 12).  In Exp-2, oral gavage of CHO-AA-1 produced 
greater skeletal muscle glucose uptake in both red and white skeletal muscle compared 
with the administration of CHO alone.  Similar to what we observed in Exp-1, this effect 
did not appear to be the result of enhanced insulin secretion in Exp-2.  Thus, these results 
indicate that amino acids can enhance insulin-stimulated muscle glucose uptake in vivo in 
the presence of insulin.   
Several studies implicate the insulin signaling protein, PI 3-kinase, in amino acid-
stimulated glucose uptake.  Doi et al. (4) used the PI 3-kinase inhibitor wortmannin to 
demonstrate that isoleucine-stimulated glucose uptake in C2C12 myotubes occurred in a 
PI 3-kinase dependent manner.  Using specific inhibitors for both PI 3-kinase and aPKC, 
Nishitani et al. (22) reported that leucine stimulated glucose uptake required both PI 3-
kinase and aPKC activation under insulin-free conditions in vitro.  It was also reported by 
Morifuji et al. (20) that whey protein hydrolysates and dipeptides of branched-chain 
amino acids increased muscle glucose uptake and glycogen storage in vivo and that the 
increase in glycogen storage was directly related to the phosphorylation of downstream 
proteins of PI 3-kinase.  
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In the present investigation we assessed the phosphorylation status of Akt/PKB 
and AS160.  Activation of PI 3-kinase results in the phosphorylation and activation of 
Akt/PKB, and possibly specific aPKCs.  AS160 is a downstream substrate of Akt/PKB, 
and the phosphorylation of AS160 by Akt/PKB inhibits its activity.  It has been proposed 
that an active GTP-bound Rab is needed for GLUT4 translocation, and that AS160 
maintains a Rab protein in its inactive GDP-bound state under basal conditions.  In the 
presence of insulin, AS160 is phosphorylated, allowing the conversion of the Rab protein 
to its activated GTP-bound form, enabling GLUT4 translocation (37).  Interestingly, we 
did not find treatment differences in Akt/PKB protein concentration or its Thr-308 
phosphorylation.  Although insulin is a strong activator of Akt/PKB, this protein is not 
known to be activated by amino acids (9, 26).  Our finding is in agreement with a 
previous report that an amino acid mixture improved glucose tolerance despite no 
increase in Akt/PKB phosphorylation in rats with liver cirrhosis (23).   
Despite no difference in Akt/PKB phosphorylation between treatments, we did 
observe enhanced phosphorylation of AS160 in rats gavaged with CHO-AA-1 compared 
with rats gavaged with CHO only.  Phosphorylation was elevated in both fast-twitch red 
and fast-twitch white muscle fibers.  Since we did not observed a difference in insulin 
concentrations between trials, our findings suggest amino acid-stimulated glucose 
transport is associated with increased AS160 phosphorylation. It is then possible that a 
protein upstream of AS160, besides Akt/PKB, phosphorylates AS160 in the presence of 
amino acids.  Akt/PKB, AMP-activated protein kinase (AMPK) and calcium signaling 
mechanisms have all been shown to activate AS160 (14. 31).  However, only Akt/PKB 
has been implicated in insulin-stimulated glucose uptake, and Doi et al. (5) reported that 
amino acids increase glucose uptake without increases in AMPK activity.  In light of no 
difference in Akt/PKB phosphorylation between the CHO-AA-1 and CHO treated rats, 
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we are unable to suggest a mechanism by which amino acids increase AS160 
phosphorylation.  However, the results of our study and others (9, 26) suggest that 
Akt/PKB is not involved and a link between amino acids and AS160 remains unclear.  
Once glucose enters the cell it is phosphorylated by hexokinase to form glucose-
6-phosphate and rapidly metabolized.  The rapid removal of glucose-6-phosphate is 
essential, as an accumulation of glucose-6-phosphate would result in product inhibition of 
hexokinase, intracellular free glucose accumulation and its counter transport.  In resting 
skeletal muscle, the majority of glucose-6-phosphate is converted to glycogen (38).  The 
rate-limiting enzyme for glycogen synthesis is glycogen synthase, which is activated by 
its dephosphorylation.  
We found that GS phosphorylation was reduced in fast-twitch red muscle of 
CHO-AA-1 treated rats compared with CHO treated rats.  We did not find a significant 
difference in the phosphorylation of GS in fast-twitch white muscle between the CHO-
AA-1 and CHO treated rats.  Interestingly, the phosphorylation pattern of mTOR was 
inversely related to that of GS.  That is, we observed a greater phosphorylation of mTOR 
in fast-twitch red muscle from CHO-AA-1 treated rats compared with CHO treated rats, 
but not in fast-twitch white muscle.   
It is well established that an increase in amino acids, as well as insulin (13) can 
result in the phosphorylation of mTOR.  Findings by Nishitani et al. (22) indicate that 
mTOR is not directly involved in amino acid-stimulated glucose transport.  Similarly, 
Doi et al, (4) reported that isoleucine-stimulated glucose transport was independent of 
activation of mTOR.  However, the ability of amino acids to activate mTOR in the 
presence of insulin (1) could have an additive effect with insulin in activating proteins 
involved in the intracellular disposal of glucose, if not transport.  Activation of mTOR 
normally leads to the phosphorylation and subsequent activation of p70S6K, which in 
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turn can inactivate GSK-3, an upstream inhibitor of GS.  Our observation that GS 
phosphorylation followed an inverse pattern to the phosphorylation of mTOR, therefore, 
suggests that the decreased in GS phosphorylation during the amino acid treatment 
occurred via the mTOR pathway.  This agrees with earlier studies in which it was 
suggested that leucine can activate GS through the PI 3-kinase and mTOR pathways (2, 
26). In addition, the combination of carbohydrate/protein supplementation post exercise 
is associated with an increase in muscle glycogen synthesis, the phosphorylation of 
mTOR and GSK-3 and the dephosphorylation of GS (10, 21, 38).  It therefore appears 
that amino acid-stimulated glucose transport in vivo is tightly coupled with an increase in 
intracellular glucose disposal.    
The present investigation suggests a role for amino acids in improved glucose 
tolerance.  However, some studies report that amino acids may induce insulin resistance 
(15, 27, 29) and it is known that circulating amino acids are increased under insulin 
resistant conditions.  Some potential mechanisms for amino acid-induced insulin 
resistance are decreased glucose transport due to reduced PI 3-kinase activity resulting 
from IRS-1 Ser/Thr phosphorylation by mTOR (15), or breakdown of the IRS-1 
associated PI 3-kinase complex (33).  Possible reasons for differences in results from the 
present investigation and those that report amino acids have no affect or reduce glucose 
tolerance, could be the methods used to administer the amino acids, the specific amino 
acids administered or the amount of amino acids consumed.  For example, Krebs et al. 
(15) and Pisters et al. (27) reported that infusing amino acids in healthy adults 
significantly reduced whole body glucose disposal.  These studies clamped insulin levels 
and continuously infused a 10% amino acid infusate, which is considerably more 
concentrated then the amino acid mixture that was gavaged in the present study.  In a 
similar manner, Tremblay et al. (32) clamped the plasma essential amino acid 
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concentration at 6 mM for 4 h and observed a decrease in glucose tolerance.  
Furthermore, it was reported that concentrations of isoleucine (4) and leucine (22) up to 2 
mM increased muscle glucose uptake in vitro, but that concentrations of 4 mM or greater 
had no effect.  Considering all the results available, it would appear that the effects of 
amino acids on blood glucose regulation and muscle glucose uptake are amino acid-
concentration dependent.   
In conclusion, the present investigation demonstrated a lower blood glucose 
response to a glucose challenge when an amino acid mixture was provided 
simultaneously with the glucose.  The lower glucose response appeared due to a greater 
rate of glucose clearance by skeletal muscle.  This response did not appear to be due to a 
greater insulin secretion, but due to a greater activation of intracellular signaling proteins 
involved in glucose transport and intracellular glucose disposal. The long-term use of a 
carbohydrate and amino acid supplement, and whether it will be useful in the treatment of 
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Figure 3.1.  (A) Exp-1 blood glucose during the OGTT.  Values are means + SE.   *, P < 
0.05 CHO vs. CHO-AA-1; #, P < 0.05 CHO vs. CHO-AA-2; †, P < 0.05 PLA vs. all other 
treatments.  (B) Exp-1 blood glucose AUC during the OGTT.  Values are means + SE. *, 









Figure 3.2.  (A) Exp-1 plasma insulin during the OGTT. Values are means + SE.  †, P < 
0.05 PLA vs. all other treatments.  (B) Exp-1 plasma insulin AUC during the OGTT.  










Figure 3.3.  (A) Exp-2 blood glucose during the OGTT.  Values are means + SE. *, P < 
0.05 CHO vs CHO-AA-1.  (B) Exp-2 blood glucose AUC during the OGTT.  Values are 










Figure 3.4.  (A) Exp-2 plasma insulin during the OGTT.  Values are means + SE.  (B) 









Figure 3.5.  Exp-2 glucose uptake in the red and white gastrocnemius during the OGTT.  


















Figure 3.6. (A) Red gastrocnemius and (B) white gastrocnemius Akt/PKB Thr-308 
phosphorylation and total protein concentration following the OGTT for Exp-2.  Values 









Figure 3.7. (A) Red gastrocnemius and (B) white gastrocnemius mTOR Ser-2448 
phosphorylation and total protein concentration following the OGTT for Exp-2.  Values 









Figure 3.8.  (A) Red gastrocnemius and (B) white gastrocnemius GS Ser-641 
phosphorylation and total protein concentration following the OGTT for Exp-2.  Values 








Figure 3.9.  (A) Red gastrocnemius and (B) white gastrocnemius AS160 Thr-642 
phosphorylation and total protein concentration following the OGTT for Exp-2.  Values 





Chapter IV: An amino acid mixture enhances insulin-stimulated glucose 
uptake and GLUT4 translocation in perfused rodent hindlimb muscle 
 
ABSTRACT 
The purpose of this study was to investigate whether an amino acid mixture 
increases glucose uptake across perfused rodent hindlimb muscle in the presence and 
absence of a submaximal insulin concentration.  Sprague Dawley rats were separated into 
one of four treatment groups: amino acid mixture with submaximal insulin (AA-sINS), 
submaximal insulin (sINS), amino acid mixture with no insulin (AA) or basal (BAS).  
Glucose uptake was greater for both insulin-stimulated treatments compared to the non-
insulin-stimulated treatment groups.  In the presence of insulin, amino acids increased the 
rate of glucose uptake compared to a perfusate with no amino acids, but had no impact on 
uptake in the absence of insulin.  Phosphatidylinositol 3-kinase (PI 3-kinase) activity was 
greater for both insulin-stimulated treatments compared to the non-insulin-stimulated 
treatment groups, but the amino acids had no additional impact on its activity.  However, 
Akt substrate of 160 kDa (AS160) phosphorylation was increased by the amino acids in 
the presence of insulin, but not in the absence of insulin.  Plasma membrane GLUT4 
protein concentration was greater in the rats treated with insulin compared to no insulin in 
the perfusate.  In the presence of insulin, amino acids enhanced GLUT4 translocation to 
the plasma membrane, but had no affect in the absence of insulin.  Collectively, these 
findings suggest that the beneficial effects of an amino acid mixture on skeletal muscle 
glucose uptake, in the presence of a submaximal insulin concentration, are due to an 
increase in AS160 phosphorylation and plasma membrane associated GLUT4 and 




Insulin is the primary regulator of glucose homeostasis.  The concentration of 
blood glucose at any given time is determined by the entry of glucose into the blood from 
the digestive system, its removal by glucose-sensitive tissues and its release from the 
liver.  In the postprandial state, a rise in blood glucose stimulates the release of insulin 
from the pancreas.  Insulin controls blood glucose within a narrow range by 
simultaneously increasing peripheral glucose uptake, primarily by the skeletal muscle, 
and decreasing liver glucose output.  Recently, our laboratory (3, 12) as well as others (5, 
7, 19) have reported that the glucose uptake process can be improved by amino acid 
supplementation.   
Amino acids have recently been reported to increase skeletal muscle glucose 
uptake in vivo (3, 5, 7, 11) and in vitro (5, 12, 18, 19).  Of the amino acids, the branched-
chain amino acids isoleucine and leucine have received the most attention.  Although 
these amino acids have been shown to significantly lower blood glucose, the exact 
mechanism remains elusive.  Using the isolated muscle technique Nishitani et al. (19) 
demonstrated that leucine-induced glucose uptake was significantly decreased when the 
incubation medium included specific inhibitors for either phosphatidylinositol 3-kinase 
(PI 3-kinase) and its downstream target atypical protein kinase C (aPKC) in the absence 
of insulin.  Doi et al. (5) also reported that isoleucine-induced glucose uptake in C2C12 
myotubes was inhibited in the presence of a specific inhibitor of PI 3-kinase.  Although it 
appears that PI 3-kinase is an important signal in amino acid-stimulated glucose uptake, it 
has also been reported that PI 3-kinase activity may be impaired by amino acids (2, 26).  
Therefore, in the presence of amino acids, the activity of PI 3-kinase, and how this kinase 
effects downstream proteins, requires further investigation.   
 67
In a recent report we showed that rats gavaged with an amino acid mixture had an 
improved glucose response to an oral glucose challenge compared to rats gavaged with 
carbohydrate only (3).  In addition we demonstrated that the improved glucose tolerance 
was associated with enhanced Akt substrate of 160 kDa (AS160) phosphorylation and 
increased skeletal muscle glucose uptake (3).  These findings raised the question as to the 
role PI 3-kinase and GLUT4 translocation, critical steps for blood glucose clearance, play 
in the increased glucose uptake.  Furthermore, the in vivo study did not allow us to 
control the release of both carbohydrate and amino acids from the gut, nor could we 
precisely control the insulin levels in order to assess the independent and/or combined 
affect of insulin and the amino acid mixture.  Therefore, in the present investigation, we 
used the hindlimb perfusion technique in order to control the amounts of carbohydrate, 
amino acids and insulin to which the muscle was exposed.  This technique also enabled 
us to observe any alterations that could be attributed to the singular and combined effects 
of insulin and the amino acid mixture.  Thus, the purpose of this investigation was to 
determine if an amino acid mixture increases glucose uptake in the perfused rodent 
hindlimb in the presence and absence of insulin, and if so, to determine if differences in 
glucose uptake were associated with differences in PI 3-kinase activity and GLUT4 
translocation to the plasma membrane.   
MATERIALS AND METHODS 
Animal care and housing.  Twenty-nine male Sprague Dawley rats 
approximately 7 weeks old were obtained from Harlan (Indianapolis, IN).  Upon arrival 
rats were randomly assigned to one of four groups:  amino acid with submaximal insulin 
(AA-sINS, n = 9), submaximal insulin (sINS, n = 7), amino acid with no insulin (AA, n = 
7) or basal (BAS, n = 6).  Rats were housed 2 per cage and provided standard laboratory 
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chow (Prolab RMH 1800 5LL2, LabDiet, Brentwood, MO) and water ad libitum. The 
temperature of the animal room was maintained at 21° C, with an artificial 12:12 h light-
dark cycle.  All experimental procedures were approved by the Institutional Animal Care 
and Use Committee (IACUC) of the University of Texas at Austin and conformed to the 
guidelines for the use of laboratory animals published by the United States Department of 
Health and Human Resources.   
Hindlimb Perfusion.  All animals were tested at approximately 9 weeks old.  
After an overnight fast rats were subjected to the hindlimb perfusion technique.  Details 
for the surgical preparation and hindlimb perfusion technique have been described 
previously (10, 22).  Perfusate flow was directed only to the right hindlimb by 
cannulating the right iliac artery and vein to the tip of the femoral artery of the rat.  After 
the cannulas were in place the rat was euthanized by a cardiac injection (65 mg/kg body 
weight) of sodium pentobarbital.  The cannulas were then placed in line with the 
perfusion system and the right hindlimb was washed out with Krebs-Henseleit buffer (pH 
7.4) containing 2 mM pyruvate at a rate of 6 ml/min.  Following the 10 min washout 
period the arterial line was switched to the perfusate containing 2 mM pyruvate, 6 mM 
glucose, 2 mM mannitol, 0.2 μCi/ml 2-[3H] deoxyglucose (2-DG) and 0.15 μCi/ml 
[14C(U)]-sucrose (14C-sucrose) in Krebs-Henseleit buffer (pH 7.4) with the flow rate set 
at 4 ml/min.  For the insulin-stimulated treatment groups (AA-sINS and sINS), 200 
μU/ml insulin was added to both the washout buffer and perfusion medium.   For the 
amino acid treatment groups (AA-sINS and AA) 2 mM of an amino acid mixture was 
also added to both the washout buffer and perfusate medium.  The amino acid mixture 
was described previously (3) and contained 5.28 mg cysteine, 3.36 mg methionine, 6.68 
mg valine, 944.8 mg isoleucine and 6.68 mg leucine per 50 ml solution.  The perfusions 
were performed at 37° C and continued for a total of 25 minutes, at which time the right 
 69
gastrocnemius was excised, freeze clamped in liquid nitrogen, and stored at −80° C for 
later analysis. 
Muscle glucose uptake.  Rates of 2-DG uptake were determined in mixed 
gastrocnemius muscle samples.  Muscle was weighed and dissolved in 1 N potassium 
hydroxide (KOH) by incubating for 15 min at 65° C.  Samples were then vortexed and 
incubated for an additional 5 min.  An equal volume of 1 N hydrochloric acid (HCl) was 
then added to neutralize the samples.  Next, an aliquot of neutralized muscle sample was 
added to a vial containing 6 ml Bio-Safe II counting cocktail (Research Products 
International, Mount Prospect, IL). Arterial perfusate samples were taken during the 
hindlimb perfusion and treated the same as the muscle homogenate.  Duplicate samples 
were counted in a liquid scintillation counter (Beckman LS 6500, Beckman Coulter, 
Fullerton, CA) preset for simultaneous counting of [3H] and [14C] DPM.  Quenching was 
determined by counting prepared standards.  The accumulation of intramuscular 2-DG 
was indicative of muscle glucose uptake.  Intramuscular 2-DG was calculated by 
subtracting the concentration of 2-DG in the extracellular space from the total muscle 2-
DG concentration.  The extracellular space for each muscle sample was determined by 
measuring the [U-14C] mannitol concentration in the muscle homogenate.   
PI 3-kinase activity.  For IRS-1 associated PI 3-kinase activity, approximately 
150 mg of muscle was homogenized (1:9) in an ice-cold homogenization buffer (pH 7.4) 
containing 20 mM HEPES, 2 mM EGTA, 50 mM sodium fluoride (NaF), 100 mM 
potassium chloride (KCl), 0.2 mM EDTA, 50 mM glycerolphosphate, 1 mM DTT, 0.1 
mM PMSF, 1 mM Benzamidine, and 0.5 mM sodium orthovandate (Na3VO4) with a 
glass tissue grinder pestle (Corning Life Sciences, Acton, MA). The homogenate was 
then centrifuged at 14,000 x g for 10 min at 4° C. Aliquots of the supernatant were stored 
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at -80° C for later analysis. The protein concentration of the homogenate was determined 
using the Lowry method (16). 
One milligram of sample protein was immunoprecipitated with 8 μg of anti-IRS-1 
(Millipore, Billerica, MA) and homogenization buffer overnight at 4° C.  Protein-A 
Sepharose (PRO-A) beads were then prepared by washing once with phosphate triton 
azide (PTA) and twice with homogenization buffer and centrifuged at 14,000 x g for 5 
min at 4° C between each wash.  After the final wash, the packed PRO-A beads were 
resuspended in homogenization buffer at a 1:1 dilution.  One hundred microliters of 
PRO-A slurry was added to the anti-IRS-1 immunoprecipitates for 1.5 h at 4° C with 
rotation.  Following the incubation, samples were centrifuged at 14,000 x g for 10 min at 
4° C.  The immunocomplex was then washed successively with the following: Buffer A 
(10% IGEPAL, 100 mM Na3VO4, 1 M DTT, phosphate buffered saline (PBS)), Buffer B 
(1 M Tris-HCl (pH 7.5), 2 M lithium chloride (LiCl2), 100 mM Na3VO4, 1 M DTT), and 
Buffer C (1 M Tris-HCl (pH 7.5), 5 M sodium chloride (NaCl), 100 mM Na3VO4, 10 mM 
EDTA, 1 M DTT).  Washing was performed once in buffers A and B and twice in buffer 
C.  The packed beads were then diluted 1:1 in a buffer provided in the kit with 1 M DTT, 
10 mM adenosine-5'-triphosphate (ATP) and 100 μM PI(4,5)P2 substrate added to it.  The 
substrate was incubated for 3 h and the product PI(3,4,5)P3 was detected by an ELISA kit 
(catalogue# K1000s, Echelon Biosciences Inc., Salt Lake City, UT).  The amount of 
phosphatidylinositol (3,4,5)-triphosate (PIP3) produced by extracted PI 3-kinase from the 
sample was proportional to the PI 3-kinase activity. 
For the determination of total PI 3-kinase activity, approximately 150 mg of 
mixed gastrocnemius muscle was homogenized (1:9) in ice-cold 0.5 M TCA.  The 
homogenate was then centrifuged at 1,500 rpm for 5 min at 4° C.  The supernatant was 
discarded and the pellet was resuspended in 3 ml of 5% TCA/1 mM EDTA.  The protein 
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concentration was then determined using the Lowry method (16).  One milligram of 
protein was then subjected to the extraction protocol in accordance to the manufacturer’s 
instructions.   The extracted substrate was incubated for 1 h and the product PI(3,4,5)P3 
was detected using an ELISA kit (catalogue# K2500s, Echelon Biosciences Inc.).  The 
amount of PIP3 produced by extracted PI 3-kinase from the sample was proportional to 
the total PI 3-kinase activity.  
AS160 Phosphorylation.  Approximately 150 mg of muscle was homogenized 
and the protein concentration of each sample determined as described above.  Sample 
protein (60 μg) was combined with an equal amount (1:1) of Laemmli sample buffer (125 
mM tris, 20% glycerol, 2% SDS, 0.008% bromophenol blue, pH 6.8) and boiled for 5 
min (14).  Next, samples were subjected to sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and the proteins separated on an 8% resolving gel for 1.5 h.  
The resolved proteins were then transferred to a polyvinylidene difluoride (PVDF) 
membrane using a semidry transfer unit and blocked in 7% nonfat dry milk in Tris-
Tween-buffered saline (NFDM/TTTBS) for 1 h at room temperature.  The membranes 
were then incubated with affinity purified anti-phospho-AS160 (Thr-642) (Millipore, 
Billerica, MA) at 4° C.  Following the overnight incubation the membranes were washed 
for 3, 5-min washes in TTBS then incubated for 2 h at room temperature with the 
species-specific secondary antibody.  The membranes were then washed with 5, 8-min 
washes with TTBS and antibody binding was visualized by enhanced chemiluminescence 
in accordance to the manufacturer’s instructions (Perkin Elmer, Boston, MA).  Images 
were captured by using a charge-coupled device camera in a ChemiDoc system (BioRad, 
Hercules, CA) and saved to a computer.  Density of the bands were quantified with 
Quantity One analysis software (BioRad) and expressed as a percentage of a standard run 
on each gel.   
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After the phosphorylation of AS160 was determined, the primary phosphorylated-
antibody was stripped from the membrane to determine alpha-tubulin protein 
concentration in order to demonstrate equal protein loading across samples.  Membranes 
were placed in a stripping solution containing 100 mM β-mercaptoethanol, 2% SDS and 
62.5 mM Tris base (pH 6.7) and heated at 60° C for 1 h.  Membranes were washed for 3, 
15-min washes with TTBS to remove the stripping solution.  The primary and secondary 
antibody incubation times, washing, exposure and quantification were the same as that 
described for AS160 phosphorylation.   
Plasma membrane fractionation.  The plasma membrane was isolated as 
described previously (15, 23).  Briefly, a portion of the gastrocnemius was homogenized 
in an ice cold buffer (8 x wt/vol) containing 20 mM HEPES (pH 7.2), 2 mM EGTA, 50 
mM β-glycerophosphate, 1 mM DTT, 1 mM Na3VO4, 10% glycerol, 3 mM benzamidine, 
10 μM leupeptin, 5 μM pepstatin A and 1 mM PMSF.  The homogenate was centrifuged 
at 33,000 rpm for 30 min at 4° C and the supernatant was collected as the crude 
homogenate fraction.  The pellet was resuspended in an ice-cold buffer (4 x wt/vol) in 
which 1% Trition X was added.  The resuspended pellet was then centrifuged at 11,000 
rpm for 10 min at 4° C.  The supernatant, representing the plasma membrane fraction, 
was collected.  In order to determine plasma membrane purity the enzymatic activity of 
the membrane marker 5’-nucleotidase in the plasma membrane fraction was compared to 
its activity in the crude homogenate as described previously (24).  The method of Fiske 
and SubbaRow (9) was used for determination of 5’nucleotidase activity.  The specific 
activities and purity indexes for the plasma membrane marker 5’-nucleotidase are 
displayed in Table 4.1.  The protein concentration for the plasma membrane and crude 
homogenate was determined using the Lowry method (16). 
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Plasma membrane GLUT4 protein concentration.  The plasma membrane 
GLUT4 protein concentration was determined from plasma membrane fractions obtained 
from mixed gastrocnemius muscle samples.  Sample protein was subjected to SDS-PAGE 
and the protein was separated on a 12% resolving gel.  Next, the resolved proteins were 
transferred to a PVDF membrane using a semidry transfer unit and blocked in NFDM-
TTBS saline for 1 h at room temperature.  Using a visible molecular weight marker (Bio-
Rad) as a guide the PVDF membranes were cut into an upper and lower membrane 
section.  The upper membrane section was probed with affinity purified anti-sodium-
potassium-ATPase (Na+K+-ATPase) antibody (Santa Cruz Biotechnology, Santa Cruz, 
CA) overnight at 4° C.  The Na+K+-ATPase pump is a ubiquitous plasma membrane 
marker used to demonstrate equal protein loading across samples.  The lower membrane 
section was probed with affinity purified anti-GLUT4 antibody (donated by Dr. Samuel 
Cushman, National Institute of Diabetes and Digestive Kidney Disease, Bethesda, MD) 
overnight at 4° C.  The secondary antibody, incubation times, washing, exposure and 
quantification were similar to that described above.   
Statistical analysis.  A one-way analysis of variance (ANOVA) was performed 
on all data.  When a significant F-ratio was obtained, a Fisher’s Least Significant 
Difference post hoc test was performed to identify statistically significant differences (P 
< 0.05) between means.  A sequential regression analysis was performed to determine the 
relationship between AS160, GLUT4 and muscle glucose uptake.  Statistical analyses 
were completed using SPSS software (SPSS Inc., Chicago, IL) and all values expressed 




Animal characteristics.  There were no significant differences in body mass 
among treatment groups (AA-sINS 293.7 + 6.5 g; sINS 291.4 + 3.1 g; AA 288.1 + 5.7 g; 
BAS 284.8 + 7.4 g) on the day of testing. 
Muscle glucose uptake.  Rates of 2-DG uptake in mixed gastrocnemius muscle 
samples were elevated for the AA-sINS and sINS treatments compared to the AA and 
BAS treatment groups (Figure 4.1).  Furthermore, rates of glucose uptake were greater in 
the AA-sINS treatment group compared to sINS.  However, under non-insulin-stimulated 
conditions, the addition of amino acids to the perfusate had no affect on glucose uptake 
compared to BAS.   
PI 3-kinase activity.  For both IRS-1 associated and total PI 3-kinase, there was 
greater activity for the insulin-stimulated treatments compared to the non-insulin-
stimulated treatment groups.  (Figure 4.2A-B).  However, among the insulin-stimulated 
treatment groups, there was no difference observed between AA-sINS and sINS 
treatment groups.  Similarly, among the non-insulin stimulated treatment groups, there 
was no difference between AA and BAS treatment groups.   
Western blotting.  Insulin-stimulation resulted in a significantly increased AS160 
Thr-642 phosphorylation compared to the non-insulin-stimulated treatment groups 
(Figure 4.3).  Moreover, AS160 phosphorylation was increased in the AA-sINS treatment 
compared to the sINS treatment group.  There was no difference between AA compared 
to BAS treatment groups. 
 Insulin-stimulation resulted in a significant elevation in plasma membrane 
GLUT4 protein concentration compared to the non-insulin-stimulated treatment groups 
(Figure 4.4).  The concentration of GLUT4 at the plasma membrane was also 
significantly greater in the AA-sINS treatment compared to the sINS treatment group.  
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There was, however, no difference in GLUT4 plasma membrane concentration in AA 
compared to BAS treatment groups. 
Using sequential multiple regression analysis, we regressed AS160 and GLUT4 
on skeletal muscle glucose uptake and found that the change in the coefficient of 
determination (ΔR2) due to AS160 was 0.716 and 0.044 for GLUT4 (Figure 4.5).  The 
total variance of glucose uptake explained by the model was 76%. 
DISCUSSION    
The primary objective of the present study was to test the ability of our amino 
acid mixture to increase skeletal muscle glucose uptake in the presence and absence of a 
submaximal insulin-stimulating concentration using the hinblimb perfusion technique.  
To achieve this objective, we compared the effects of perfusing the hindlimb musculature 
with four different experimental treatments, AA-sINS, sINS, AA or basal BAS on 
glucose uptake.  Our study results demonstrated that skeletal muscle glucose uptake 
during the hindlimb perfusion was significantly greater for the AA-sINS treatment 
compared to sINS.  This finding confirms our previous studies reporting that our amino 
acid mixture enhances glucose uptake both in vitro (12) and in vivo (3) in the presence of 
insulin.  We were able expand this in the present investigation by demonstrating that the 
increase in amino acid-stimulated glucose uptake was directly related to an increase in 
AS160 phosphorylation and plasma membrane associated GLUT4 protein concentration.  
We, however, could not confirm our previous data reporting that our amino acid mixture 
increases skeletal muscle glucose uptake in the absence of insulin (12).   
Activation of the insulin receptor results in cellular mechanisms that directly 
mediate the number of glucose transporters translocated to the plasma membrane.  Once 
insulin is bound to its receptor, the insulin receptor phosphorylates tyrosine residues on 
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IRS-1.  In turn, phosphorylated IRS-1 binds and activates PI 3-kinase which then 
catalyzes the conversion of phosphatidylinositol (4,5)-bisiphosate (PIP2) to PIP3.  This is 
a critical step in classical insulin signaling as blocking PI 3-kinase is known to inhibit 
insulin-stimulated glucose uptake.  The subsequent activation of the downstream proteins 
protein kinase B (Akt/PKB), aPKC and AS160 leads to GLUT4 translocation to the 
plasma membrane.  Thus, glucose uptake is a highly coordinated process and is highly 
correlated with the number of GLUT4 transporters located at the plasma membrane (8, 
13, 17).  
In the present investigation we found that insulin had a strong stimulatory effect 
on skeletal muscle glucose uptake.  Submaximal insulin-stimulation resulted in 
approximately a 3 fold difference in glucose uptake compared to the non-insulin-
stimulated conditions.  Furthermore, the combination of amino acids and insulin resulted 
in a 36% increase in glucose uptake compared to insulin alone.  Doi et al, (5) and 
Nishitani et al. (19) also demonstrated a beneficiary impact of amino acids on glucose 
uptake.  Doi et al. (5) reported that glucose uptake was enhanced when isoleucine was 
added to C2C12 myotubes.  But when LY294002, a potent PI 3-kinase inhibitor, was 
added to the same medium, a significant decrease in glucose uptake was observed.  
Furthermore, Nishitani et al. (19) reported that leucine stimulated glucose uptake across 
the isolated soleus muscle preparation but leucine-induced glucose uptake was inhibited 
in the presence of LY294002.  These in vitro studies provide support for the involvement 
of PI 3-kinase in amino acid-stimulated skeletal muscle uptake.  These in vitro studies 
also infer that amino acids induce glucose uptake via PI 3-kinase leading to GLUT4 
translocation.  To the best of our knowledge, there are no previous studies investigating 
the link between amino acids, PI 3-kinase activity, GLUT4 translocation and skeletal 
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muscle glucose uptake. Therefore, in an effort to determine how amino acids increase 
skeletal muscle glucose uptake we first measured PI 3-kinase activity.   
In the present study, both IRS-1 associated and total PI 3-kinase activity were 
significantly increased in the presence of insulin compared to a perfusate with no insulin.  
In fact, there was approximately a 3 fold difference between insulin and non-insulin 
stimulated PI 3-kinase activity, which correlates well with the approximately 3 fold 
difference found with glucose uptake. However, adding the amino acid mixture to the 
perfusate had no further impact on PI 3-kinase activity in the presence and absence of 
insulin, suggesting that amino acid-stimulated glucose uptake is independent of PI 3-
kinase.  A major difference between our current study and the in vitro studies discussed 
above (5, 19) is that we actually measured PI 3-kinase activity, rather than determine the 
necessity of PI 3-kinase in amino acid-stimulated glucose uptake.  Although amino acids 
do not appear to enhance PI 3-kinase activity, it is possible that there is a permissive 
amount of PI 3-kinase activity required for this process.        
The exact role PI 3-kinase plays in amino acid-stimulated glucose uptake has been 
elusive.  In vitro studies using inhibitors to block PI 3-kinase suggest that the protein 
kinase may be involved in this process (5, 19).  But it must be noted that the inhibitor 
used in these studies, LY294002, blocks all classes of PI 3-kinase (27).  Nevertheless, it 
is difficult to ascertain its importance when it has been demonstrated that amino acids 
attenuate the length of time PI 3-kinase is activated (2, 21, 26), suggesting that over time 
glucose uptake would be reduced as well, possibly via an mTOR mediated negative 
feedback mechanism on IRS-1 (26).  Baum et al. (2) reported that rats gavaged with 
either carbohydrate or a carbohydrate plus leucine supplement had similar IRS-1 
associated PI 3-kinase activity 15 min post supplementation.  However, from 30-90 min 
post supplementation, carbohydrate treated rats displayed significantly higher kinase 
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activity compared to carbohydrate plus leucine.  Interestingly, glucose uptake was still 
normal despite the decreased amino acid-induced PI 3-kinase activity suggesting that the 
early activation of the kinase may have been sufficient to initiate glucose uptake (2).  In 
the present investigation, there was no difference in IRS-1 associated or total PI 3-kinase 
activity between sINS and AA-sINS treatment groups perfused for a total of 35 min. 
Because the activity of PI 3-kinase was not enhanced by amino acids, these results 
suggest that PI 3-kinase may only play a permissive role in amino acid-stimulated 
glucose uptake.  In agreement, it has been reported that leucine-stimulated PI 3-kinase 
activity is independent of its association with IRS-1 in L6 muscle cells (21).  Thus, future 
studies investigating alternate proteins linking amino acids to PI 3-kinase and/or different 
classes of PI 3-kinase are warranted.   
In our effort to determine a mechanism for amino acid-induced skeletal muscle 
glucose uptake we next looked at the impact of our amino acid mixture on AS160 
phosphorylation. AS160, a distal signal in the insulin signaling cascade, prevents GLUT4 
translocation.  Once phosphorylated, however, its inhibitory effect on GLUT4 
translocation is removed and GLUT4 is able to move from an intracellular storage pool to 
the plasma membrane.  We previously reported that our amino acid mixture increased 
AS160 phosphorylation in vivo (3) and in vitro (12) and the increase in AS160 
phosphorylation was associated with an amino acid-induced increase in muscle glucose 
uptake.  In agreement, the current investigation found that perfusing our amino acid 
mixture also increased AS160 phosphorylation.  But this affect was only observed in the 
presence of a submaximal insulin concentration, not in the absence of insulin.  Using the 
isolated muscle preparation we previously demonstrated that amino acids increase both 
AS160 phosphorylation and muscle glucose uptake without Akt/PKB activation (12).  
This finding would agree with our current PI 3-kinase data as Akt/PKB is activated by PI 
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3-kinase.  Therefore, this suggests that amino acids increase the phosphorylation of 
AS160 via a mechanism independent of the insulin signaling pathway.   
Using carbon tetrachloride (CCl4) induced liver cirrhotic rats, administration of 
leucine and isoleucine lowered the blood glucose response to an oral glucose challenge, 
increased skeletal muscle glucose uptake and increased plasma membrane associated 
GLUT4 protein concentration compared to control (20).  The positive impact amino acids 
had on glucose homeostasis occurred without differences in insulin secretion.  However, 
amino acid administration could have resulted in in vivo changes that increased the 
effectiveness of insulin and not directly increase GLUT4 translocation.  In the present 
investigation, plasma membrane GLUT4 protein concentration was significantly 
increased when insulin was added to the perfusate.  Furthermore, the number of glucose 
transporters located at the plasma membrane was even greater when the perfusate 
contained both insulin and our amino acid mixture demonstrating amino acids have a 
direct role in regulating GLUT4 translocation.  Enhanced amino acid-stimulated GLUT4 
translocation fits well with our earlier work as we have previously reported our amino 
acid mixture increased AS160 phosphorylation and glucose uptake (3, 12) and adds to the 
data because we are now able to demonstrate a direct link between AS160, GLUT4 and 
glucose uptake.  Using sequential regression analysis we found that the increase in 
GLUT4 translocation could account for approximately 4% of the increase in glucose 
uptake.  While the increase in AS160 could account for approximately 72% of the 
increase in glucose uptake.  This indicates that the amino acid induced increase in AS160 
phosphorylation is responsible for GLUT4 translocation.   
Although we found a strong correlation between AS160, GLUT4 translocation 
and muscle glucose uptake, given what is currently know about insulin signaling, it is 
interesting that the increase in plasma membrane GLUT4 occurred without an increase in 
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IRS-1 associated PI 3-kinase activity.  There are several possibilities that may explain 
this observation.  First of all, the energy sensor 5'-AMP-activated protein kinase (AMPK) 
can also recruit GLUT4 to the plasma membrane.  However, this appears unlikely as it 
has been demonstrated that isoleucine-stimulated glucose uptake is not mediated through 
an AMPK dependent mechanism (6).  Secondly, the mammalian target of rapamycin 
(mTOR) which is activated by amino acids and plays a role in amino acid-stimulated 
protein synthesis (1) is another possibility.  However, this also appears unlikely as several 
studies have shown that blocking mTOR with its specific inhibitor, rapamycin, has no 
impact on amino acid-stimulated glucose uptake (5, 19).  Thirdly, a downstream signal 
from PI 3-kinase, PKC may play a role in the amino acid induced increase in plasma 
membrane GLUT4 protein concentration as it has been reported that the activation of 
PKC may regulate GLUT4 translocation through AS160 (25).  In vitro studies report that 
blocking PKC with its specific inhibitor, GF109203X, results in significantly reduced 
amino acid-stimulated glucose uptake (5, 19).  Therefore, it is possible that amino acids 
activate PKC, in a yet to be determined manner, to enhance GLUT4 translocation.   
Despite the fact perfusing rodent hindlimb muscle with our amino acid mixture 
and insulin significantly increased glucose uptake, we did not observe increased amino 
acid-stimulated glucose uptake in the absence of insulin.  In contrast, using the isolated 
muscle preparation, our laboratory previously demonstrated that our amino acid mixture 
increased glucose uptake across the epitrochlearis muscle in the absence of insulin (12).  
This is in agreement with earlier in vitro studies reporting that leucine (19), isoleucine (5) 
and isoleucine-leucine dipeptides (18) increased glucose uptake independent of insulin.  
Furthermore, in in vivo studies, insulin appears to only play a permissive role in amino-
acid stimulated glucose uptake.  Oral administration of isoleucine significantly lowered 
blood glucose and increased skeletal muscle glucose uptake but did not raise plasma 
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insulin levels compared to rats treated with saline (6, 7).  Consistent with these reports, 
our laboratory found that there was no difference in insulin secretion between rats orally 
gavaged with an amino acid mixture and those gavaged with a carbohydrate supplement, 
but the amino acid mixture resulted in a reduced blood glucose response (3).  
Collectively, these findings suggest that the effects of amino acids on glucose uptake are 
independent of insulin.  In addition, when we added a submaximal and a maximal insulin 
concentration to the isolated muscle incubation medium, we found that the insulin and 
amino acid effects were additive (12).  This would suggest that not only are the effects of 
amino acids on glucose uptake independent of insulin, but also suggests that amino acids 
may act independently from the classical insulin signaling cascade.  
The discrepancy between studies that report a stimulatory effect of amino acids on 
glucose uptake in the absence of insulin, and the present study in which we observed no 
effect, is likely due to the experimental model employed in the respective studies.  For 
example, the fidelity of the hindlimb perfusion technique may not be as good so small 
differences between treatments may be more difficulty to identify.  Those reporting that 
amino acids enhanced glucose uptake in the absence of insulin were in vitro studies and 
performed with cell culture and the isolated muscle preparation.  Both the isolated muscle 
and hindlimb perfusion techniques are widely accepted approaches for metabolic studies, 
and the advantage and disadvantages of each have been extensively review elsewhere (4).  
Nevertheless, blood flow is not a factor for the in vitro isolated muscle preparation.  The 
relatively small and thin soleus (19) and epitroclearis (12) muscles allow excellent 
muscle fiber access to amino acids in solution.  In contrast, the perfusion technique uses 
an intact circulatory system and exposes the entire hindlimb musculature to the different 
experimental treatments.  Insulin is a vasodilator and therefore may influence perfusate 
flow through the capillary beds during hindlimb perfusion.  Thus, we may not have 
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observed increased amino acid-stimulated muscle glucose uptake in the absence of 
insulin because blood flow was shunted to the large blood vessels of the hindlimb and not 
all the muscle capillary beds were open.  In contrast, when a submaximal insulin 
concentration was added to the perfusate, blood flow to the muscle capillary beds was 
improved in a nitric oxide dependent manner, contributing to the significantly greater 
uptake observed in the presence of insulin.  
In summary, our amino acid mixture was found to increase skeletal muscle 
glucose uptake compared to a perfusate with no amino acids in the presence of insulin.  
However, the present study would suggest that insulin is required for the improvement in 
glucose tolerance as a perfusate containing the amino acid mixture, but no insulin, was 
found not to be anymore beneficial compared to BAS.  While the mechanism by which 
amino acids work is not fully understood, our findings demonstrated that amino acid-
stimulated skeletal muscle glucose uptake was not due to increased PI 3-kinase activity.  
Rather, the amino acid induced improvements in glucose tolerance appear due to 
increased AS160 phosphorylation and enhanced GLUT4 translocation to the plasma 
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 AA-sINS sINS AA BAS 
PM 24.0 + 1.7 * 21.1 + 1.5 * 24.0 + 2.1 * 21.7 + 0.7 * 
CR 3.5 + 0.3 3.0 + 0.2 3.4 + 0.4 3.1 + 0.1 
Purity index 7.0 + 0.4 7.1 + 0.5 7.4 + 0.6 7.1 + 0.3 
 
Table 4.1.  5’-nucleotidase activity in the plasma membrane and crude homogenate.  5’-
nucleotidase activity is expressed as μmol/mg protein/min.  Values are means are + SE.  














































Figure 4.1.  Glucose uptake in mixed gastrocnemius samples obtained from rats 
subjected to the hindlimb perfusion technique.  Values are means + SE.  *, P < 0.05 vs 











































































# † # †
 
 
Figure 4.2.  (A) IRS-1 associated PI 3-kinase activity and (B) total PI 3-kinase activity in 
mixed gastrocnemius samples obtained from rats subjected to the hindlimb perfusion 







Figure 4.3.  AS160 Thr-642 phosphorylation in mixed gastrocnemius samples obtained 
from rats subjected to the hindlimb perfusion technique. Values are means + SE.  *, P < 
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Figure 4.4.  Plasma membrane GLUT4 protein concentration in mixed gastrocnemius 
samples obtained from rats subjected to the hindlimb perfusion technique.  AA-sINS, 
perfusate contained 6 mM carbohydrate, 200 μU/ml insulin and a 2 mM amino acid 
mixture; sINS, perfusate contained 6 mM carbohydrate and 200 μU/ml insulin; AA, 
perfusate contained 6 mM carbohydrate and 2 mM amino acid mixture; BAS, perfusate 
contained 6 mM carbohydrate.   Values are means + SE.  *, P < 0.05 vs sINS, #, P < 0.05 











































Figure 4.5.  Relationship between the increase in muscle glucose uptake associated with 










Chapter V: An amino acid mixture improves glucose tolerance and 
lowers insulin resistance in the obese Zucker rat 
 
ABSTRACT 
The purpose of this investigation was to test an amino acid mixture on glucose 
tolerance in obese Zucker rats (experiment [Exp]-1) and determine whether differences in 
blood glucose were associated with alterations in muscle glucose uptake (experiment 
[Exp]-2).  Exp-1 rats were gavaged with either carbohydrate (OB-CHO), carbohydrate 
plus an amino acid mixture (OB-AA-1), carbohydrate plus an amino acid mixture with 
increased leucine concentration (OB-AA-2) or water (OB-PLA).  The glucose response in 
OB-AA-1 and OB-AA-2 were similar, and both were lower compared to OB-CHO.  
There was no difference in insulin among treatment groups.  Rats in Exp-2 were gavaged 
with either carbohydrate (OB-CHO), carbohydrate plus an amino acid mixture (OB-AA-
1) or water (OB-PLA).  Lean Zucker rats were gavaged with carbohydrate (LN-CHO).  
Fifteen minutes after gavage a radiolabeled glucose analogue was infused through a 
catheter previously implanted in the right jugular vein.  Blood glucose was significantly 
lower in OB-AA-1 compared to OB-CHO while the insulin responses were similar.  
Glucose uptake was greater in OB-AA-1 compared with OB-CHO, and similar to that in 
LN-CHO in red gastrocnemius muscle (5.15 + 0.29, 3.8 + 0.27, 5.18 + 0.34 umol/100 g 
/min, respectively).  Western blot analysis showed that Akt substrate of 160 kDa (AS160) 
phosphorylation was enhanced for OB-AA-1 and LN-CHO compared to OB-CHO.  
These findings suggest that an amino acid mixture improves glucose tolerance in an 
insulin resistant model and that these improvements are associated with an increase in 




Type 2 diabetes is a disease that is characterized by severe insulin resistance of 
insulin sensitive tissues such as skeletal muscle, liver and adipose tissue.  When the body 
is presented with a glucose challenge, insulin is released into the general circulation and 
binds to its specific receptor.  The binding of insulin to its plasma membrane receptor 
triggers a series of phosphorylative events which leads to the removal of glucose from the 
circulation via glucose transporter 4 (GLUT4).   Because skeletal muscle is the primary 
site for postprandial glucose disoposal (10, 20), it is therefore, important in regulating 
glucose homeostasis.    
Dietary supplementation has become popular in many populations for improving, 
for example, athletic performance and one’s general well being.  It is often advertised as 
a natural alternative to a pharmacologic based approach.  Thus, dietary supplementation 
is particularly attractive for diabetics and those with insulin resistance as supplementation 
can be used for weight and/or glycemic control.  Recent investigations have focused on 
amino acid supplementation as a means of controlling the postprandial glucose response.  
Of the amino acids, the branched-chain amino acids (BCAAs) have generated much 
research interest as these have been shown to markedly lower blood glucose (11, 12, 27).  
These recent reports demonstrated both leucine and isoleucine to be the most potent of 
the BCAAs in enhancing skeletal muscle glucose uptake.  Thus, the ability of amino acid 
supplementation to lower blood glucose holds great clinical significance for individuals 
with impaired glucose tolerance such as that observed in insulin resistant and diabetic 
states.       
Obese Zucker rats are a widely accepted research model for the study of insulin 
resistance.  These rats are characterized by a genetic disorder that causes them to be 
obese and have impaired insulin resistance.  Obese Zucker rats display severe 
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hyperinsulinemia, glucose intolerance and elevated plasma insulin response to a glucose 
challenge, similar to that observed in insulin resistant human subjects.  Our lab has 
recently shown that an amino acid mixture improves glucose tolerance, both in vivo and 
in vitro, in healthy, non-insulin resistant tissue (5, 22) and this enhancement appears to be 
due, at least in part, to changes in insulin cellular signaling and increased skeletal muscle 
glucose uptake.  However, little is known as to the effect of amino acid supplementation 
in an insulin resistant model.  Therefore, the purpose of this investigation was to 
determine if an amino acid mixture improves glucose tolerance in Obese Zucker rats 
(experiment [Exp]-1), and if so, are alterations in glucose tolerance due to differences in 
skeletal muscle glucose uptake and cell signaling (experiment [Exp]-2).      
MATERIALS AND METHODS 
Animals.  Exp-1: Thirty-five female obese Zucker rats approximately 7 weeks old 
were obtained from Charles River (Wilmington, MA).  The obese Zucker rats were 
randomly assigned to one of four groups:  obese-carbohydrate (OB-CHO, n = 9), obese-
carbohydrate plus a 5 amino acid mixture (OB-AA-1, n = 9), obese-carbohydrate plus a 5 
amino acid mixture with increased leucine concentration (OB-AA-2, n = 9) or obese-
placebo (OB-PLA, n = 8).  Rats were housed individually and provided standard 
laboratory chow (Prolab RMH 1800 5LL2, LabDiet, Brentwood, MO) and water ad 
libitum. The temperature of the animal room was maintained at 21° C, and an artificial 
12:12 h light-dark cycle set.  All experimental procedures were approved by the 
Institutional Animal Care and Use Committee (IACUC) of the University of Texas at 
Austin and conformed to the guidelines for the use of laboratory animals published by the 
United States Department of Health and Human Resources.   
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Exp-2: Eighteen female obese Zucker rats and six lean Zucker rats approximately 
7 weeks old were obtained from Charles River.  The obese Zucker rats were then 
randomly assigned to either obese-carbohydrate (OB-CHO, n = 6), obese-carbohydrate 
plus a 5 amino acid mixture (OB-AA-1, n = 7) or obese-placebo (OB-PLA, n = 5).  Lean 
Zucker rats were assigned to the carbohydrate group (LN-CHO, n = 6).  Rats were 
housed individually and provided standard laboratory chow and water ad libitum as 
described for Exp-1.  Animal care and university approval was similar to that described 
for Exp-1.   
Experimental protocol.  Exp-1: Following 2 weeks of acclimation, rats were 
orally gavaged with distilled water and wrapped in a towel each day for 6 days prior the 
testing to become accustomed to the experimental procedures.  After a 12 h fast each rat 
was wrapped in a towel and the tip of their tail cut and bled prior the oral glucose 
tolerance test (OGTT).  Rats were orally gavaged (8 ml/kg body weight) with 1 of 4 
solutions: 1) OB-CHO (22.5% glucose), OB-AA-1 (amino acid mixture in 22.5% 
glucose), OB-AA-2 (amino acid mixture with increased leucine concentration in 22.5% 
glucose), or OB-PLA (distilled water). The amino acid mixture contained 5.28 mg 
cysteine, 3.36 mg methionine, 6.68 mg valine, 944.8 mg isoleucine and 6.68 mg leucine 
per 50 ml solution.  The leucine concentration was increased to 50 mg/50 ml for the OB-
CHO-AA-2 treatment.  Blood was taken from the tail immediately before the gavage and 
15, 30, 60 and 120 min after.  Immediately after rats were released from the towel wrap 
and returned to their cage until the next blood collection.  Blood was collected in one test 
tube containing ethylenediaminetetraacetic acid (EDTA) (24 mg/ml, pH 7.4) and another 
with 10% perchloric acid (PCA) for later analysis.  Immediately after the 120 min blood 
sample, rats were sacrificed with a cardiac injection of sodium pentobarbital (65 mg/kg 
body weight). 
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Exp-2: Following 2 weeks of acclimatization, rats were orally gavaged with 
distilled water and wrapped in a towel each day for 6 days prior testing to become 
accustomed to the experimental procedures.  Four days before the OGTT rats were 
prepared for surgical implantation of a jugular vein catheter.  Rats were placed under 
isoflurane gas anesthesia in order to perform the jugular vein catheterization.  Briefly, the 
right jugular vein was accessed above the clavicle by making a small incision over the 
ventral thorax.  After removing the surrounding tissue to expose the jugular vein, 
ligatures were placed around the vein and a catheter containing heparinized saline 
inserted into the vein and guided down to the right atrium.  The catheter was then guided 
from the thorax and out a small incision on the head.  To ensure that the catheter was in 
the proper position a small amount of blood was drawn, flushed and heparinized saline 
stored in the catheter to prevent clotting.  The incision sites over the thorax and head 
were then sutured and the catheter was sealed with a silicone patch to prevent backflow 
of the stored heparinized saline.  A small strip of Velcro with a hole was sutured over the 
incision behind the head.  The catheter was then threaded through the Velcro and the 
remaining catheter was coiled and placed between 2 Velcro strips for protection (2).  
Each morning leading up to the experimental day the rats had their catheter 
flushed to maintain catheter patency and gavaged with saline to familiarize them with the 
OGTT procedure.  Four days post surgery, and following a 12 h fast rats were wrapped in 
a towel and the tip of their tail cut and bled as discussed in the above section.  The rats 
were then orally gavaged (8 ml/kg body weight) with either 22.5% glucose (OB-CHO 
and LN-PLA), an amino acid mixture in 22.5% glucose (OB-AA-1) or distilled water 
(OB-PLA).  The amino acid mixture was described previously in Exp-1.  Fifteen min 
after the gavage, a bolus containing 40 μCi/kg body weight [3H] 2-deoxyglucose (2-DG) 
and 20 μCi/kg body weight [U-14C] mannitol was injected by syringe via the jugular 
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catheter.  The tail was bled and blood collected as describe above at 2, 10, 20 and 45 min 
after the radioactive tracers were infused for later analysis.  Immediately after the 45 min 
blood sample, corresponding to 60 min after gavage, the rats were anesthetized with an 
intraperitoneal injection of sodium pentobarbital (75 mg/kg body weight) at which time 
the red and white gastrocnemius were excised, freeze clamped in liquid nitrogen and 
stored at -80° C for later analysis.  Rats were then euthanized by cardiac injection of 
sodium pentobarbital.          
Blood analysis.  A drop of blood was used to measure blood glucose with a 
portable glucose analyzer (One Touch Ultra 2; LifeScan Inc., Milpitas, CA).  EDTA 
samples were then centrifuged 14,000 x g for 10 min at 4° C and the plasma insulin 
determined by a radioimmunoassay kit according to the manufactures instructions (Linco, 
St. Charles, MO).  
Muscle glucose uptake.  Rates of 2-DG uptake were determined in both red and 
white gastrocnemius muscle samples.  Approximately 80-100 mg of muscle were 
dissolved in 1 N potassium hydroxide (KOH) by incubating for 15 min at 65° C, vortexed 
then incubated for an additional 5 min at 65° C.  Next, an equal volume of 1 N 
hydrochloric acid (HCl) was added to the digested samples and vortexed to neutralize the 
samples.  To determine the specific activity of the blood, an aliquot of the PCA extract 
was added to 1 N KOH, then neutralized with an equal volume of 1 N HCL.  A 300 μl 
aliquot of neutralized muscle and blood samples were then added to a vial containing 6 
ml Bio-Safe II counting cocktail (Research Products International, Mount Prospect, IL).  
Duplicate samples were counted in a liquid scintillation counter (Beckman LS 6500, 
Beckman Coulter, Fullerton, CA) preset for simultaneous counting of [3H] and [14C] 
DPM.  Quenching was determined by counting prepared standards.  The accumulation of 
intracellular 2-DG was indicative of muscle glucose uptake.  The specific activity of the 
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blood for [3H] and [14C] was determined using the integral of the plasma 2-DG and [U-
14C] mannitol over the 15-60 min per glucose molecule.  The extracellular space was 
calculated using the total muscle 14C DPM and its specific activity.  The intramuscular 
accumulation of 2-DG was calculated by subtracting its extracellular space DPM from its 
total muscle DPM divided by its specific activity.   
Tissue processing.  Approximately 60 mg of muscle was homogenized (1:9) in 
an ice-cold buffer (pH 7.4) containing 20 mM 4-(2-hydroxyethyl) piperazine-1-
ethanesulfonic acid (HEPES), 2 mM ethylene glycol tetraacetic acid (EGTA), 50 mM 
sodium fluoride (NaF), 100 mM potassium chloride (KCl), 0.2 mM EDTA, 50 mM 
glycerolphosphate, 1 mM DL-Dithiothreitol (DTT), 0.1 mM phenylmethanesulphonyl 
fluoride (PMSF), 1 mM Benzamidine, and 0.5 mM sodium Vanadate (1 ml/100 mg 
muscle) with a glass tissue grinder pestle (Corning Life Sciences, Acton, MA). The 
homogenate was then centrifuged at 14,000 x g for 10 min at 4° C. Thereafter aliquots of 
the supernatant were stored at -80° C for later analysis. The protein concentration of the 
homogenate was determined using the Lowry method (26).   
Western blotting.  The phosphorylation of protein kinase B (Akt/PKB), mTOR, 
Akt substrate of 160 kDa (AS160) and glycogen synthase (GS) were used as an indirect 
measurement of activity.  Sample protein (100 μg for Akt/PKB, 70 μg mTOR and AS160 
and 60 μg for GS) was combined with an equal amount (1:1) of Laemmli sample buffer 
(125mM tris, 20% glycerol, 2% sodium dodecyl sulfate (SDS), 0.008% bromophenol 
blue, pH 6.8) (23) and boiled for 5 min.  Next, sample proteins were subject to sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and the proteins 
separated on either an 8% (mTOR and AS160) or 12% polyacrylamide (Akt/PKB and 
GS) resolving gel for either 1 h (Akt/PKB) or 1.5 h (mTOR, AS160 and GS).  The 
resolved proteins were then transferred to a polyvinylidene difluoride (PVDF) membrane 
 100
using a semidry transfer unit and blocked in 7% nonfat dry milk in Tris-Tween-buffered 
saline (NFDM/TTTBS) for 1 h at room temperature.  The membranes were then 
incubated with either affinity purified anti-phospho-Akt/PKB (Thr-308) (Cell Signaling 
Technology, Danvers, MA), anti-phospho-mTOR (Ser-2448) (Cell Signaling 
Technology), anti-phospho-AS160 (Thr-642) (Millipore, Billerica, MA) or anti-phospho-
GS (Ser-641) (Cell Signaling Technology) overnight at 4° C.  These phosphorylation 
sites were chosen as an indirect measurement of activity because they represent the 
primary sites of phosphorylation of the respective protein under insulin-stimulated 
conditions (15, 32, 33, 35).  The primary antibodies were diluted to either 1:500 
(phospho-Akt/PKB), 1:800 (phospho-AS160) or 1:1000 (phospho-mTOR and phospho-
GS) in TTBS containing 2% NFDM.  Following the overnight incubation the membranes 
were washed for 3, 5-min washes in TTBS then re-blocked in 7% NFDM for an 
additional 15 min.  Next, membranes were washed in TTBS and then incubated for either 
1 h (Akt/PKB and GS) or 2 h (mTOR and AS160) at room temperature with the species-
specific (anti-rabbit) immunoglobulin G (IgG) secondary antibodies (Cell Signaling 
Technology).  The secondary antibodies were diluted to either 1:750 (Akt/PKB and 
AS160), 1:900 (mTOR) or 1;2000 (GS) in TTBS containing 2% NFDM.  The membranes 
were washed for 5, 8-min washes with TTBS and antibody binding was visualized by 
enhanced chemiluminescence in accordance to the manufacture’s instructions (Perkin 
Elmer, Boston, MA).  Images were captured by using a charge-coupled device camera in 
a ChemiDoc system (BioRad, Hercules, CA) and saved to a computer.  Density of the 
bands quantified with Quantity One analysis software (BioRad) and expressed as a 
percentage of a standard run on each gel.   
After the phosphorylation status of each protein had been determined, the primary 
phospho-antibody was stripped from the membrane to determine the total protein 
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concentration.  Membranes were placed in a stripping solution containing 100 mM β-
mercaptoethanol, 2% SDS and 62.5 mM Tris base (pH 6.7) and heated at 60° C for 1 h.  
Membranes were washed for 3, 15-min washes with TTBS to remove the stripping 
solution.  The primary and secondary antibody concentrations, incubation times, washing 
and quantification were the same as that described for the determination of 
phosphorylation status.   
Statistics.  A two-way analysis of variance (ANOVA) was performed on the 
blood data (treatment x time).  A one-way ANOVA was performed for the muscle tissue 
analysis.  When a significant F-ratio was obtained, a Fisher’s Least Significant Difference 
(LSD) post hoc test was performed to identify statistically significant differences (P < 
0.05) between means.  All statistical analyses were completed using SPSS software 
(SPSS Inc., Chicago, IL) and all values expressed as means + standard error (SE).   
RESULTS 
Animal characteristics.  For Exp-1, there were no significant differences in body 
mass among treatment groups (OB-CHO 336.6 + 9.3; OB-AA-1 344.9 + 6.5; OB-AA-2 
338.2 + 8.7; OB-PLA 333.5 + 10.0) on the day of testing.  For Exp-2, there was no 
difference in  body mass between the obese Zucker rat treatment groups (OB-CHO 338.7 
+ 5 g; OB-AA-1 340.3 + 13.2 g; OB-PLA 329 + 15.9 g) on the day of testing.  However, 
the lean Zucker rats were significantly smaller (185 + 6.9 g) than all obese Zucker 
treatment groups.   
OGTT glucose and insulin.  For both experiments, glucose and insulin 
concentrations were determined following a 12 h fast and during the OGTT.  For Exp-1, 
there were no significant differences in fasting glucose or insulin levels among treatment 
groups.  There was little change in the blood glucose response for OB-PLA throughout 
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the OGTT during Exp-1.  This would indicate no undue stress on the animals throughout 
the OGTT.  In Exp-1, blood glucose was significantly lower for OB-AA-1 and OB-AA-2 
compared to OB-CHO at 15, 30, 60 and 120 min post supplementation (Figure 5.1A).  
The glucose area under the curve (AUC) was also lower for both the low and high amino 
acid treatments compared to carbohydrate alone in the obese Zucker rats (Figure 5.1B).  
Although there were no statistically significant differences in plasma insulin at any time 
point between OB-CHO, OB-AA-1 or OB-AA-2 (Figure 5.2A), both amino acid 
treatment groups had a greater insulin AUC compared to the carbohydrate only treatment 
(Figure 5.2B).   
For Exp-2, there was no difference in fasting blood glucose levels among the 
obese treatment groups (Figure 5.3A).  However, the fasting blood glucose of the lean 
rats was significantly lower compared to each obese treatment group.  The blood glucose 
response for OB-PLA was crucial to this study as this measurement indicated that the rats 
were properly familiarized and had recovered from the surgical procedure.  The small 
increase in blood glucose measured for OB-PLA was similar to the changes observed in 
the initial studies, suggesting that the rats had recovered from surgery and were not 
stressed by the OGTT procedure.  The blood glucose response for LN-CHO was 
significantly lower compared to OB-CHO and OB-AA-1 at all time points post 
supplementation.  Blood glucose was also significantly reduced for OB-AA-1 compared 
to OB-CHO at 27, 37, 47 and 60 min.  The glucose AUC displayed a similar trend (figure 
5.3B).  OB-PLA was lower than all other treatment groups, and the glucose AUC was 
reduced in LN-CHO compared to the obese Zucker rat treatment groups.  In addition, the 
glucose AUC was significantly lower in OB-AA-1 compared to OB-CHO.   
There was no difference in fasting plasma insulin between the obese rat 
treatments in Exp-2 (Figure 5.4A).  However, fasting insulin was significantly lower in 
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the lean rats compared to obese rats.  The insulin for LN-CHO was lower than all obese 
treatments at each time point during the OGTT.  OB-PLA, which was gavaged with 
distilled water, had little change in insulin over the 60 min OGTT, and their insulin was 
significantly lower than OB-CHO and OB-AA-1 at all time points.  There was no 
difference in plasma insulin detected between OB-CHO and OB-AA-1 at 0, 17, 27, 47 or 
60 min.  When the insulin AUC was calculated there was no difference between OB-
CHO and OB-AA-1 (figure 5.4B).  The insulin AUC was significantly lower for LN-
CHO compared to OB-CHO and OB-AA-1, but not different from OB-PLA. 
Muscle glucose uptake.  Rates of skeletal muscle 2-DG uptake for Exp-2 are 
shown in Figure 5.5A-B.  Glucose uptake was significantly increased in all treatment 
groups compared to OB-PLA in the red gastrocnemius.  Glucose uptake for OB-AA-1 
and LN-CHO treatment groups were significantly increased compared to OB-CHO in the 
red gastrocnemius.  Similar to that observed in the red muscle, glucose uptake was 
increased for all treatment groups compared to OB-PLA in the white gastrocnemius.  
However, there were no differences detected for rates of glucose uptake between OB-
CHO, OB-AA-1 and LN-CHO treatment groups in the white gastrocnemius.     
Protein concentration and phosphorylaiton status of signaling proteins.  
There was no difference between treatment groups in the total protein concentration for 
Akt/PKB, mTOR, GS or AS160 detected following acute supplementation in either the 
red or white gastrocnemius in Exp-2.  The phosphorylation status for these proteins were 
then assessed as an indirect measurement of activity.  There was also no difference 
between treatment groups for the phosphorylation of Akt/PKB (Figure 5.6A-B), mTOR 
(Figure 5.7A-B), or GS (Figure 5.8A-B) in both red and white gastrocnemius.  However, 
treatment difference did exist in the red gastrocnemius for AS160 phosphorylation 
(Figure 5.9A).  AS160 phosphorylation was significantly increased in OB-AA-1 
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compared to OB-CHO, and was similar to that in LN-CHO.  While all treatment groups 
were significantly elevated above OB-PLA.  In the white gastrocnemius, there was no 
difference in AS160 phosphorylation between, OB-CHO, OB-AA-1 and LN-CHO, but 
each was increased compared to OB-PLA (Figure 5.9B)        
DISCUSSION 
The primary finding of the present investigation was that our amino acid mixture 
consisting of isoleucine, leucine, cysteine, methionine and valine improved glucose 
tolerance in insulin resistant obese Zucker rats on an acute basis.  This affect does not 
appear to be due to an elevated plasma insulin concentration.  Rather, the improved 
glucose tolerance appears due to increased skeletal muscle glucose uptake and enhanced 
AS160 phosphorylation.  Previously, our laboratory reported that the addition of an 
amino acid mixture significantly lowered the blood glucose response to an oral glucose 
challenge in Sprague Dawley rats.  Using the radioactive glucose analogue 2-DG we then 
determined that the attenuated glucose response was due to enhanced skeletal muscle 
glucose clearance with no differences in the plasma insulin response between amino acid 
and carbohydrate treatment groups (5).  Thus, the present investigation adds to what we 
previously reported in healthy, non-insulin resistant tissue, and demonstrates that the 
enhanced amino acid induced glucose uptake can be applied to an insulin resistant model 
as well.   
Insulin is the primary regulator of glucose uptake during the postabsorptive state.  
In general, the greater the insulin response, the greater insulin stimulated glucose uptake.  
Therefore, ways to increase the insulin response have been investigated as a mean to 
increase the amount of glucose cleared by the muscle.  Ingesting carbohydrates elicit 
rapid insulin secretion from the pancreas, however, co-ingesting carbohydrate with 
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proteins and/or amino acids has been shown to further elevate the increase insulin 
response (18, 29, 38, 39, 41).  The branched-chain amino acid leucine in particular is 
known to stimulate in vivo insulin secretion (16, 18).  With this in mind, for Exp-1, we 
increased the leucine concentration of the amino acid mixture from 0.13 mg/ml to 1 
mg/ml.  Despite increasing the leucine concentration of the amino acid mixture we did 
not observe a further increase in plasma insulin, nor did we observe an additional affect 
of the added leucine on blood glucose levels.  Therefore, we proceeded to use the amino 
acid mixture containing the low leucine concentration for our second experiment.  
Possible reasons we were unable to elicit a greater insulin response by adding more 
leucine to the amino acid mixture could be due to the relatively low amount of leucine in 
the mixture, the rate amino acids were released into the gut or possibly because the 
insulin levels were already in excess in the obese Zucker rat.  These findings are similar 
to what we reported previously in healthy non-insulin resistant tissue (5) and suggest that 
the lower blood glucose response to the carbohydrate plus amino acid mixture was not 
due to increased insulin secretion for the amino acid treatment groups. 
Although we are unable to completely rule out the involvement of insulin for 
amino acid-stimulated glucose uptake using our in vivo model, it does appear that insulin 
does not play a significant role in this process.  It is noteworthy that the primary 
ingredient of our amino acid mixture is the BCAA isoleucine, which has been shown to 
increase glucose uptake in vivo without a synergistic increase in insulin secretion in rats 
(11) and in human subjects (30).  Lowered blood glucose response with amino acids, 
then, if not due to increased insulin concentrations, may be associated with improved 
intracellular signaling.  Using the specific inhibitors for phosphatidylinositol 3-kinase (PI 
3-kinase) and mTOR, Doi et al. (11) reported that isoleucine increased glucose uptake in 
C2C12 myotubes via a PI 3-kinase dependent and mTOR independent mechanism.  In 
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agreement, using an isolated soleus preparation, Nishitani et al. (27) found that leucnine-
stimulated glucose uptake occurred via a PI 3-kinase and protein kinase C (PKC) 
dependent mechanism, and mTOR was not involved in this process.  Collectively, these 
studies would suggest that amino acids improve intracellular signaling through the PI 3-
kinase pathway, resulting in increased GLUT4 translocation to the plasma membrane and 
increased glucose removed by skeletal muscle.  Thus, it has been demonstrated, in rats 
with liver cirrhosis, that both leucine and isoleucine increase skeletal muscle glucose 
uptake by increasing GLUT4 translocation to the plasma membrane (28).   
Our previous investigation using Sprague Dawley rats found that the amino acid 
mixture stimulated muscle glucose uptake by enhancing intracellular signaling, 
specifically at GS and AS160 (5).  It is noteworthy that our amino acid mixture decreased 
the glucose response to a carbohydrate load in a model in which blood glucose clearance 
was already optimal.  Therefore, we wanted to investigate whether the amino acid 
mixture had a similar affect in an insulin resistant model, and if so, would the 
mechanisms for improvement be the same.     
We first sought to determine the effect of insulin resistance on glucose uptake and 
the associated insulin signaling proteins.  We found that the glucose uptake in the obese 
treatment group was reduced by 36% across the red gastrocnemius compared to the lean 
Zucker rats when treated with the carbohydrate supplement.  This is in agreement with 
previous reports, and the insulin resistance of obese Zucker rats is believed due to a 
combination of insulin receptor and post receptor defects (6, 7, 8, 9, 34).  In the present 
investigation the amino acid mixture resulted in a 35% increase in glucose uptake in 
obese Zucker rats compared to obese Zuckers treated with carbohydrate only.  
Interestingly, we observed a similar increase in skeletal muscle glucose uptake for both 
the LN-CHO and OB-AA, suggesting that the amino acid mixture was able to restore 
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glucose disposal in the insulin resistant rats, although it required a much greater insulin 
response.  We did not, however, observed differences in the total protein expression 
between lean and obese Zucker rats for Akt, mTOR, GS or AS160.  Thus, the reduced 
glucose uptake in the obese Zucker rats does not appear due to reduced total protein 
expression of these specific insulin signaling proteins (4, 19).   
We also did not observe differences in the phosphorylaiton status between lean 
and obese Zucker rats for Akt, mTOR, or GS when treated with carbohydrate or the 
amino acid mixture.  We did, however, find that the amino acid mixture significantly 
increased red gastrocnemius AS160 phosphorylation compared to OB-CHO.  The 
phosphorylation and subsequent inhibition of AS160 by Akt/PKB is a critical step in 
GLUT4 translocation to the plasma membrane.  Under basal conditions AS160 maintains 
a Rab protein in its inactive GDP-bound state.  Upon insulin stimulation, AS160 is 
phosphorylated, allowing the conversion of the Rab protein to its activated GTP-bound 
form, enabling GLUT4 translocation and tissue glucose uptake (40).  Thus, not being able 
to attribute the increase in AS160 phosphorylation to increased Akt/PKB phosphorylation 
is noteworthy, but in agreement with our findings in Sprague Dawley rats (5, 22).  In our 
previous study testing the amino acid mixture in Sprague Dawley rats we reported a 61% 
increase in AS160 phosphorylation for rats gavaged with the amino acid mixture 
compared to carbohydrate alone (5).  Nevertheless, the 37% increase in amino acid-
stimulated AS160 phosphorylation translated to a 35% increase in glucose uptake in the 
present investigation, and the 61% increase in AS160 phosphorylation in Sprague 
Dawley rats resulted in a 59% increase in glucose uptake.  The reasons why there was 
less of an affect of the amino acid mixture in obese Zuckers relative to Sprague Dawley 
rats is not clear, but it is likely related to the muscular and/or systemic effects of insulin 
resistance.   
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It is noteworthy that we did not observe a difference in glucose uptake between 
lean and obese Zucker rats treated with carbohydrate in the white gastrocnemius, 
suggesting that the white muscle was not insulin resistance.  However, the glucose uptake 
in the white muscle was very low in both the obese and lean Zuckers relative to that 
observed in red muscle.  The average glucose uptake in the white gastrocnemius for OB-
CHO, OB-AA-1 and LN-CHO was 0.387 μmol/100 g/min compared to 4.72 μmol/100 
g/min, respectively, in the red gastrocnemius.  Therefore, rates of glucose uptake in white 
muscle were approximately 1/12th of that seen in red muscle.  Some possible reasons for 
this is that white muscle is more glycolytic, has fewer capillaries surrounding the muscle 
fiber (30), and has significantly less GLUT4 (3, 17, 22) compared to the more oxidative 
red muscle.  As a result of these fiber type differences, it would be expected that there be 
reduced blood flow, insulin-stimulation and glucose uptake in the white gastrocnemius.  
Thus, it is also possible that the very low glucose uptake in the white muscle prevented us 
from detecting differences in uptake between OB-CHO, OB-AA-1 and LN-CHO.   
Despite the positive results obtained in the present investigation using the amino 
acid mixture, some studies suggest that amino acid supplementation actually contributes 
to insulin resistance.  It has been reported that circulating amino acids are elevated in 
obese individuals (13, 14) and that diets high in protein are associated with impaired 
glucose metabolism (24, 25).  Thus, several studies propose that amino acids attenuate 
glucose uptake via a negative feedback mechanism through mTOR (36, 37).  
Accordingly, elevated amino acids activate the mTOR/p70 pathway which then inhibit PI 
3-kinase through serine phosphorylation of insulin receptor substrate-1 (IRS-1) leading to 
skeletal muscle insulin resistance (36).  Amino acids, especially the BCAA leucine, is a 
strong activator of mTOR signaling.  However, isoleucine is not believed to activate 
mTOR (1).  Since the predominate ingredient of our amino acid mixture is isoleucine, 
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rather than leucine, this may help explain the discrepancy among studies.  Although 
leucine has been shown to increase glucose uptake it is feasible that relatively low 
concentrations of leucine are beneficial for glucose metabolism while high concentrations 
of leucine may impair this process (27).  Nevertheless, future studies exploring the dose 
and temporal response relationship of leucine and glucose uptake are warranted.            
In conclusion we demonstrated that an amino acid mixture enhanced skeletal 
muscle glucose uptake in obese Zucker rats during an oral glucose challenge.  The effects 
of the amino acid mixture appear to be independent of insulin and due, at least in part, to 
increased AS160 phosphorylation.  These finding suggest that the acute ingestion of an 
amino acid mixture consisting predominately of isoleucine can improve insulin 
resistance.  However, further research is needed to determine the long term affects of 
amino acid supplementation on insulin resistance and whether the positive results found 
in the present investigation translates to humans and those with more severe insulin 
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Figure 5.1.  (A) Exp-1 blood glucose during the OGTT.  Values are means + SE. *, P < 
0.05 OB-CHO vs. OB-AA-1; #, P < 0.05 OB-CHO vs. OB-AA-2; †, P < 0.05 OB-PLA 
vs. all other treatments.  (B) Exp-1 blood glucose AUC during the OGTT.  Values are 




Figure 5.2.  (A) Exp-1 plasma insulin during the OGTT. Values are means + SE.  †; P < 
0.05 OB-PLA vs. all other treatments.  (B) Exp-1 plasma insulin AUC during the OGTT. 




Figure 5.3.  (A) Exp-2 blood glucose during the OGTT.  Values are means + SE. *, P < 
0.05 OB-CHO vs. OB-AA-1; #, P < 0.05 OB-CHO vs. LN-CHO; §, OB-AA-1 vs. LN-
CHO; †, P < 0.05 OB-PLA vs. all other treatments.  (B) Exp-2 blood glucose AUC during 
the OGTT in Zucker rats.  Values are means + SE. *, P < 0.05 vs. OB-CHO; #, vs. OB-






Figure 5.4.  (A) Exp-2 Plasma insulin during the OGTT in Zucker rats. Values are means 
+ SE. *, P < 0.05 OB-CHO vs. OB-AA-1; #, P < 0.05 OB-CHO vs. LN-CHO; §, OB-AA-
1 vs. LN-CHO; ×, P < 0.05 OB-PLA vs LN-CHO †, P < 0.05 OB-PLA vs. all other 
treatments.  (B) Exp-2 plasma insulin during the OGTT in Zucker rats.  Values are means 
+ SE. *, P < 0.05 vs. OB-CHO; #, vs. OB-AA-1 †, P < 0.05 OB-PLA. 
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Figure 5.5.  Exp-2 glucose uptake in the (A) red gastrocnemius and (B) white 
gastrocnemius during the OGTT in Zucker rats.  Values are means + SE.  *, P < 0.05 vs. 








Figure 5.6.  Exp-2 Akt Thr-308 phosphorylation following the OGTT in Zucker rats 
from the (A) red gastrocnemius and (B) white gastrocnemius muscles.  Values are means 







Figure 5.7.  Exp-2 mTOR Ser-2448 phosphorylation following the OGTT in Zucker rats 
from the (A) red gastrocnemius and (B) white gastrocnemius muscles.  Values are means 








Figure 5.8.  Exp-2 glycogen synthase Ser-641 phosphorylation following the OGTT in 
Zucker rats from the (A) red gastrocnemius and (B) white gastrocnemius muscles.  







Figure 5.9. Exp-2 AS160 Thr-642 phosphorylation following the OGTT in Zucker rats 
from the (A) red gastrocnemius and (B) white gastrocnemius muscles.  Values are means 





Chapter VI: Detailed Materials Methods 
 
EXPERIMENTAL ANIMALS AND ANIMAL CARE 
Sprague Dawley and Zucker rats were obtained for the completion of these series 
of studies.  The Sprague Dawley rats were chosen because they are one of the most 
commonly used outbred rat strains in medical research.  These are considered very 
general rats, known for there ease of handling and a homogenous genetic background that 
yields consistent results.  Zucker rats were selected because these rats are the most 
commonly used rodent model for obesity and insulin resistance research.  The obese and 
their lean Zucker littermates are a substrain rat species characterized by a defective leptin 
receptor in the brain. Leptin is a molecule that binds to specific receptors in the 
hypothalamus and controls satiety.  Under normal conditions, such as in the lean Zucker 
rat leptin will bind to its receptor causing the rat to feel full and stop eating.  In contrast, 
obese Zucker rats have defective leptin receptors in which leptin cannot bind to its 
receptor leading to the rat continuously eating because it does no feel full.  The excess 
caloric intake leads to the rapid development of obesity and insulin resistance.   
Upon arrival at the University of Texas Animal Resource Center (ARC) rats were 
transported to the Bellmont Hall Animal Facility.  Rats were housed individually and 
provided standard laboratory chow (Prolab RMH 1800 5LL2, LabDiet, Brentwood, MO) 
and water ad libitum. The temperature of the animal room was maintained at 21° C and an 
artificial 12:12 h light-dark cycle was set.  A reverse light cycle was used so rats would 
be tested during the dark cycle, which corresponds to their most active time.  All 
experimental procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) of the University of Texas at Austin and conformed to the 
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guidelines for the use of laboratory animals published by the United States Department of 
Health and Human Resources. 
Study 1 Experimental Design.  For Study 1 Experiment-1 (Exp-1), 24 male 
Sprague Dawley rats approximately 7 weeks old were obtained from Harlan 
(Indianapolis, IN).  Rats were randomly assigned to 1 of 4 groups:  carbohydrate (CHO, n 
= 6), carbohydrate plus a 5-amino acid mixture (CHO-AA-1, n = 6), carbohydrate plus a 
5-amino acid mixture with increased leucine concentration (CHO-AA-2, n = 6) or 
placebo (PLA, n = 6).  These rats were used for the 2 h oral glucose tolerance test 
(OGTT).  A second group of rats, 12 male Sprague Dawley rats approximately 12 weeks 
old were obtained from the ARC for Study 1 Exp-2.  These rats were used for the 
determination of glucose uptake and for tissue analysis.  The rats were randomly assigned 
to either carbohydrate (CHO, n = 6) or carbohydrate plus a 5-amino acid mixture (CHO-
AA-1, n = 6).  Following 1 week of acclimation, all rats were orally gavaged with 
distilled water and wrapped in a towel each day for 6 days prior to the testing to 
familiarize them with the experimental procedures.   
Study 2 Experimental Design.  For Study 3, 29 male Sprague Dawley rats 
approximately 7 weeks old were obtained from Harlan.  Upon arrival rats were randomly 
assigned to 1 of 4 groups:  amino acid with submaximal insulin (AA-sINS, n = 9), 
submaximal insulin (sINS, n = 7), amino acid with no insulin (AA, n = 7) or basal (BAS, 
n = 6).  Following 1 week of acclimation, all rats were handled daily to familiarize them 
with the experimental procedures.  
Study 3 Experimental Design.  For Study 2 Exp-1, 35 female obese Zucker rats 
approximately 7 weeks old were obtained from Charles River (Wilmington, MA).  The 
obese Zucker rats were randomly assigned to 1 of 4 groups:  obese-carbohydrate (OB-
CHO, n = 9), obese-carbohydrate plus a 5 amino acid mixture (OB-AA-1, n = 9), obese-
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carbohydrate plus a 5 amino acid mixture with increased leucine concentration (OB-AA-
2, n = 9) or obese-placebo (OB-PLA, n = 8).  These rats were used for the 2 h OGTT.  A 
second group of rats, 18 female obese and 6 lean Zucker rats approximately 7 weeks old 
were obtained from Charles River for Study 2 Exp-2.  These rats were used for the 
determination of glucose uptake and for tissue analysis.  The rats were randomly assigned 
to either obese-carbohydrate (OB-CHO, n = 6), obese-carbohydrate plus a 5 amino acid 
mixture (OB-AA-1, n = 7) or obese-placebo (OB-PLA, n = 5).  Lean Zucker rats were 
assigned to the carbohydrate group (LN-CHO, n = 6).  Following 1 week of acclimation, 
all rats were orally gavaged with distilled water and wrapped in a towel each day for 6 
days prior to the testing to familiarize them with the experimental procedures.    
ORAL GLUCOSE TOLERANCE TEST 
An oral glucose tolerance test (OGTT) was performed on rats for both Study 1 
and Study 3.  For the Sprague Dawley rats in Study 1 Exp-1, following the 
familiarization period and after a 12 h fast, each rat was wrapped in a towel and the tip of 
their tail cut and bled.  Rats were orally gavaged (8 ml/kg body weight) with 1 of 4 
solutions: 1) CHO (22.5% glucose), 2) CHO-AA-1 (amino acid mixture in 22.5% 
glucose), 3) CHO-AA-2 (amino acid mixture with increased leucine concentration in 
22.5% glucose) or 4) PLA (distilled water).  For the obese Zucker rats in Study 2 Exp-1 
following the familiarization period and after a 12 h fast, each rat was wrapped in a towel 
and the tip of their tail cut and bled.  Rats were orally gavaged (8 ml/kg body weight) 
with 1 of 4 solutions: 1) OB-CHO (22.5% glucose), 2) OB-CHO-AA-1 (amino acid 
mixture in 22.5% glucose), 3) OB-CHO-AA-2 (amino acid mixture with increased 
leucine concentration in 22.5% glucose) or 4) OB-PLA (distilled water).   
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The amino acid mixture and OGTT used in Exp-1 was similar for Study 1 and 
Study 3.  The amino acid mixture contained 5.28 mg cysteine, 3.36 mg methionine, 6.68 
mg valine, 944.8 mg isoleucine and 6.68 mg leucine per 50 ml solution.  The leucine 
concentration was increased to 50 mg/50 ml for the CHO-AA-2 treatment.  Blood (0.5 
ml) was taken from the tail immediately before the gavage and 15, 30, 60 and 120 min 
after.  Blood was collected in one test tube containing EDTA (24 mg/ml, pH 7.4), and 0.1 
ml of the EDTA blood sample was transferred to another test tube containing 10% 
perchloric acid (PCA).  These tubes were stored at -80° C for later analysis.  Immediately 
after the 120 min blood sample, rats were anesthetized with an intraperitoneal injection of 
sodium pentobarbital (75.0 mg/kg body weight) at which time the red and white 
gastrocnemius were excised, freeze clamped in liquid nitrogen and stored at -80° C for 
later analysis.  Rats were then euthanized by cardiac injection of sodium pentobarbital 
(65 mg/kg body weight).          
For Study 1 and Study 2 Exp-2, an OGTT was performed once again but with 
some modifications which allowed for the determination of skeletal muscle glucose 
uptake.  For the Sprague Dawley rats in Study 1 Exp-1, following the familiarization 
period and after a 12 h fast, each rat was wrapped in a towel and the tip of their tail cut 
and bled.  The rats were then orally gavaged (8 ml/kg body weight) with either CHO 
(22.5% glucose) or CHO-AA-1 (amino acid mixture in 22.5% glucose).  The amino acid 
mixture was described previously in Exp-1.  Fifteen min after the gavage, a bolus 
containing 40 μCi/kg body weight [3H] 2-deoxyglucose (2-DG) and 20 μCi/kg body 
weight [U-14C] mannitol was injected.  Blood samples were collected before gavage, and 
at 2, 10, 20 and 45 min after the radioactive tracers were infused. Immediately after the 
45 min blood sample, corresponding to 60 min after gavage, the rats were anesthetized 
with an intraperitoneal injection of sodium pentobarbital (75 mg/kg body weight) at 
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which time the red and white gastrocnemius were excised, freeze clamped with tongs 
cooled in liquid nitrogen and stored at -80° C for later analysis.  Rats were then 
euthanized by cardiac injection of sodium pentobarbital (65 mg/kg body weight).              
JUGULAR VEIN CATHETERIZATION 
For the obese and leans Zucker rats in Study 3 Exp-2, all rats had a jugular vein 
catheter surgically implanted four days before the OGTT.  Rats were placed on a heating 
pad covered with an underpad and subjected to isoflurane gas anesthesia for 
approximately 45 minutes in order to perform the jugular vein catheterization.  The 
isoflurane (1.5%) was delivered from a vaporizer set at 1 L/min via a nose cone.  The 
right jugular vein was accessed just above the clavicle.  The hair over this site was first 
removed with hair clippers and cleaned with iodine.  A small incision was made over the 
ventral thorax and immediately over the jugular vein.  The vein was then cleared from the 
surrounding tissue until a small section of the vein could be visualized.  A silk ligature 
was secured to the cranial portion of the vein to prevent blood flow going to the heart.  
Next, a small incision was made in the vein just distal to the cranial ligature.  A 6 in thin 
walled catheter containing heparinized saline was carefully inserted into the vein and 
guided about 2 cm as to not enter the right atrium.  A silk ligature was then tied around 
the inserted catheter to secure it in place.  Next, the hair on the head and between the ears 
of the rat was removed with hair clippers, and cleaned with iodine, where a small incision 
was made.  A hemostat was used to make a subcutaneous tunnel leading from the incision 
on the head to that over the thorax.  The hemostat was then used to grasp the catheter and 
guide it back through the incision on the head of the rat.  To ensure that the catheter was 
in the proper position a small amount of blood was drawn, flushed and heparinized saline 
stored in the catheter to prevent clotting.  The incision sites over the thorax and head 
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were then sutured, providing both internal and external protection for the catheter.  A 
small amount of Neosporin was applied along the surgery site during closure of the 
incisions to prevent infection.  The catheter was sealed with a silicone patch and super 
glue.  In order to prevent the rat from accessing the catheter a small strip of Velcro with a 
hole in it was sutured over the incision behind the head.  The catheter was then threaded 
through the Velcro and the remaining 3-4 inches of the catheter coiled and placed 
between 2 Velcro strips (1). The rat was then removed from the isoflurane gas anesthesia, 
returned to a clean cage and placed on a heating pad.  The rat remained under the 
supervision of the surgeon for approximately 30 min, or until it was able to right itself 
and move about its cage.  After the rat had recovered from the anesthesia, post operative 
pain was controlled with a subcutaneous injection of carprofen (5 mg/kg body weight).   
Each morning leading up to the experimental day the rats had their catheter 
flushed to maintain catheter patency and gavaged with saline to familiarize them with the 
OGTT procedure.  Four days post surgery, and following a 12 hour fast, the rats were 
subjected to an OGTT.  The rats were then orally gavaged (8 ml/kg body weight) with 
either 22.5% glucose (OB-CHO and LN-PLA), an amino acid mixture in 22.5% glucose 
(OB-AA-1) or distilled water (OB-PLA).  The amino acid mixture was described 
previously in Exp-1.  Fifteen min after the gavage, a bolus containing 40 μCi/kg body 
weight [3H] 2-deoxyglucose (2-DG) and 20 μCi/kg body weight [U-14C] mannitol was 
injected by syringe via the jugular vein catheter.  The tail was bled and blood collected as 
describe above at 2, 10, 20 and 45 min after the radioactive tracers were infused for later 
analysis.  Immediately after the 45 min blood sample, the rats were anesthetized with an 
intraperitoneal injection of sodium pentobarbital (75 mg/kg body weight) at which time 
the red and white gastrocnemius were excised, freeze clamped in liquid nitrogen and 
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stored at -80° C for later analysis.  Rats were then euthanized by cardiac injection of 
sodium pentobarbital (65 mg/kg body weight).              
PERFUSATE PREPARATION 
All perfusates for the hindlimb perfusion technique consisted of 6% bovine serum 
albumin (BSA) in KHB.  First, a 23% BSA solution was made in KHB.  The dissolved 
BSA was then sealed in dialysis tubing and allowed to dialyze for 48 h in 15 L KHB at 4° 
C.  After 48 h the BSA concentration was check using a refractometer and the appropriate 
volume of KHB added to bring the BSA concentration to 8%.  The BSA was filtered two 
times through fiberglass filter paper using a vacuum pump.  The BSA concentration was 
checked again with a refractometer and then adjusted to 6% (pH 7.4).  The 6% BSA 
solution was separated into 2 parts for the washout and perfusate.  The washout contained 
2 mM pyruvte as a cellular energy source.  The perfusate contained 2 mM pyruvate, 6 
mM glucose, 2 mM mannitol, 0.2 μCi/ml 2-[3H] deoxyglucose (2-DG) and 0.15 μCi/ml 
[14C(U)]-sucrose (14C-sucrose).  For the insulin-stimulated treatment groups (AA-sINS 
and sINS) 200 μU/ml insulin was added to both the washout buffer and the perfusate.   
For the amino acid treatment groups (AA-sINS and AA) 2 mM of an amino acid mixture 
was also added to both the washout buffer and the perfusate.  The amino acid mixture 
contained 5.28 mg cysteine, 3.36 mg methionine, 6.68 mg valine, 944.8 mg isoleucine 
and 6.68 mg leucine per 50 ml solution.   
HINDLIMB PERFUSION  
For Study 2, rats were subjected to the hindlimb perfusion technique.  The 
purpose of the surgical preparation for this technique is to direct perfusate flow to the 
iliac artery, through the capillary bed of the hindlimb and out of the abdominal section of 
the inferior vena cava.  This was done by ligating all the major vessels branching from 
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the abdominal aorta and vena cava, except for the common iliac artery, iliac vein and the 
great vessels. Only the right hindblimb was perfused during the equilibrium and tracing 
periods.  Following a 12 h fast, rats were anesthetized with an intraperitoneal injection of 
sodium pentobarbital (75 mg/kg body weight).  Rats were then placed on a heating pad 
covered with an underpad in order to maintain normal body temperature and circulation 
throughout the surgery.  A ligature was first tied around the tail.  A midline abdominal 
incision was then made through the skin and abdominal wall from the pubic symphysis to 
the ziphoid process.  The superficial epigastric arteries leading the skin were exposed by 
retracting the skin, the vessels then ligated with sutures.  The stomach, spleen, pancreas 
and intestinal tract were removed from the abdominal cavity and wrapped in parafilm 
allowing access to the inferior vena cava and descending aorta.  The hypogastric arteries 
on the inside of the abdominal wall were then ligated.  The bladder, testis and inferior 
mesenteric arteries were also ligated.  The descending colon was ligated just inferior to 
the transvers colon and just superior to the rectum, then excised.  Using dampened gauze, 
adipose tissue and any remaining fascia in the abdominal cavity anterior to the aorta and 
vena cava was removed.  The iliolumbar arteries and veins and pubic-epigastric truck 
were also ligated. 
Ligatures were then placed loosely around the aorta and vena cava inferior to the 
renal vessels and around the vena cava superior to the iliolumbar vessels.  A  igature was 
placed around the left iliac artery and tightened to prevent perfusate flow to the left 
hindlimb.  The ligature around the descending aorta was tightly secured and a small 
incision was made.  A polyethylene catheter was inserted and threaded to the tip of the 
femoral artery.  Saline solution was pushed through the catheter from a 10 ml syringe.  
The superior ligature around the inferior vena cava was then tightened causing the vessel 
to distend.  The venous catheter was then inserted and positioned below the distal 
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ligature.  The distal ligature was then tied in order to secure the catheter.  Approximately 
10 ml of saline was pushed through the arterial catheter, flushing the right hindlimb and 
to prevent clotting.  During the infusion of saline solution the rat was euthanized with an 
intracardiac injection of sodium pentobarbital (65 mg/kg body weight).  After the 
infusion the catheters were placed in line with the hindlimb perfusion apparatus.  The 
right hindlimb was washed out with Krebs-Henseleit buffer (KHB) at a flow rate of 6 
ml/min.  Following the 10 min washout period the arterial line was switch to the 
perfusate and set at a flow rate of 4 ml/min.  The perfusions were performed at 37° C and 
continued for a total of 25 minutes, at which time the right gastrocnemius excised, freeze 
clamped in liquid nitrogen, and stored at - 80°C for later analysis.      
The perfusion system consisted of an arterial reservoir, roller pump, lung, water 
jacket, bubble trap and effluent reservoir enclosed in a Plexiglas chamber accessible from 
the front.  The perfusate was mixed continuously on a magnetic stir plate.  The perfusate 
was drawn from the arterial reservoir and passed through a roller pump.  The perfusate 
then passed through an artificial lung and gassed with a mixture of 95% O2 and 5% CO2.  
The perfusate then passed through a heated water jacket maintained at 37° C, and then 
through a bubble trap before entering the hindlimb of the rat via the arterial catheter. The 
bubble trap was equipped with a manometer to measure the arterial pressure.  After 
circulating through the right hindlimb, the perfusate exited through the venous catheter 
and dripped into the effluent reservoir.   
MUSCLE GLUCOSE UPTAKE 
Rates of 2-DG uptake were determined in both red and white gastrocnemius 
muscle samples for Study 1 Exp-2 and Study 3 Exp-2 and in mixed gastrocnemius 
muscle samples in Study 2.  2-DG is a non-metabolized glucose analogue that has similar 
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rates of removal from the blood into the muscle tissue as glucose under a physiological 
range of insulin concentrations.  The amount of tracer contained within the extracellular 
space was determined by the amount of 14C mannitol (14C sucrose for Study 3) retained in 
the tissue.  Mannitol and sucrose are sugars that are not transported by glucose 
transporters and therefore occupy only the extracellular space.  Approximately 80-100 
mg of muscle were dissolved in 1 ml of 1 N potassium hydroxide (KOH) by incubating 
for 15 min at 65° C, vortexed then incubated for an additional 5 min at the same 
temperature.  Next, an equal volume of 1 N hydrochloric acid (HCl) was added to the 
digested samples and vortexed to neutralize the samples.  To determine the specific 
activity of the blood, a 200 μl aliquot of the PCA extract was added to 1 ml of 1 N KOH, 
then neutralized with an equal volume of 1 N HCL.  A 300 μl aliquot of neutralized 
muscle and blood samples were then added to a vial containing 6 ml Bio-Safe II counting 
cocktail (Research Products International, Mount Prospect, IL).  Duplicate samples were 
counted in a liquid scintillation counter (Beckman LS 6500, Beckman Coulter, Fullerton, 
CA) preset for simultaneous counting of [3H] and [14C] DPM.  Quenching was 
determined by counting prepared standards.  The accumulation of intracellular 2-DG was 
indicative of muscle glucose uptake.  For Study 1 Exp-2 and Study 3 Exp-2, the specific 
activity of the blood for [3H] and [14C] was determined using the integral of the plasma 2-
DG and [U-14C] mannitol over the 15-60 min per glucose molecule.  The specific activity 
of the perfusate for [3H] and [14C] in Study 2 was determined by calculating the perfusate 
2-DG and [U-14C] mannitol per glucose molecule.  The extracellular space was calculated 
using the total muscle 14C DPM and its specific activity.  The intramuscular accumulation 
of 2-DG was calculated by subtracting its extracellular space DPM from its total muscle 
DPM divided by its specific activity.   
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BLOOD ANALYSIS 
 A drop of blood was used to measure blood glucose with a portable glucose 
analyzer (One Touch Ultra 2; LifeScan Inc., Milpitas, CA).  The system was calibrated 
according to the manufacturer’s instructions.  A drop of blood was placed on a reading 
strip inserted into the glucose analyzer.  The reliability and validity of the system was 
verified using the Trinder assay (5). 
Spun down EDTA samples were used for the determination of plasma insulin.  .  
Plasma insulin was determined by a radioimmunoassay kit (Linco, St. Charles, MO) 
using a double antibody procedure.  The 125I-labeled insulin was added to tubes 
containing plasma samples, standards and quality controls.  Rat insulin antiserum was 
then added to these tubes and incubated overnight at 4° C during which time the 125I-
labeled and unlabeled insulin competed for antibody binding.  This antibody-antigen 
complex was then precipitated by the addition of a carrier and an antibody to the carrier.  
The bound and free 125I-labeled insulin was separated by centrifugation.  Standards were 
used to construct a standard curve and samples were plotted on this curve.   
WESTERN BLOT ANALYSIS 
Approximately 150 mg of muscle was homogenized (1:9) in an ice-cold buffer 
(pH 7.4) containing 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), 2 mM ethylene glycol tetraacetic acid (EGTA), 50 mM sodium fluoride (NaF), 
100 mM potassium chloride (KCl), 0.2 mM ethylenediaminetetraacetic acid (EDTA), 50 
mM glycerolphosphate, 1 mM dithiothreitol (DTT), 0.1 mM phenylmethylsulfonyl 
fluoride (PMSF), 1 mM Benzamidine, and 0.5 mM sodium Vanadate (Na3VO4) with a 
glass tissue grinder pestle (Corning Life Sciences, Acton, MA). The homogenate was 
then centrifuged at 14,000 x g for 10 min at 4° C. Aliquots of the supernatant were stored 
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at -80° C for later analysis. The protein concentration of the homogenate was determined 
using the Lowry method (4). 
The phosphorylation of protein kinase B (Akt/PKB), mammalian target of 
rapamycin (mTOR), Akt substrate of 160 kDa (AS160) and glycogen synthase (GS) were 
used as an indirect measurement of activity for Study 1 Exp-2, Study 2 and Study 3 Exp-
2.  Sample protein (100 μg for Akt/PKB, 70 μg mTOR, AS160 and 60 μg for GS) was 
combined with an equal amount (1:1) of Laemmli sample buffer (125 mM Tris, 20% 
glycerol, 2% sodium dodecyl sulfate (SDS), 0.008% bromophenol blue, pH 6.8) (3) and 
boiled for 5 min.  Next, sample proteins were subjected to sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and the proteins separated on either an 
8% (mTOR and AS160) or 12% (Akt/PKB and GS) polyacrylamide resolving gel for 
either 1 h (Akt/PKB) or 1.5 h (mTOR, AS160 and GS).  The resolved proteins were then 
transferred to a polyvinylidene difluoride (PVDF) membrane using a semidry transfer 
unit and blocked in 7% nonfat dry milk in Tris-Tween-buffered saline (NFDM/TTTBS) 
for 1 h at room temperature.  The membranes were then incubated with either affinity 
purified anti-phospho-Akt/PKB (Thr-308) (Cell Signaling Technology, Danvers, MA), 
anti-phospho-mTOR (Ser-2448) (Cell Signaling Technology), anti-phospho-AS160 (Thr-
642) (Millipore, Billerica, MA) or anti-phospho-GS (Ser-641) (Cell Signaling 
Technology) overnight at 4° C.  These phosphorylation sites were chosen as an indirect 
measurement of activity because they represent the primary sites of phosphorylation of 
the respective protein under insulin-stimulated conditions.  The primary antibodies were 
diluted to either 1:500 (phospho-Akt/PKB), 1:800 (phospho-AS160) or 1:1000 (phospho-
mTOR and phospho-GS) in TTBS containing 2% NFDM.  Following the overnight 
incubation the membranes were washed for 3, 5-min washes in TTBS then incubated for 
either 1 h (Akt/PKB and GS) or 2 h (mTOR and AS160) at room temperature with the 
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species-specific (anti-rabbit) immunoglobulin G (IgG) secondary antibodies (Cell 
Signaling Technology).  The secondary antibodies were diluted to either 1:750 (Akt/PKB 
and AS160), 1:900 (mTOR) or 1;2000 (GS) in TTBS containing 2% NFDM.  The 
membranes were washed with 5, 8-min washes with TTBS and antibody binding was 
visualized by enhanced chemiluminescence (ECL) in accordance to the manufacturer’s 
instructions (Perkin Elmer, Boston, MA).  Images were captured by using a charge-
coupled device camera in a ChemiDoc system (BioRad, Hercules, CA) and saved to a 
computer.  Density of the bands were quantified with Quantity One analysis software 
(BioRad) and expressed as a percentage of a standard run on each gel.   
After the phosphorylation status of each protein had been determined, the primary 
phosphorylated-antibody was stripped from the membrane to determine either the total 
protein concentration or alpha-tubulin to confirm that an equal amount of protein was 
loaded onto each gel.  Membranes were placed in a stripping solution (100 mM β-
mercaptoethanol, 2% SDS and 62.5 mM Tris base (pH 6.7)) and heated at 60° C for 1 h.  
Membranes were washed for 3, 15-min washes with TTBS to remove the stripping 
solution.  The primary and secondary antibody concentrations, incubation times, washing 
and quantification were the same as those described for the determination of 
phosphorylation status.   
PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY 
Both the insulin receptor substrate-1 (IRS-1) associated and total 
phosphatidylinositol 3-kinase (PI 3-kinase) activity was determined in mixed 
gastrocnemius muscle obtained from Study 2 using an enzyme-linked immunosorbent 
assay (ELISA) kit.  For IRS-1 associated PI 3-kinase activity, approximately 150 mg of 
muscle was homogenized (1:9) in an ice-cold homogenization buffer as described above.  
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Aliquots of the supernatant were stored at -80° C for later analysis. The protein 
concentration of the homogenate was determined using the Lowry method (4). 
One milligram of sample protein were immunoprecipitated with 8 μg of anti-IRS-
1 (Millipore, Billerica, MA) and homogenization buffer overnight at 4° C.  Protein-A 
Sepharose (PRO-A) beads were then prepared by washing once with phosphate triton 
azide (PTA) and twice with homogenization buffer and centrifuged at 14,000 x g for 5 
min at 4° C between each wash.  After the final wash, the packed PRO-A beads were 
resuspended in homogenization buffer at a 1:1 dilution.  One hundred microliters of 
PRO-A slurry was added to the anti-IRS-1 immunoprecipitates for 1.5 h at 4° C with 
rotation.  Following the incubation, samples were centrifuged at 14,000 x g for 10 min at 
4° C.  The immunocomplex was then washed successively with the following: Buffer A 
(10% octylphenoxypolyethoxyethanol (IGEPAL), 100 mM Na3VO4, 1 M DTT, 
phosphate buffered saline (PBS)), Buffer B (1 mol/L Tris-HCl (pH 7.5), 2 M lithium 
chloride (LiCl2), 100 mM Na3VO4, 1 M DTT), and Buffer C (1 M Tris-HCl (pH 7.5), 5 
M sodium chloride (NaCl), 100 mM Na3VO4, 10 mM EDTA, 1 M DTT).  Washing was 
performed once in buffers A and B and twice in buffer C.  The packed beads were then 
diluted 1:1 in 5 x KBZ buffer (provided in kit), 1 M DTT, 10 mM adenosine-5'-
triphosphate (ATP) and 100 μM PI(4,5)P2 substrate.  The substrate was incubated for 4 h 
and the product PI(3,4,5)P3 and was detected by an ELISA kit (catalogue# K1000s, 
Echelon Biosciences Inc., Salt Lake City, UT).  The amount of phosphatidylinositol 
(3,4,5)-triphosate (PIP3) produced by extracted PI 3-kinase from the sample was 
proportional to the PI 3-kinase activity. 
For the determination of total PI 3-kinase activity approximately 150 mg of mixed 
gastrocnemius muscle was homogenized (1:9) in an ice-cold 0.5 M TCA.  The 
homogenate was then centrifuged at 1,500 rpm for 5min at 4° C.  The supernatant was 
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discarded and the pellet was resuspended in 3 ml of 5% TCA/1 mM EDTA.  The protein 
concentration was then determined using the Lowry method (4).  One milligram of 
protein was then subjected to the extraction protocol in accordance to the manufacturer’s 
instructions.   The extracted substrate was incubated for 1 h and the product PI(3,4,5)P3 
was detected by an ELISA kit (catalogue# K2500s, Echelon Biosciences Inc.).  The 
amount of PIP3 produced by extracted PI 3-kinase from the sample was proportional to 
the total PI 3-kinase activity.  
PLASMA MEMBRANE GLUCOSE TRANSPORTER 4 PROTEIN CONCENTRATION 
The plasma membrane glucose transporter 4 (GLUT4) protein concentration was 
determined in mixed gastrocnemius muscle samples obtained from Study 2.  
Approximately 150 mg of muscle sample was homogenized in an ice cold buffer (8 x 
wt/vol) containing 20 mM HEPES (pH 7.2), 2 mM EGTA, 50 mM β-glycerophosphate, 1 
mM DTT, 1 mM Na3VO4, 10% glycerol, 3 mM benzamidine, 10 μM leupeptin, 5 μM 
pepstatin A and 1 mM PMSF.  The homogenate was centrifuged at 33,000 rpm for 30 
min at 4° C and the supernatant was collected as the cytosolic fraction.  The pellet was 
resuspended in an ice-cold buffer (4 x wt/vol) in which 1% Trition X was added.  The 
resuspended pellet was then centrifuged at 11,000 rpm for 10 min at 4° C.  The 
supernatant, representing the plasma membrane, was collected.   
To ensure that purified plasma membrane fractions were being used for analysis 
the enzymatic activity of the plasma membrane marker 5’-nucleotidase in the plasma 
membrane was compared to its activity in the cytosolic fraction according to the 
manufactures instructions based on the method developed by Fiske and SubbaRow (2).  
Ten microliters of the plasma membrane or cytosolic fractions were added to 200 ul of a 
reaction cocktail containing 0.5 M glycine, 0.01 M magnesium chloride (MgCl2) and 
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0.005 M adenosime monophosphate (AMP).  The reaction was run for 45 min at which 
time 400 μl of 8% trichloroacetic acid (TCA) was used to stop the reaction.  Samples 
were then centrifuged at 2500 rpm for 10 min and 200 μl of the supernatant was aliquoted 
to a test tube containing acid molybdate and water.  The tubes were mixed by gently 
vortexing and then 25 μl of Fiske SubbaRow cocktail was added.  Following a 10 min 
incubation period the absorbance was read at 660 nm using spectrophotometer.    
The plasma membrane GLUT4 protein concentration was determined in the 
presence and absence of a submaximal insulin concentration.  The protein concentration 
for the plasma membrane and crude homogenate was determined using the Lowry 
method (4).  Sample protein (40 μg) was subjected to SDS-PAGE and the protein was 
separated on a 12% resolving gel.  Next, the resolved proteins were transferred to a 
PVDF membrane using a semidry transfer unit and blocked in NFDM-TTBS for 1 h at 
room temperature.  Using a visible molecular weight marker (Bio-Rad) as a guide the 
PVDF membranes were cut into an upper and lower membrane section.  The upper 
membrane section was probed with affinity purified anti-sodium-potassium-ATPase 
(Na+K+-ATPase) antibody (Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4° 
C.  The Na+K+-ATPase pump is a ubiquitous plasma membrane marker used to 
demonstrate equal protein loading across samples.  The lower membrane section was 
probed with affinity purified anti-GLUT4 antibody (donated by Dr. Samuel Cushman, 
National Institute of Diabetes and Digestive Kidney Disease, Bethesda, MD) overnight at 
4° C.  Following 3, 5-min washes in TTBS the membrane was incubated for 1 h at room 
temperature with the species-specific immunoglobulin G secondary antibody.  The 
membrane was then washed with 3, 5-min washes in TTBS and antibody binding was 
visualized by ECL in accordance to the manfacturer’s instructions (Perkin Elmer). 
Images were captured by using a charge-coupled device camera in a ChemiDoc system 
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(BioRad) and saved to a computer.  The density of each band was quantified using 
Quantity One analysis software (BioRad) and expressed as a percentage of an insulin-
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Chapter VII: Summary 
 
Recent investigations have demonstrated that amino acids, specifically the 
branch-chained amino acid, are involved in blood glucose regulation.  Of the branchd-
chain amino acids, two of them, isoleucine and leucine, have been reported to have direct 
actions on blood glucose levels.  Several studies have shown that both of these branched-
chain amino acids may acutely lower circulating blood glucose levels (1, 2, 6) in healthy 
tissue.  But the ability of amino acids to lower the blood glucose response holds great 
clinical significance for individuals afflicted by insulin resistance.  Many questions 
remain, however, as to how amino acids exert their affect on blood glucose levels.  
Several lines of questioning that have been explored in this dissertation, as well as in 
other laboratories, are the roles of insulin secretion, cellular signaling and skeletal muscle 
glucose uptake.   
It is well established that consuming carbohydrates with either protein (7, 10) or 
amino acids (8, 9) synergistically enhance insulin secretion.  The attenuated blood 
glucose response to these treatments has been attributed to greater insulin secretion (4, 8, 
10).  However, recent studies have reported that both leucine and isoleucine enhanced 
skeletal muscle glucose uptake in the absence of insulin (1, 6) in vitro.  These findings 
suggest a minor role for insulin in amino acid-induced glucose clearance.  Therefore, 
improved skeletal muscle glucose clearance, and alterations to its underlying signaling 
pathways may explain the enhanced glucose response.   
Some investigators have begun to explore the significance of cell signaling in 
amino acid-induced glucose clearance in vitro.  Both leucine and isoleucine have been 
found to increase skeletal muscle glucose uptake in the absence of insulin in vitro (1, 2, 
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6).  Nishitani et al. (6) reported that both phosphatidylinositol 3-kinase (PI 3-kinase) and 
protein kinase C (PKC) were involved in leucine-induced glucose uptake across isolated 
soleus muscle as uptake was significantly reduced when the respective specific inhibitors 
for each kinase was introduced to the incubation medium.  In contrast, pre-treatment with 
rapamycin, a specific inhibitor of the mammalian target of rapamycin (mTOR) had no 
effect.  In agreement, Doi et al. (1) reported that isoleucine-induced glucose uptake in 
C2C12 myotubes was inhibited in the presence of a specific inhibitor of PI 3-kinase but 
not in the presence of an inhibitor of mTOR, suggesting that PI 3-kinase signaling, rather 
than mTOR signaling, may be involved in amino acid-induced glucose uptake.  
The in vitro results support the involvement of PI 3-kinase signaling in amino 
acid-induced muscle glucose uptake.  However, there has not been a comprehensive 
investigation of the in vivo impact of amino acid ingestion on glucose homeostasis.  
Furthermore, despite the lack of evidence for a direct link of mTOR to glucose uptake, a 
potential role for mTOR warrants further investigation as this protein is activated by 
amino acids and may be involved in glycogen synthesis.  Thus, the primary objective of 
these dissertation studies was to determine the effects of amino acid supplementation on 
glucose tolerance, insulin resistance, insulin secretion and cellular signaling.   
STUDY 1 
In Study 1 Experiment-1 (Exp-1), the primary aim was to determine if an amino 
acid mixture lowers the blood glucose response to an oral glucose challenge and if the 
potency of the mixture was enhanced by increasing the leucine concentration.  Briefly, 
Sprague Dawley rats were orally gavaged (8ml/kg body weight) with one of four 
supplements:  carbohydrate (CHO), carbohydrate plus a 5 amino acid mixture (CHO-AA-
1, carbohydrate plus a 5 amino acid mixture with increased leucine concentration (CHO-
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AA-2) or placebo (PLA).  Blood was collected from the tail at 0, 15, 30, 60 and 120 min 
post supplementation.  There were no significant differences in fasting blood glucose 
levels among the treatment groups.  Following water supplementation for the PLA group, 
there were only minimal changes in blood glucose.  The fact that there was little change 
in blood glucose response for the PLA group was crucial as it suggests that the rats were 
familiarized with the procedure for the appropriate amount of time and not under stress 
throughout the oral glucose tolerance test (OGTT).  Blood glucose was significantly 
lowered compared to the other treatment groups post supplementation for PLA.  The 
blood glucose response peaked at 15 min for CHO, CHO-AA-1 and CHO-AA-2, but was 
significantly lower for both CHO-AA-1 and CHO-AA-2 at 15, 30 and 60 min after 
supplementation.  However, there was no statistical difference in blood glucose between 
CHO-AA-1 and CHO-AA-2 at any time point.  The lower blood glucose response in the 
amino acid groups were further demonstrated when the area under the curve (AUC) was 
calculated.  Since the blood glucose response was similar between CHO-AA-1 and CHO-
AA-2, the carbohydrate plus amino acid mixture with the lower leucine concentration 
(CHO-AA-1) was used for the remainder of the Sprague Dawley OGTT studies. 
Because insulin is the primary hormonal regulator of blood glucose, the plasma 
insulin response during the OGTT was determined to assess whether an increase in 
insulin secretion could explain the lower blood glucose response in the amino acid treated 
rats.  Fasting insulin levels were similar between treatment groups and the PLA plasma 
insulin was significantly lower than the other treatment groups at 15 and 30 min post 
supplementation.  There were no significant differences in the insulin response between 
CHO-AA-1 and CHO-AA-2 at 15, 30, 60 and 120 min post supplementation.  
Furthermore, insulin levels were similar between these treatment groups when the AUC 
was calculated.   
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Several labs have report that individual amino acids, especially leucine and 
isoleucine when administered alone, increase muscle glucose uptake in vitro.  The 
evidence to date suggests that isoleucine is a more potent glucose lowering agent 
compared to leucine.  This may begin to partially explain why we did not observe a lower 
glucose response when the concentration was increased for the CHO-AA-2 treatment.  
Results from Study 1 Exp-1 demonstrated that the blood glucose response was attenuated 
by the amino acid mixture, and that the improved glucose tolerance was not associated 
with an increase in insulin secretion.  These findings also suggested that increasing the 
leucine concentration of the amino acid mixture does not provide additional 
improvements for the glucose and insulin responses.   
In Study 1 Exp-2, the primary aim was to determine if the improved glucose 
tolerance observed in Study 1 Exp-1 was due to increased skeletal muscle glucose uptake 
and if differences in uptake were characterized by alterations in protein signaling.  
Briefly, Sprague Dawley rats were orally gavaged (8ml/kg body weight) with either 
carbohydrate (CHO) or carbohydrate plus the amino acid mixture (CHO-AA-1).  Fifteen 
min after the gavage, a bolus containing a radiolabled glucose analogue was injected by 
syringe via a tail vein.  The tail was bled and blood collected at 0, 17, 27, 37, 47 and 60 
min post supplementation.  Immediately after the 60 min blood draw, the rats were 
sacrificed and muscle excised from the hindlimb.  The blood glucose response to the 
glucose challenge was reduced in the CHO-AA-1 treatment group compared to CHO.  
The difference in blood glucose was likely not due to alterations in insulin secretion as 
plasma insulin was similar between treatment groups.        
Next, it was determined whether the lower blood glucose was due to enhanced 
amino acid-induced skeletal muscle glucose uptake.  Rates of glucose uptake were 
significantly greater in both red and white gastrocnemius muscles for the CHO-AA-1 
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treatment group compared to CHO.  Since glucose uptake was increased with no 
differences in the plasma insulin response between treatment groups, it raised the 
possiblity that cell signaling may play an important role in the amino acid-stimulated 
glucose clearance.   
The increased glucose uptake observed with the amino acid mixture is 
presumably a result of increased plasma membrane glucose transporter 4 (GLUT4).  
GLUT4 protein concentration was not measured because the glucose transporter would 
likely have been recycled from the plasma membrane 1 h post supplementation.  There 
was no difference in total protein concentration for Akt/PKB, mammalian target of 
rapamycin (mTOR), glycogen synthase (GS) or Akt substrate of 160 kdDa (AS160) to 
the acute ingestion of either the carbohydrate or amino acid mixture.  However, the 
phosphorylation of mTOR, GS and AS160 were increased by the amino acid mixture in 
the red gastrocnemius.  AS160 phosphorylation was increased in the white gastocnemius 
as well.  Therefore, the lower glucose response for the amino acid treatment appeared due 
to a greater rate of blood glucose clearance and this response was associated with 
increased phosphorylation of intracellular signaling proteins rather than greater insulin 
secretion.  
In conclusion, Study 1 demonstrated that the amino acid mixture attenuates the 
blood glucose response to an oral glucose challenge and this appears due to enhanced 
skeletal muscle glucose uptake and intracellular signaling.  The fact that the amino acid 
mixture improved glucose tolerance in a rodent model in which glucose metabolism was 
already adequate was intriguing.  The results from Study 1 clearly demonstrate the 
potential for the amino acid mixture to improve glucose tolerance in an insulin resistant 
rodent model.  
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STUDY 2 
The primary aim of Study 2 was to determine if perfusing the amino acid mixture 
increased skeletal muscle insulin-stimulated and non-insulin-stimulate glucose uptake 
and if differences in glucose uptake were associated with alterations in PI 3-kinase 
activity, AS160 physorylation and/or plasma membrane GLUT4 protein concentration.  
Sprague Dawley rats were perfused with a perfusate containing no insulin (BAS), a 
submaximal insulin concnetraiton (sINS), an amino acid mixture with no insulin (AA) or 
an amino acid mixture with a submaximal insulin concentration (AA-sINS).  Following 
the 25 min perfusion period rats were sacrificed and the gastrocnemius excised.  Rates of 
skeletal muscle glucose uptake were significantly increased in both insulin-stimulated 
treatments, compared to the non-insulin-stimulated treatment groups.  Glucose uptake 
was greater in the AA-sINS treatment group compared to sINS.  However, under non-
insulin-stimulated conditions, the addition of amino acids to the perfusate had no impact 
on glucose uptake compared to BAS.  The fact that the amino acid mixture alone did not 
increase glucose uptake is in contrast to in vitro studies demonstrating that amino acids 
enhance glucose uptake in the absence of insulin (1, 5, 6).  These differences are likely 
due to differences in methodology and the muscles used to compare rates of glucose 
uptake.     
 Because the activation of PI 3-kinase is an important signal in insulin-stimulated 
GLUT4 translocation, both the insulin receptor-1 (IRS-1) associated and total PI 3-kinase 
activity were determined.  Previous in vitro studies suggest that PI 3-kinase is required 
for amino acid-induced glucose uptake (1, 6) but it was not clear from these studies 
whether the IRS-1 associated PI 3-kinase or another class of PI 3-kinase was involved in 
this process.  Insulin significantly increased both IRS-1 associated and total PI 3-kinase 
activity compared to when no insulin was in the perfusate.  But there was no difference in 
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IRS-1 associated PI 3-kinase activity or total PI 3-kinase activity when the amino acid 
mixture was added to the perfusate in the presence or absence of insulin.  This finding 
suggests that PI 3-kinase may play only a permissive role in amino acid-stimulated 
glucose uptake and that amino acids enhance glucose uptake via a mechanism 
independent of PI 3-kinase.    
 AS160, a distal signal in the insulin signaling cascade, prevents GLUT4 
translocation.  However, once phosphorylated, its inhibitory effect on GLUT4 
translocation is removed and GLUT4 is able to move from an intracellular storage pool to 
the plasma membrane.  In Study 2, insulin-stimulation resulted in a significant increase in 
AS160 phosphorylation compared to the non-insulin-stimulated condition.  Furthermore, 
the addition of the amino acid mixture to the perfusate had a significantly greater effect 
on AS160 phosphorylation compared to the absence of amino acids under insulin-
stimulated conditions.  This same phenomenon was not observed when amino acids were 
added to the perfusate in the absence of insulin.  These findings suggest that amino acids 
act either directly or indirectly to increase glucose uptake by increasing AS160 
phosphorylation and possibly GLUT4 translocation to the plasma membrane.              
Glucose uptake across the muscle is directly related to the number of GLUT4 
transporters at the plasma membrane (3).  Because GLUT4 likely had returned to the 
cytosol by the time muscle was excised from the rats post supplementation, the impact of 
the amino acid mixture on GLUT4 translocation could not be determined in Study 1.  
However, theses studies found that intracellular signaling was improved by the amino 
acid mixture, providing evidence that GLUT4 translocation may have been improved as 
well.  In Study 2, insulin-stimulation resulted in a significant elevation in plasma 
membrane GLUT4 protein concentration compared to the non-insulin-stimulated 
treatment groups.  There was no difference in plasma membrane GLUT4 in the AA group 
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compared to BAS but the concentration of GLUT4 at the plasma membrane was 
significantly greater for AA-sINS compared to the sINS treatment group.   
In conclusion, Study 2 found that the amino acid mixture increased glucose 
uptake when it was perfused with insulin.  But in the absence of insulin, the amino acid 
mixture had no additional impact on glucose uptake.  The amino acid-stimulated glucose 
uptake was no due to increased IRS-1 associated PI 3-kinase activity.  However, the 
phosphorylation status of AS160 and plasma membrane associated GLUT4 protein 
concentration mirrored the results of glucose uptake.  These findings suggest that the 
amino acid mixture increases AS160 phosphorylation and enhances GLUT4 translocation 
to the plasma membrane and this was likely the mechanism for the increased amino acid-
stimulated skeletal muscle glucose uptake.     
STUDY 3 
The purpose of Study 3 Exp-1 was to determine if the amino acid mixture lowered 
the blood glucose response to an oral glucose challenge in insulin resistant obese Zucker 
rats.  Briefly, obese Zucker rats were orally gavaged with either carbohydrate (OB-CHO), 
carbohydrate plus a 5 amino acid mixture (OB-CHO-AA-1), carbohydrate plus a 5 amino 
acid mixture with increased leucine concentration (OB-CHO-AA-2) or placebo (OB-
PLA).  Blood was collected throughout the OGTT as described above for Study 1 Exp-1.  
There was no difference in fasting blood glucose between treatment groups.  Once again, 
there was very little change in blood glucose throughout the OGTT in the PLA group, 
suggesting that the rats were not under stress during this procedure.  There was a similar 
peak increase in blood glucose 15 min after supplementation among OB-CHO, OB-CHO-
AA-1 and OB-CHO-AA-2 groups.  However, beyond the 15 min time point blood 
glucose was significantly lower for both amino acid mixtures compared to OB-CHO.  
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The trend for lower blood glucose for the amino acid mixtures would remain for the 
duration of the OGTT.  There was also no statistical difference in blood glucose at any 
time point between OB-CHO-AA-1 and OB-CHO-AA-2, suggesting that there may be a 
threshold as to the amount of leucine that is optimal for lowering blood glucose.  The 
glucose AUC showed the amino acid mixture treatment groups to be similar.  However, 
the AUC further displayed the dramatic decrease in blood glucose for the amino acid 
mixture treatment groups compared to OB-CHO.  Since the blood glucose response was 
similar between OB-CHO-AA-1 and OB-CHO-AA-2, the amino acid mixture with the 
lower leucine concentration (OB-CHO-AA-1) was used as the carbohydrate plus amino 
acid mixture for the remainder or the Zucker studies.    
Because insulin is primarily responsible for controlling blood glucose the plasma 
insulin levels were assessed to see if this hormone could explain the differences observed 
in blood glucose during the OGTT.  Fasting blood glucose was not different among the 
four treatment groups.  There were no statistical differences in insulin levels between 
OB-CHO, OB-CHO-AA-1 and OB-CHO-AA-2 at any time point during the OGTT.  
However, there appeared to be a trend toward higher insulin levels in the amino acid 
mixture treatment groups so the insulin AUC was calculated.  The AUC showed that 
plasma insulin was greater in both amino acid mixture treatment groups compared to OB-
CHO.  This finding would suggest that the lower blood glucose in the animals treated 
with either amino acid mixture could be, at least partially, explained by enhanced insulin 
secretion.  It is noteworthy that the insulin AUC for the obese Zucker rats, but not the 
HSD rats, was statistically significant between the carbohydrate and amino acid mixtures.  
This finding is likely a result of the different animal models being tested.  Thus, it is 
feasible that HSD rats, which are not insulin resistant, do not require elevated insulin for 
further improvements in glucose tolerance.  In contrast, for the insulin resistant obese 
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Zucker rats, it is possible that a greater insulin response to the amino acid mixture is 
required to improve glucose tolerance.   
The purpose of Study 3 Exp-2 was to determine if the lowered improved insulin 
resistance observed in Study 3 Exp-1 was due to increased skeletal muscle glucose 
clearance.  This study also sought to determine whether differences in blood glucose 
uptake could be attributed to changes in protein signaling.  Because the tail of a Zucker 
rat is dark colored, making it difficult to visualize a tail vein, a jugular catheter was 
surgically implanted in order to deliver the radiolabeled glucose analogue for the 
determination of glucose uptake.  This is in contrast to the SD rats in which the tail vein 
was used for infusions but this change in methodology was warranted because infusing 
via a tail vein in Zucker rats was difficult and did not yield consistent results in the pilot 
studies.   
On the day of testing, obese Zucker rats were orally gavaged (8 ml/kg body 
weight) with either carbohydrate (OB-CHO) or carbohydrate plus the 5 amino acid 
mixture (OB-CHO-AA-1) or placebo (OB-PLA).  Lean Zucker rats were orally gavaged 
(8 ml/kg body weight) with carbohydrate (LN-CHO).  Fifteen min after the gavage, a 
bolus containing a radiolabeled glucose analogue was injected syringe via the jugular 
vein catheter.  The tail was cut bleed and blood collected at 0, 17, 27, 37, 47 and 60 min 
post supplementation and the rat sacrificed after the 60 min blood draw.          
There was no difference in fasting blood glucose levels among the obese 
treatment groups.  However, the fasting blood glucose of the lean rats was significantly 
lower compared to each obese treatment group.  The blood glucose response for OB-PLA 
was crucial to this study as this measurement indicates that the rats were properly 
familiarized and have recovered from the surgical procedure.  The small increase in blood 
glucose measured for OB-PLA was similar to the changes observed in Study 1 Exp-1, 
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suggesting that the rats had recovered from surgery and were not stressed by the OGTT 
procedure.  The blood glucose response for LN-CHO was significantly lower compared 
to OB-CHO and OB-CHO-AA-1 at all time points post supplementation.  Blood glucose 
was also significantly reduced for OB-CHO-AA-1 compared to OB-CHO at 27, 37, 47 
and 60 min.  The glucose AUC shows a similar trend.  OB-PLA was lower than all other 
treatment groups, and the glucose AUC was reduced in LN-CHO compared to OB-CHO 
and OB-CHO-AA-1.  In addition, the glucose AUC was significantly lower in OB-CHO-
AA-1 compared to OB-CHO.  These findings once again strongly suggest that the blood 
glucose response is attenuated by the amino acid mixture. 
The lower blood glucose response for OB-CHO-AA compare to OB-CHO to the 
glucose challenge did not appear to be due to enhanced insulin secretion.  There was no 
difference in fasting plasma insulin between the obese rat treatments.  However, fasting 
insulin was significantly lower in the lean rats compared to obese rats.  The insulin for 
LN-CHO was lower than all obese treatments at each time point during the OGTT.  OB-
PLA, which was gavaged with distilled water, had little change in insulin over the 1 h 
OGTT, and their insulin was significantly lower than OB-CHO and OB-CHO-AA at all 
time points.  There was no difference in plasma insulin detected between OB-CHO and 
OB-CHO-AA 0, 17, 27, 47 or 60 min.  When the insulin AUC was calculated there was 
no difference between OB-CHO and OB-CHO-AA.  The insulin AUC was significantly 
lower for LN-CHO compared to OB-CHO and OB-CHO-AA, but not different from OB-
PLA. 
Since skeletal muscle is the primary site for blood glucose clearance during an 
OGTT, skeletal muscle glucose uptake was determined across red and white fiber types.  
Rates of glucose uptake were significantly enhanced in OB-CHO-AA-1 compared to OB-
CHO in the red gastrocnemius but not the white gastrocnemius mucle.  Glucose uptake 
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was significantly lower in OB-PLA compared to all other treatments across fiber types.  
Interestingly, the glucose uptake in OB-CHO-AA-1 was similar to that of LN-CHO in 
each fiber type.  The glucose uptake data suggest that the lower blood glucose response 
and improved glucose tolerance in obese Zucker rats during the OGTT may be due to 
increased skeletal muscle glucose clearance. 
In Study 3 Exp-2 it is unlikely that the increased glucose uptake in obese Zucker 
rats was due to enhanced insulin secretion. As noted above, glucose uptake into the 
muscle is a coordinated process involving a chain of intracellular proteins.  It is the 
activation of specific proteins which allow for the translocation of GLUT4 to the plasma 
membrane for the subsequent removal of glucose from the blood.  Therefore, the activity 
of specific proteins known to be involved in the glucose transport processes was 
determined.  The acute ingestion of either, distilled carbohydrate or the amino acid 
mixture did not result in changes to the total protein content.  Furthermore, there was no 
difference in phosphorylation status between treatment groups for Akt/PKB, mTOR or 
GS.  This finding differs from what was observed in non-insulin resistant Sprague 
Dawley rats from Study 1 Exp-2 which showed enhanced activation in red muscle for 
mTOR and GS.  However, in agreement with what was found in Sprague Dawley rats, 
AS160 phosphorylation was increased in the amino acid treatment group in both red and 
white muscle.  This is a significant finding because it is thought that AS160 regulates 
GLUT4 translocation.  This would then suggest that there was greater GLUT4 
translocation to the plasma membrane when the amino acid mixture was consumed, 
providing a potential mechanism to explain the improved glucose tolerance.  
In conclusions, results from Study 3 suggest that the amino acid mixture can 
acutely lower the insulin resistance in obese Zucker rats and this improvement appears 
due to enhanced skeletal muscle glucose uptake and increased AS160 phosphorylation.      
 155
FUTURE DIRECTIONS 
This series of studies demonstrated the beneficial effects amino acid 
supplementation has on glucose tolerance in both healthy and insulin resistant rodent 
skeletal muscle.  These studies have also addressed some of the potential mechanisms 
through which the amino acids lower blood glucose.  However, several areas of 
investigation are still warranted to fully understand the impact amino acids have on 
glucose tolerance and its potential as a therapeutic in the fight against insulin resistance 
and type 2 diabetes mellitus.   
Although the present series of experiments were able to answer many questions 
regarding the impact of amino acids on glucose tolerance and insulin resistance, it also 
serves as the basis for many new questions.  The hindlimb perfusion technique could be 
used to include specific inhibitors, such as Wortmanin, in the perfusate to assess the 
importance of PI 3-kinase in amino acid stimulated glucose uptake.  Including maximally 
stimulated concentration of insulin and/or amino acids could be used to determine 
whether the effects of amino acids and insulin were additive and if the amino acids are 
working via an alternative signaling pathway.  Study 3 perfused a 2 mM concentration of 
amino acids, thus, it is not clear if a lesser dose would achieve the same effect or if the 
impact of amino acids would be greater with an increased concentration.  
The combined effects of amino acids and muscle contraction are not well 
understood.  It is well established that the stimulatory affects of muscle contraction on 
glucose uptake are insulin independent, and are mediated by both calcium and AMP-
activated protein kinase (AMPK) dependent mechanisms.  It does not appear that amino 
acids work through either calcium or AMPK.  Thus, it would be interesting to investigate 
whether the amino acids and contraction signals interact or are independent of each other.    
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Expanding investigations using the amino acid mixture to include humans would 
broaden our understanding of supplementation and ultimately determine the therapeutic 
potential of amino acids.  The potential for the amino acid mixture to serve as a non-
pharmacological therapeutic to improve insulin resistance is also not currently known.  
The present investigation demonstrated that the amino acid mixture can lower insulin 
resistance on an acute basis.  However, whether the same acute benefits can be duplicated 
with chronic administration is unclear.  If the chronic administration of the amino acid 
mixture did work, then it would be important to determine if the acute and chronic 
mechanisms were the same or different.  The acute administration increased the 
phosphorylation of key signaling proteins and increased GLUT4 translocation to the 
plasma membrane.  A chronic study could be designed to answer questions regarding the 
impact of amino acid supplementation on body weight, long-term glycemic control, total 
protein concentration and muscle glycogen levels.   
The effects of the amino acid mixture on exercise performance and recovery is 
open to future investigations.  The components of the amino acid mixture were chosen 
based on their reported effects on different aspects of carbohydrate metabolism.  
Theoretically, this amino acid mixture would be an excellent ergogenic aid and recovery 
supplement.  Thus, future studies could investigate questions related to time to fatigue, 
muscle damage, glycogen synthesis, protein synthesis and immune function.  Because its 
been reported that single amino acids cause gastrointestinal distress in some individuals, 
it would also be of interest to determine how tolerable an amino acid supplement regime 
would be.  Finally, it is likely that studies would need to address whether the 
concentrations of the amino acids in the current supplement are adequate, and if their 
concentrations would need to be adjusted to meet one’s dietary, exercise and recovery 
goals.   
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Appendix A: Hindlimb Perfusion 
Krebs-Henseleit Buffer (KHB) for BSA Dialysis (15 L) 
Reagent Formula Weight Concentration(mM) Amount 
NaCl 58.44 116 101.53 
KCl 74.56 4.6 5.14 
CaCl2-2H2O 147 2.5 5.51 
KH2PO4 136.1 1.16 2.37 
MgSO4-7H2O 246.48 1.16 4.29 
Reagents were added in the order listed to 12.5 L ddH2O stirring on a magnetic plate and 
brought to volume with ddH2O.   
KHB Stock I (1 L) 
Reagent Formula Weight Concentration(mM) Amount (g) 
NaCl 58.44 1160 67.79 
KCl 74.56 46 3.43 
KH2PO4 136.1 11.6 1.58 
NaHCO3 84.01 253 21.25 
Reagents were added in the order listed to 800 ml ddH2O stirring on a magnetic plate and 
brought to volume with ddH2O.   
KHB Stock II (1 L) 
Reagent Formula Weight Concentration(mM) Amount (g) 
CaCl2H2O 147 25 3.68 
MgSO4·H2O 246.48 11.6 2.86 
Reagents were added in the order listed to 800 ml ddH2O stirring on a magnetic plate and 
brought to volume with ddH2O.   
 160
Amino Acid Mixture (50 ml) 
Amino Acid Formula Weight Concentration(mM) Amount (g) 
Cysteine 121 0.87 5.28 
Methionine 149 0.45 3.36 
Valine 117 1.14 6.68 
Isoleucine 131 144.24 944.8 
Leucine 131 1.02 6.68 
Add amino acids in the order listed to 45 ml KHB stirring on a magnetic plate and bring 
to volume with KHB.  
Solution Preparation Proceduce  
1. Prepare KHB for dissolving BSA (1 L) 
a. 100 ml KHB Stock I 
b. Gas with O2/CO2 (95%/5%) for 45 min 
c. 100 ml Stock II KHB 
d. Bring to volume with ddH2O. 
2. Prepare 6% BSA 
a. 90 g BSA  
b. 390 ml gassed KHB 
c. Stir until dissolved 
3. Fill (~ 1/3 full) pre-wet dialysis tubing with BSA and clamp both ends of the 
tubing to prevent leaking. 
4. Place dialysis tube into tank with 15 L of KHB for dialysis and stir for 48 h. 
5. The day before the perfusion prepare the amino acid mixture. 
6. After dialyzing BSA, and on the day of the perfusion, check the BSA 
concentration using a refractometer. 
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7. Dilute the BSA to 6% with gassed KHB. 
8. Filter 2x through fibroglass filter paper using a vacuum pump.  
9. Prepare the washout in 6% BSA (125 ml/rat). 
 
                       Treatment Group 
 AA-sINS sINS AA BAS 
2 mM Sodium- 
pyruvate 
X X X X 
500 μU/ml 
Insulin 
X X   
2 mM Amino  
acid mixture 














10. Prepare the perfusate in 6% BSA (150 ml/rat). 
 
                                                                    Treatment Group 
 AA-sINS sINS AA BAS 
2 mM Sodium- 
pyruvate 
X X X X 
500 μU/ml 
Insulin 
X X   
2 mM Amino  
acid mixture 
X  X  
6 mM Glucose 
 
X X X X 
2 mM Mannitol 
 
X X X X 
0.2 μCi/ml 3H-
2DG 
X X X X 
0.15 μCi/ml 
14C-Sucrose 
X X X X 
 
Calculation for washout volume 
# of rats = 1 
Flow rate = 6 ml/min 
Time = 10 min 
Dead space of tubing = 35 ml 
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6 ml/min x 10 min = 60 ml + 35 ml = 95 ml 
Prepare 125 ml washout per rat. 
Calculation for Perfusate Volume 
 # of rats = 1 
Flow rate = 4 ml/min 
Time = 25 min 
Dead space of tubing = 35 ml 
4 ml/min x 25 min = 100 ml + 35 ml = 135 ml 















Appendix B: Glucose Uptake 
Glucose Uptake Procedure 
1. Place 80-100 mg of muscle sample in a glass test tube containing 1 ml 1 N KOH. 
2. Incubate sample for 15 min at 65° C, vortex, then incubate for an additional 5 min 
at 65° C until the muscle is dissolved. 
3. Add 1 ml of 1 N HCl to each test tube sample and vortex to neutralize the 
digested sample. 
4. For muscle samples, aliquot 300 μl of neutralized muscle to a scintillation vial 
containing 6 ml of Bio-Safe II counting cocktail. 
5. To determine the specific activity of the blood aliquot 200 μl of PCA extract to a 
glass test tube containing 1 ml of 1 N KOH and 1 ml of 1 N HCl and vortex.  To 
determine the specific activity of the perfusate aliquot 200 μl of perfusate to a 
glass test tube containing 1 ml of 1 N KOH and 1 ml of 1 N HCl and vortex.  
6. Aliquot 300 μl of neutralized blood or perfusate to a scintillation vial containing 6 
ml of Bio-Safe II counting cocktail. 
7. Put all samples in a scintillation counting rack and place rack in a liquid 







Appendix C: Muscle Homogenization 
Muscle Homogenization Buffer (100 ml, pH 7.4) 
Reagent Formula Weigh Concentration(mM) Amount (g) 
HEPES 238.3 20 0.477 
EGTA 380.4 2 0.076 
NaF 41.9 50 0.209 
KCl 74.6 100 0.746 
EDTA 292.2 0.2 0.0074 
β-Glycerophosphate 216.0 50 1.08 
DTT 154.3 1 0.015 
PMSF 174.2 0.1 0.00174 
Benzamidine 156.6 1 0.0157 
Sodium vanadate 181.9 0.5 0.0092 
Add reagents in the order listed to 80 ml ddH2O stirring on a magnetic plate, pH to 7.4 
and bring to volume with ddH2O.   
Homogenization Procedure 
1. Weight approximately 150 mg of muscle sample. 
2. Dilute muscle 1:8 (wt/vol) in homogenization buffer. 
3. Homogenize muscle on ice (3 x 10 sec strokes) with a glass tissue grinder set at 
3000 rpm. 
4. Centrifuge samples at 14,000 x g for 10 min at 4° C. 
5. Aliquot the supernatant into microcentrifuge tubes and store at - 80° C.  
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Appendix D: Lowery Protein Assay 
0.1 N NaOH (1000 ml) 
Reagent Amount 
NaOH 4 g 
Add NaOH 950 ml ddH2O stirring on a magnetic plate and bring to volume with ddH2O.   
2% Sodium Carbonate (1000 ml) 
Reagent Amount 
Sodium carbonate 20 g 
Add sodium carbonate to 950 ml ddH2O stirring on a magnetic plate and bring to volume 
with ddH2O. 
1% Cupric Sulfate (200 ml) 
Reagent Amount 
Cupric sulfate 2 g 
Add cupric sulfate to 150 ml ddH2O stirring on a magnetic plate and bring to volume 
with ddH2O. 
2% Sodium Potassium Tartrate (200 ml) 
Reagent Amount 
Sodium potassium tartrate 4 g 
Add sodium potassium tartrate to 150 ml ddH2O stirring on a magnetic plate and bring to 
volume with ddH2O. 
Protein Assay Procedure 
1. Thaw BSA (5 mg/ml) on ice. 
2. Dilute samples 1:40 by aliquoting 7 μl of sample to a labeled microcentrifuge 
tube containing 273 μl of ddH2O and vortex. 
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3. Prepared standard curve. 
 





Blank 1.0 0 0 
A 1.8 0.2 BSA Stock 0.5 
B 0.2 0.8 of A 0.4 
C 0.5 0.5 of B 0.2 
D 0.5 0.5 of C 0.1 
E 0.5 0.5 of D 0.05 
F 0.5 0.5 of E 0.25 
 
4.  Make Solution A by adding the following: 
a. 96 ml of 2% sodium carbonate 
b. 2 ml of 2% sodium potassium tartrate 
c. 2 ml of 1% cupric sulfate 
5. Add 0.1 ml of each standard or sample to the corresponding glass test tube in 
dublicate. 
6. Add 1 ml of Solution A to each sample and standard test tube except to the blank 
and vortex. 
7. Incubate samples and standards for 10 min at room temperature. 
8. Dilute the Folin and Ciocalteu’s Phenol Reagent 1:2 by adding 1.5 ml of phenol 
reagent to 3 ml of ddH2O. 
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9. After the 10 min incubation period, add 0.1 ml of phenol solution to each sample 
and standard test tube and vortex.     
10. Incubate samples and standards for 30 min at room temperature. 
11. Measure the absorbance of each standard and sample at 750 nm using a 
spectrophotometer.  
Calculation 
1. Generate a standard curve from the absorbance of the standards.  Using the 
equation from the standard curve calculate the concentration of each sample. 
2. Multiply the protein concentration (as determined by the standard curve) by the 














Appendix E: Plasma Membrane Fractionation 
Aussie Buffer I (1 L) 
Reagent Formula Weigh Concentration(mM) Amount 
HEPES 1 M (pH 7.2) 20 20 ml 
EGTA 380.4 2 0.76 g 
β-Glycerophosphate 216.0 50 10.8 g 
DTT 154.3 1 154.25 mg 
Sodium vanadate 181.9 1 183.91 mg 
Glycerol 100% 10% 10 ml 
Benzamidine 156.6 3 469.83 mg 
PMSF 174.2 1 0.174 g 
Leupeptin 426.6 10 μM 0.0004 g 
Pepstati A 50 mM (in DMSO) 5 μM 100 μl 
Add reagents in the order listed to 950 ml ddH2O stirring on a magnetic plate and bring to 
volume with ddH2O.   
Aussie Buffer II (1 L) 
Add 1% Triton X to Aussie Buffer I 
Plasma Membrane Fractionation Procedure 
1. Weight approximately 150 mg of muscle sample. 
2. Dilute muscle 1:8 (wt/vol) in Aussie Buffer I. 
3. Homogenize muscle on ice (3 x 10 sec strokes) with a glass tissue grinder set at 
3000 rpm. 
4. Balance samples with Aussie Buffer I and centrifuge at 33,200 rpm for 30 min at 
4° C. 
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5. Remove supernatant and store at - 80° C.  This is the cytosolic fraction. 
6. Resuspend pellet in 4 x the original muscle weight in Aussie Buffer II.   
7. Balance samples with Aussie Buffer II and centrifuge at 11,100 rpm for 10 min at 
4° C. 




















Appendix F: 5’-Nucleotidase Activity 
5’-Reaction Cocktail (15 ml) 
Reagent Formula Weight Concentration(mM) Amount (g) 
Glycine 75.07 50 0.0561 
MgCl2 95.21 10 0.0141 
AMP 347.22 5 0.0261 
Add reagents in the order listed to 10 ml ddH2O stirring on a magnetic plate and bring to 
volume with ddH2O.   
Fiske and SubbaRow Cocktail  
Reagent Amount 
Fiske and SubbaRow 1.0 g 
ddH2O 6.3 ml 
Add the Fiske and SubbaRow to ddH2O and vortex until dissolved.  Keep this solution 
covered as it is light sensitive. 
Stop Solution-8% TCA (25 ml) 
Reagent Amount 
TCA 2 g 
Add the TCA to 20 ml ddH2O stirring on a magnetic plate and bring to volume with 
ddH2O.   
5’-Nucleotidase Procedure 
1. Add 200 μl of 5’-reaction cocktail to labeled microcentrifuge tubes for the 
samples (not standards). 
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2. Set a timer at 45 min and add 10 μl of the plasma membrane or cytosolic fraction 
to each tube at 30 sec intervals.  Gently vortex and place on heat block set at 37° 
C.  
3. At the end of 45 min add 400 μl of 8% TCA to stop the reaction 
4. Centrifuge samples at 2500 rpm for 10 min.   
5. To a second set of labeled sample tubes add the following: 
a. 300 μl ddH2O 
b. 200 μl supernatant 
c. 100 μl acid molybdate 
d. Vortex at low speed 
6. To the BLANK add the following 
a. 200 μl 5’-reaction cocktail 
b. 300 μl ddH2O 
c. 100 μl acid molybdate 












7. Prepare the standard curve: 
 




ddH2O (μl) Final 
Concentration 
(μM) 
1 0 100 500 0 
2 25 100 475 27.08 
3 50 100 450 54.17 
4 75 100 425 81.25 
5 100 100 400 108.33 
6 125 100 375 135.42 
 
8. To all sample tubes, blank and standards and 25 μl of Fiske and SubbaRow 
cocktail, gently vortex and let stand at room temperature for 10 min. 
9. Measure the absorbance of each sample at 660 nm using a spectrophotometer. 
Calculation 
1. Generate a standard curve from the absorbance of the standards.  Using the 
equation from the standard curve calculate the concentration of each sample. 
2. Divide the concentration of each sample by 45 (time in minutes) to get μM/min. 
3. Obtain the protein concentration (μg/μl) from the Lowery Protein assay and 
multiple by 10 to get the total protein concentration in the 10 μl sample. 
4. Divide this value by 1000 to get mg of protein. 
5. Divide the μM/min value by mg of protein to get μM/min/mg.  
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Appendix G: Western Blot 
30% Acrylamide and 1% Bisacrylamide Mixture (200 ml) 
Reagent Amount 
Acrylamide 58 g 
Bisacrylamide 2 g 
Add reagents in the order listed to 150 ml ddH2O stirring on a magnetic plate and bring to 
volume with ddH2O.  Filter solution through Whatman #1 filter paper and store in a dark 
bottle as this solution is light sensitive.  Store at 4° C.   
1.5 M Tris, pH 8.8 (500 ml) 
Reagent Amount 
Trisbase 90.82 g 
Add Trisbase to 400 ml ddH2O stirring on a magnetic plate and bring to volume with 
ddH2O.  Adjust pH to 8.8 with concentrated HCl.  Store at 4° C.   
1.0 M Tris, pH 6.8 (500 ml) 
Reagent Amount 
Trisbase 60.57 g 
Add Trisbase to 400 ml ddH2O stirring on a magnetic plate and bring to volume with 
ddH2O.  Adjust pH to 6.8 with concentrated HCl.  Store at 4° C.   
10% SDS (100 ml) 
Reagent Amount 
SDS 10 g 
Add SDS to 80 ml ddH2O stirring on a magnetic plate and bring to volume with ddH2O.  
Filter solution through Whatman #1 filter paper. 
   
 175
20% SDS (100 ml) 
Reagent Amount 
SDS 20 g 
Add SDS to 80 ml ddH2O stirring on a magnetic plate and bring to volume with ddH2O.  
Filter solution through Whatman #1 filter paper. 
10% APS (1 ml) 
Reagent Amount 
APS 100 mg 
Add APS to 1 ml ddH2O and vortex until dissolve.  Make fresh daily. 
0.25% Bromophenol Blue (5 ml) 
Reagent Amount 
Bromophenol blue 0.0125 g 
Add Bromophenol blue to 5 ml ddH2O stirring on a magnetic plate. 
2x Sample Buffer (50 ml) 
Reagent Amount 
1.0 M Tris, pH 6.8 5 ml 
Glycerol 10 ml 
20% SDS 5 ml 
β-Mercaptoethanol 2.25 ml 
0.25% Bromophenol blue 1.6 ml 
Add reagents in the order listed to 40 ml ddH2O stirring on a magnetic plate and bring to 




10x Running Buffer (1 L) 
Reagent Amount 
Trisbase 30.28 g 
Glycine 144.2 g 
Add reagents in the order listed to 800 ml ddH2O stirring on a magnetic plate and bring to 
volume with ddH2O.   
10x TBS pH 7.5 (1 L) 
Reagent Amount 
Trisbase 60.05 g 
NaCl 87.6 g 
Add reagents to 800 ml ddH2O stirring on a magnetic plate and bring to volume with 
ddH2O.  Adjust pH to 7.8 with concentrated HCl.   
Anode I (1 L) 
Reagent Formula Weight Concentration Amount 
Trisbase 121.1 300 mM 36.33 g 
SDS 288.4 0.05% 0.5 g 
Methanol 32.0 10% 100 ml 
β-Mercaptoethanol 78.1 10 mM 0.78 ml 
Add reagents in the order listed to 800 ml ddH2O stirring on a magnetic plate and bring to 






Anode II (1 L) 
Reagent Formula Weight Concentration Amount 
Trisbase 121.1 25 mM 3.025 g 
SDS 288.4 0.05% 0.5 g 
Methanol 32.0 10% 100 ml 
β-Mercaptoethanol 78.1 10 mM 0.78 ml 
Add reagents in the order listed to 800 ml ddH2O stirring on a magnetic plate and bring to 
volume with ddH2O.   
Cathode (1 L) 
Reagent Formula Weight Concentration Amount 
Trisbase 121.1 25 mM 3.025 g 
α-amino-hexanoic 
acid 
131.2 40 mM 5.25 g 
SDS  0.05% 0.5 g 
Methanol 32.0 10% 100 ml 
β-Mercaptoethanol 78.1 10 mM 0.78 ml 
Add reagents in the order listed to 800 ml ddH2O stirring on a magnetic plate and bring to 
volume with ddH2O.   
Western Blot Procedure 
1. Assemble the gel apparatus in casing stands according to the manufacturer’s 
instructions. 
2. Preparing resolving gel solution (10% resolving gel for 2 gels): 
a. 4 ml ddH2O 
b. 3.3 ml acrylanide mix 
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c. 2.5 ml 1.5 M Tris, pH 8.8 
d. 0.1 ml 20% SDS 
e. 0.1 ml 10% APS 
f. 0.004 ml TEMED 
g. Plunge solution with a glass pipette to mix 
3. Fill the caster ~ 3/4 full then overlay with 200 μl butanol.  Allow 1 h for gel to 
polymerize. 
4. After gel polymerization, pour off butanol from the resolving gel and rinse 
between casting plates with ddH2O.  Dry between casting plates with KimWipes.   
5. Prepare stacking gel solution (for 2 gels): 
a. 3.4 ml ddH2O 
b. 0.83 ml acrylamide mix 
c. 0.63 ml 1.0 M Tris, pH 6.8 
d. 0.05 ml 20% SDS 
e. 0.05 ml APS 
f. 0.005 ml TEMED 
g. Plunge solution with a glass pipette to mix 
6. Fill the caster with stacking gel solution then gently put combs into place.  Allow 
45 min for stacking gel to polymerize. 
7. During the stacking gel polymerization, prepare samples. 
a. Thaw samples on ice 
b. Dilute samples 1:2 with 2x sample buffer in labeled microcentrifuge tubes.  
c. Vortex then place in boiling water (~ 100° C) for 5 min 
d. Centrifuge at 14,000 x g for ~ 5 sec  
8. Prepare 1x running buffer 
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a. 895 ml ddH2O 
b. 100 ml 10x running buffer 
c. 5 ml 20% SDS 
9. After stacking gel has polymerized, carefully remove combs and assemble gel 
apparatus and electrophoresis chamber according to the manufacturer’s 
instructions.  Fill inner chamber with 1x running buffer and outer chamber ~ 1/3 
full with 1x running buffer. 
10. Load the appropriate amount of sample, standard and molecular weight marker to 
each gel lane.  
11. Electrophoresis at 200 V for 1 h. 
12. After the electorphoresis, prepare for the semi-dry transfer. 
13. Carefully separate casing plates, cut off stacking gel and place resolving gel in 
Anode I for at least 10 min.   
14. Pre-wet PVDF membranes in methanol for 30 sec then place in Anode I for at 
least 10 min. 
15. Pre-wet filter paper in Anode II and Cathode for at least 10 min.  
16. Transfer the proteins from the resolving gel to the membrane according to the 
manufacturer’s instructions. 
17. Transfer the proteins at 25 V for 25 min. 
18. During the transfer, prepare TTBS solution 
a. 900 ml ddH2O 
b. 100 ml 10x TBS 
c. 600 μl Tween 20 
19. During the transfer prepare 2% non-fat dry milk (NFDM).  Prepare 50 ml per 
membrane.  (ie 100 ml for 2 membranes) 
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a. 7 g NFDM 
b. 100 ml TTBS 
20. After the transfer is complete, place each PVDF membrane a container with 7% 
NFDM and block for 1 h with gently agitation. 
21. After blocking the membrane, wash 2x, 5 min in 25 ml TTBS 
22.  Incubate membranes with the appropriate primary antibody overnight at 4° C 
with gently agitation.   
23. After the overnight incubation with the primary antibody, wash membranes 2x, 5 
min in 25 ml TTBS. 
24. Incubate membranes with the species specific secondary antibody for 1 h at room 
temperature.   
25. After the incubation with the secondary antibody, wash membranes 2x, 5 min in 
25 ml TTBS. 
26. Visualize protein bands using an ECL detection kit and Bio-Rad ChemiDoc 
detection system according to the manufacturer’s instructions.   










Appendix H: Raw Data for Study 1 
Study 1: Experiment 1 
Blood Glucose (mmol/L) 
 
 Time 
Rat # Treatment 0 15 30 60 120 AUC 
12 CHO 4.8 10.7 9.4 7.0 5.7 319.6 
15 CHO 5.4 9.6 9.0 8.6 7.4 347.6 
21 CHO 4.8 8.7 8.5 6.5 4.8 218.6 
23 CHO 5.5 9.1 7.9 7.3 5.8 196.9 
27 CHO 4.9 8.2 7.3 6.6 5.3 193.7 
29 CHO 5.3 9.0 8.6 6.9 5.8 215.3 
3 CHO-AA-1 4.6 8.6 7.3 5.9 5.4 200.9 
13 CHO-AA-1 5.7 6.6 6.0 6.0 5.4 25.2 
14 CHO-AA-1 5.1 7.9 6.8 6.3 6.0 158.0 
19 CHO-AA-1 4.4 8.9 7.9 5.9 4.3 208.3 
26 CHO-AA-1 5.1 7.8 7.4 6.5 5.1 157.0 
31 CHO-AA-1 4.9 9.8 7.0 5.9 4.6 159.5 
5 CHO-AA-2 4.8 8.4 7.1 5.6 5.2 155.0 
16 CHO-AA-2 5.7 8.0 6.7 6.5 5.8 201.9 
17 CHO-AA-2 3.8 7.4 7.3 5.9 4.2 239.6 
24 CHO-AA-2 4.9 8.2 6.1 6.0 5.7 151.0 
25 CHO-AA-2 5.2 7.9 6.6 6.4 5.4 134.3 
32 CHO-AA-2 5.2 7.6 6.6 5.6 4.5 64.5 
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10 PLA 4.5 5.8 5.5 5.1 4.2 57.1 
18 PLA 4.5 5.2 5.2 4.7 4.4 30.6 
20 PLA 5.6 5.9 5.8 5.8 5.1 -33.2 
22 PLA 5.3 5.7 5.7 5.4 4.6 -0.8 
28 PLA 5.1 6.2 6.2 5.8 4.2 43.4 
30 PLA 5.2 5.9 6.0 5.2 4.2 -4.2 
  
Study 1: Experiment 1 
Plasma Insulin (pmol/L) 
 
 Time 
Rat # Treatment 0 15 30 60 120 AUC 
12 CHO 86.8 399.0 272.3 90.7 56.4 8092.5 
15 CHO 60.6 260.1 137.6 70.4 39.9 4492.5 
21 CHO 46.2 408.1 201.3 59.2 52.9 9699.4 
23 CHO 51.8 415.5 131.6 49.7 48.3 7026.8 
27 CHO 47.6 274.1 156.8 76.7 48.0 7123.5 
29 CHO 89.3 322.4 200.9 79.1 54.6 4542.4 
3 CHO-AA-1 61.6 380.1 253.1 74.6 61.6 9619.9 
13 CHO-AA-1 72.1 203.7 83.3 67.2 29.8 747.0 
14 CHO-AA-1 79.8 357.4 128.5 49.7 53.6 3091.9 
19 CHO-AA-1 35.0 922.6 222.6 60.2 55.0 19267.5 
26 CHO-AA-1 83.7 322.4 215.6 94.2 67.6 6496.9 
31 CHO-AA-1 35.0 286.0 167.7 50.4 43.1 7683.4 
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5 CHO-AA-2 99.1 849.8 421.8 95.6 58.1 17142.0 
16 CHO-AA-2 45.5 179.2 80.2 40.6 37.5 2263.1 
17 CHO-AA-2 35.7 262.9 159.6 78.1 60.6 8810.3 
24 CHO-AA-2 47.3 428.1 138.3 56.7 56.0 8477.3 
25 CHO-AA-2 74.9 552.7 311.9 109.6 70.7 13918.9 
32 CHO-AA-2 22.1 472.5 211.8 58.1 26.6 12789.8 
10 PLA 76.3 121.1 98.0 88.6 74.9 1705.5 
18 PLA 64.8 48.0 56.7 49.4 43.1 -1807.1 
20 PLA 48.0 48.3 36.4 21.7 16.5 -2386.9 
22 PLA 62.3 53.9 58.8 36.8 15.4 -2725.5 
28 PLA 93.8 148.8 118.3 99.8 58.8 569.3 
30 PLA 32.2 21.7 26.3 14.0 14.0 -1632.4 
 
Study 1: Experiment 2 
Blood Glucose (mmol/L) 
 
 Time 
Rat # Treatment 0 18 25 35 45 60 AUC 
4 CHO 4.6 8.7 10.6 12.7 14.1 13.5 442.3 
7 CHO 4.7 10.6 11.9 11.2 11.1 10.8 394.9 
8 CHO 4.5 10.3 13.1 12.3 11.9 11.2 454.2 
11 CHO 4.1 10.3 11.0 10.3 9.7 9.3 368.7 
12 CHO 5.2 9.5 11.2 10.7 12.7 13.9 378.8 
15 CHO 4.1 11.9 16.6 18.5 19.6 21.1 747.2 
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5 CHO-AA-1 4.5 10.1 11.3 11.8 11.5 10.0 400.0 
6 CHO-AA-1 5.3 10.0 8.5 7.9 7.9 7.7 180.5 
9 CHO-AA-1 4.7 8.7 9.5 7.5 7.4 6.8 206.1 
10 CHO-AA-1 4.3 8.3 10.7 10.7 10.2 9.2 349.1 
13 CHO-AA-1 4.8 10.0 11.0 11.2 11.4 9.8 363.6 
14 CHO-AA-1 3.3 6.9 9.8 9.0 8.6 8.2 215.6 
 
Study 1: Experiment 2 
Plasma Insulin (pmol/L) 
 
 Time 
Rat # Treatment 0 18 25 35 45 60 AUC 
4 CHO 59.9 160.3 275.8 337.8 307.3 234.2 8904.1 
7 CHO 70.0 328.7 197.1 246.8 260.1 162.4 8270.7 
8 CHO 57.4 168.4 179.2 152.6 165.9 103.6 4640.9 
11 CHO 56.7 227.5 148.8 132.0 109.9 119.0 4686.6 
12 CHO 77.0 99.4 139.0 86.8 180.3 246.4 2740.5 
15 CHO 135.5 199.5 289.1 248.2 335.0 272.0 5637.0 
5 CHO-AA-1 86.8 302.1 258.0 74.6 90.3 126.0 4759.8 
6 CHO-AA-1 202.7 283.2 344.4 395.2 221.2 58.8 3586.5 
9 CHO-AA-1 52.2 68.3 49.7 62.7 64.8 85.4 597.8 
10 CHO-AA-1 80.9 197.8 381.2 341.3 393.1 268.5 10269.6
13 CHO-AA-1 104.7 273.7 224.0 388.9 202.0 107.5 6900.6 
14 CHO-AA-1 83.3 370.7 265.7 238.0 276.2 289.8 9765.4 
 185
Study 1: Experiment 2 
Skeletal Muscle Glucose Uptake (μmol/g/h) 
 
Rat # Treatment RG WG 
4 CHO 3.5 1.0 
7 CHO 6.7 1.6 
8 CHO 4.4 1.2 
11 CHO 5.8 1.1 
12 CHO 7.6 1.4 
15 CHO 3.7 0.3 
5 CHO-AA-1 11.0 2.9 
6 CHO-AA-1 9.7 2.2 
9 CHO-AA-1 5.2 1.5 
10 CHO-AA-1 4.1 1.0 
13 CHO-AA-1 12.1 1.2 
14 CHO-AA-1 7.9 2.3 
 
Study 1: Experiment 2 
Akt/PKB (% of Standard) 
 
 Total Protein Thr-308 Phosphorylation 
Rat # Treatment RG WG RG WG 
4 CHO 154.3 93.8 20.5 26.1 
7 CHO 129.4 91.7 17.8 27.4 
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8 CHO 101.7 101.5 30.9 33.6 
11 CHO 130.5 104.7 28.8 24.0 
12 CHO 138.0 196.4 23.8 76.0 
15 CHO 215.2 131.3 42.2 10.6 
5 CHO-AA-1 90.8 80.6 20.4 26.9 
6 CHO-AA-1 138.3 98.2 16.6 26.2 
9 CHO-AA-1 128.3 88.6 32.9 26.3 
10 CHO-AA-1 135.4 111.3 40.7 24.6 
13 CHO-AA-1 167.3 181.1 26.6 67.3 
14 CHO-AA-1 234.3 175.8 59.4 23.8 
 
Study 1: Experiment 2 
mTOR (% of Standard) 
 
 Total Protein Ser-2448 Phosphorylation 
Rat # Treatment RG WG RG WG 
4 CHO 74.2 65.6 54.5 41.8 
7 CHO 82.1 67.8 33.0 44.7 
8 CHO 49.5 49.6 30.8 35.5 
11 CHO 77.5 41.8 33.8 25.4 
12 CHO 72.2 41.1 34.8 28.3 
15 CHO 70.8 52.1 37.5 34.4 
5 CHO-AA-1 43.6 59.7 52.7 43.6 
6 CHO-AA-1 65.9 62.7 43.9 52.5 
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9 CHO-AA-1 65.3 40.7 51.4 30.5 
10 CHO-AA-1 55.1 31.3 55.5 28.5 
13 CHO-AA-1 84.6 37.7 52.6 28.8 
14 CHO-AA-1 78.3 48.6 65.3 36.6 
 
Study 1: Experiment 2 
GS (% of Standard) 
 
 Total Protein Ser-641 Phosphorylation 
Rat # Treatment RG WG RG WG 
4 CHO 100.8 90.4 100.6 81.2 
7 CHO 88.5 88.3 79.5 66.3 
8 CHO 105.5 77.7 58.3 76.4 
11 CHO 118.5 100.4 86.3 46.5 
12 CHO 116.7 72.3 69.0 65.4 
15 CHO 30.1 107.1 80.2 70.1 
5 CHO-AA-1 85.7 113.6 56.0 55.3 
6 CHO-AA-1 81.5 110.4 51.1 75.2 
9 CHO-AA-1 94.3 84.6 49.9 65.2 
10 CHO-AA-1 87.0 76.2 40.4 58.1 
13 CHO-AA-1 98.2 75.5 72.0 53.2 




Study 1: Experiment 2 
AS160 (% of Standard) 
 
 Total Protein Thr-642 Phosphorylation 
Rat # Treatment RG WG RG WG 
4 CHO 104.4 111.9 69.9 57.7 
7 CHO 82.7 55.1 52.5 38.3 
8 CHO 109.8 87.2 70.2 46.1 
11 CHO 76.0 77.0 45.2 36.1 
12 CHO 131.3 89.4 48.0 42.9 
15 CHO 95.0 81.1 26.8 37.8 
5 CHO-AA-1 86.7 60.8 58.9 90.8 
6 CHO-AA-1 78.8 68.5 63.1 52.6 
9 CHO-AA-1 87.1 77.1 81.0 54.7 
10 CHO-AA-1 107.4 83.1 75.4 70.1 
13 CHO-AA-1 86.4 63.5 54.5 65.6 







Appendix I: Raw Data for Study 2 
Study 2 
Skeletal Muscle Glucose Uptake (μmol/g/h) 
 
Rat # Treatment Gastrocnemius 
2 AA-sINS 5.7 
3 AA-sINS 6.6 
4 AA-sINS 5.5 
6 AA-sINS 5.0 
7 AA-sINS 5.0 
10 AA-sINS 6.7 
13 AA-sINS 6.0 
18 AA-sINS 5.2 
19 AA-sINS 5.2 
1 sINS 3.4 
1A sINS 4.9 
11 sINS 5.3 
15 sINS 4.5 
17 sINS 4.3 
30 sINS 4.0 
33 sINS 2.8 
5 AA 1.97 
8 AA 2.3 
12 AA 1.16 
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14 AA 2.27 
16 AA 1.83 
21 AA 2.66 
22 AA 1.6 
9 BAS 1.4 
17A BAS 2.6 
20 BAS 2.1 
20A BAS 2.2 
24 BAS 1.1 
32 BAS 1.0 
 
Study 2 
IRS-1 Associated PI 3-Kinase Activity (pmol/mg) 
 
Rat # Treatment PI 3-Kinase 
2 AA-sINS 2.16 
3 AA-sINS 2.17 
4 AA-sINS 2.57 
6 AA-sINS 2.03 
7 AA-sINS 2.47 
10 AA-sINS 1.93 
13 AA-sINS 2.06 
18 AA-sINS 2.30 
19 AA-sINS 2.05 
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1 sINS 2.01 
1A sINS 2.36 
11 sINS 2.19 
15 sINS 2.06 
17 sINS 2.05 
30 sINS 2.22 
33 sINS 1.85 
5 AA 0.58 
8 AA 0.48 
12 AA 0.55 
14 AA 0.74 
16 AA 0.51 
21 AA 0.79 
22 AA 0.87 
9 BAS 0.75 
17A BAS 0.57 
20 BAS 0.67 
20A BAS 0.41 
24 BAS 0.79 







Total PI 3-Kinase Activity (pmol/mg) 
 
Rat # Treatment PI 3-Kinase 
2 AA-sINS 2.99 
3 AA-sINS 3.07 
4 AA-sINS 4.11 
6 AA-sINS 2.71 
7 AA-sINS 2.51 
10 AA-sINS 3.03 
13 AA-sINS 2.92 
18 AA-sINS 2.36 
19 AA-sINS 3.07 
1 sINS 2.71 
1A sINS 4.41 
11 sINS 2.70 
15 sINS 2.73 
17 sINS 2.40 
30 sINS 2.71 
33 sINS 2.76 
5 AA 0.96 
8 AA 0.79 
12 AA 0.97 
14 AA 0.88 
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16 AA 1.04 
21 AA 0.99 
22 AA 0.78 
9 BAS 0.63 
17A BAS 1.24 
20 BAS 0.81 
20A BAS 0.87 
24 BAS 0.86 
32 BAS 0.73 
 
Study 2 
AS160 (% of Standard) 
 
Rat # Treatment Thr-642 Phosphorylation 
2 AA-sINS 105.42 
3 AA-sINS 79.92 
4 AA-sINS 102.78 
6 AA-sINS 113.54 
7 AA-sINS 121.31 
10 AA-sINS 92.10 
13 AA-sINS 96.99 
18 AA-sINS 86.52 
19 AA-sINS 80.41 
1 sINS 84.69 
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1A sINS 69.42 
11 sINS 97.64 
15 sINS 76.98 
17 sINS 99.71 
30 sINS 54.15 
33 sINS 85.10 
5 AA 42.25 
8 AA 48.67 
12 AA 42.07 
14 AA 32.61 
16 AA 47.25 
21 AA 34.68 
22 AA 50.97 
9 BAS 39.27 
17A BAS 51.37 
20 BAS 52.79 
20A BAS 29.59 
24 BAS 32.80 








Alpha-Tubulin (% of Standard) 
 
Rat # Treatment Alpha-Tubulin 
2 AA-sINS 118.18 
3 AA-sINS 101.50 
4 AA-sINS 99.21 
6 AA-sINS 89.63 
7 AA-sINS 100.42 
10 AA-sINS 100.11 
13 AA-sINS 115.16 
18 AA-sINS 89.42 
19 AA-sINS 87.73 
1 sINS 129.32 
1A sINS 76.00 
11 sINS 104.19 
15 sINS 72.80 
17 sINS 90.38 
30 sINS 113.53 
33 sINS 91.46 
5 AA 109.30 
8 AA 99.84 
12 AA 88.73 
14 AA 91.77 
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16 AA 102.88 
21 AA 92.92 
22 AA 101.84 
9 BAS 122.29 
17A BAS 110.49 
20 BAS 83.05 
20A BAS 77.62 
24 BAS 91.01 
32 BAS 91.74 
 
Study 2 
5’-Nucleotidase Activity (umol/min/mg) 
 





2 AA-sINS 28.3 4.4 6.3 
3 AA-sINS 20.2 2.4 8.3 
4 AA-sINS 16.6 2.5 6.8 
6 AA-sINS 22.9 2.6 8.8 
7 AA-sINS 28.1 4.5 6.2 
10 AA-sINS 21.9 3.6 6.1 
13 AA-sINS 18.9 3.0 6.3 
18 AA-sINS 28.6 3.5 8.2 
19 AA-sINS 30.7 5.1 6.1 
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1 sINS 19.6 2.5 7.8 
1A sINS 27.0 3.6 7.6 
11 sINS 20.1 2.4 8.5 
15 sINS 16.9 3.3 5.1 
17 sINS 25.6 3.1 8.2 
30 sINS 20.9 3.5 5.9 
33 sINS 17.8 2.6 6.9 
5 AA 15.0 2.8 5.4 
8 AA 18.1 2.2 8.3 
12 AA 27.4 3.3 8.3 
14 AA 26.6 3.7 7.3 
16 AA 27.3 3.0 9.3 
21 AA 24.1 3.2 7.4 
22 AA 29.6 5.4 5.5 
9 BAS 20.7 2.5 8.1 
17A BAS 24.3 3.3 7.4 
20 BAS 20.3 2.8 7.3 
20A BAS 19.8 3.5 5.7 
24 BAS 21.9 3.3 6.7 







Plasma Membrane GLUT4 (% of Standard) 
 
Rat # Treatment PM GLUT4 
2 AA-sINS 70.3 
3 AA-sINS 105.2 
4 AA-sINS 161.8 
6 AA-sINS 72.5 
7 AA-sINS 162.3 
10 AA-sINS 101.9 
13 AA-sINS 91.7 
18 AA-sINS 66.0 
19 AA-sINS 63.8 
1 sINS 44.8 
1A sINS 34.9 
11 sINS 64.8 
15 sINS 69.6 
17 sINS 41.8 
30 sINS 60.8 
33 sINS 42.0 
5 AA 12.2 
8 AA 12.5 
12 AA 12.7 
14 AA 15.2 
 199
16 AA 16.9 
21 AA 13.3 
22 AA 8.9 
9 BAS 11.7 
17A BAS 9.1 
20 BAS 12.2 
20A BAS 12.6 
24 BAS 13.8 
32 BAS 13.8 
 
Study 2 
Plasma Membrane Na+K+-ATPase (% of Standard) 
 
Rat # Treatment PM Na+K+-ATPase 
2 AA-sINS 107.66 
3 AA-sINS 112.32 
4 AA-sINS 101.2 
6 AA-sINS 78.71 
7 AA-sINS 84.33 
10 AA-sINS 111.9 
13 AA-sINS 107.54 
18 AA-sINS 104.2 
19 AA-sINS 87.55 
1 sINS 96.57 
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1A sINS 117.37 
11 sINS 121.02 
15 sINS 81.75 
17 sINS 97.43 
30 sINS 111.96 
33 sINS 105.84 
5 AA 107.44 
8 AA 86.22 
12 AA 93.1 
14 AA 114.87 
16 AA 110.72 
21 AA 130.09 
22 AA 82.68 
9 BAS 112.33 
17A BAS 76.65 
20 BAS 81.94 
20A BAS 93.79 
24 BAS 109.71 





Appendix J: Raw Data for Study 3 
Study 3: Experiment 1 
Blood Glucose (mmol/L) 
 
 Time 
Rat # Treatment 0 15 30 60 120 AUC 
2 OB-CHO 5.3 15.1 14.0 12.8 7.5 746.7 
4 OB-CHO 5.3 15.7 14.1 10.6 7.9 670.4 
8 OB-CHO 6.3 20.1 18.4 13.0 8.7 851.1 
13 OB-CHO 5.2 14.2 16.0 9.7 6.3 613.5 
20 OB-CHO 6.2 14.2 14.2 11.8 7.0 573.5 
22 OB-CHO 5.3 13.0 10.5 8.1 6.3 388.8 
25 OB-CHO 6.3 12.3 12.3 11.7 8.6 538.6 
32 OB-CHO 5.6 14.7 13.8 9.8 7.4 562.6 
34 OB-CHO 5.1 12.5 14.7 11.3 6.1 636.8 
5 OB-AA-1 5.7 13.3 12.8 8.2 6.9 422.3 
10 OB-AA-1 5.3 14.6 12.9 10.0 7.4 583.4 
11 OB-AA-1 5.8 16.1 14.0 6.8 6.3 396.5 
16 OB-AA-1 6.1 14.1 9.9 8.4 7.7 356.5 
18 OB-AA-1 5.2 13.6 10.4 7.9 6.6 405.8 
23 OB-AA-1 5.3 12.9 12.1 6.5 6.1 343.8 
27 OB-AA-1 6.1 12.3 9.8 6.7 6.2 204.3 
31 OB-AA-1 6.3 10.6 9.8 7.3 6.7 198.4 
37 OB-AA-1 6.0 16.0 15.6 9.9 6.9 567.7 
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3 OB-AA-2 5.3 14.8 13.8 11.4 6.9 656.5 
6 OB-AA-2 5.8 14.5 16.2 11.1 7.1 641.7 
7 OB-AA-2 6.1 15.3 13.1 8.5 7.0 428.2 
15 OB-AA-2 5.5 12.8 12.0 6.3 6.5 320.4 
19 OB-AA-2 5.9 15.7 13.6 11.5 7.4 617.8 
21 OB-AA-2 5.8 13.0 10.4 8.4 7.2 368.6 
28 OB-AA-2 4.9 12.4 9.8 4.8 5.1 223.0 
30 OB-AA-2 5.4 13.2 12.5 8.7 6.5 459.5 
36 OB-AA-2 5.8 12.4 11.1 6.8 5.9 265.0 
1 PLA 5.8 10.9 10.1 8.2 8.2 353.4 
12 PLA 5.3 8.6 9.8 9.3 8.1 415.3 
14 PLA 5.0 5.8 5.9 5.3 5.2 52.7 
17 PLA 5.7 7.4 7.3 6.5 6.3 116.4 
26 PLA 5.0 5.4 5.6 5.5 5.4 51.7 
29 PLA 6.4 6.4 6.4 6.5 6.5 11.2 
33 PLA 5.3 7.0 6.4 6.1 6.2 111.9 
35 PLA 4.8 5.5 5.6 5.6 5.5 84.0 
 
Study 3: Experiment 1 
Plasma Insulin (pmol/L) 
 
 Time 
Rat # Treatment 0 15 30 60 120 AUC 
2 OB-CHO 770.0 2738.8 1461.3 1111.3 901.3 64378.1 
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4 OB-CHO 787.5 2660.0 1111.3 603.8 848.8 28940.6 
8 OB-CHO 945.0 4313.8 2030.0 787.5 1219.8 76098.8 
13 OB-CHO 1548.8 6982.5 4418.8 1680.0 1277.5 143850.0
20 OB-CHO 805.0 3981.3 2283.8 962.5 721.9 85509.4 
22 OB-CHO 761.3 5171.3 2213.8 1071.9 743.8 112284.4
25 OB-CHO 1121.8 3551.6 3276.9 1464.8 1156.8 101423.4
32 OB-CHO 793.6 2790.4 2599.6 848.8 661.5 69103.1 
34 OB-CHO 1564.5 5950.0 2091.3 1519.2 1295.0 67510.9 
5 OB-AA-1 1291.5 5075.0 3473.8 945.0 1127.0 85325.6 
10 OB-AA-1 861.9 2240.0 2056.3 1394.8 990.5 75383.4 
11 OB-AA-1 862.8 5066.3 2366.0 765.6 816.4 91113.8 
16 OB-AA-1 826.0 6578.3 2586.5 1384.3 1509.4 171517.5
18 OB-AA-1 503.1 7611.6 825.1 1780.6 618.6 174825.0
23 OB-AA-1 710.5 3809.8 2086.0 650.1 728.0 75245.6 
27 OB-AA-1 1391.3 7787.5 5582.5 1753.5 1132.3 198778.1
31 OB-AA-1 1015.0 4151.0 2485.0 889.0 1091.1 76728.8 
37 OB-AA-1 942.4 9187.5 5188.8 1531.3 908.3 244695.9
3 OB-AA-2 829.5 2309.1 1727.3 850.5 855.8 44126.3 
6 OB-AA-2 1417.5 4033.8 4051.3 2353.8 1120.0 131709.4
7 OB-AA-2 1075.4 4375.0 2450.0 787.5 892.5 61982.8 
15 OB-AA-2 784.9 5950.0 3570.0 840.0 848.8 144539.1
19 OB-AA-2 761.3 4033.8 1960.0 892.5 778.8 82490.6 
21 OB-AA-2 1207.5 6326.3 2301.3 1426.3 997.5 104934.4
28 OB-AA-2 968.6 11987.5 7097.1 1162.9 738.5 305011.9
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30 OB-AA-2 904.8 7291.4 3447.5 1334.4 1729.0 197071.9
36 OB-AA-2 843.5 4477.4 3590.1 1020.3 914.4 126387.2
1 PLA 568.8 560.0 778.8 448.9 550.4 -1351.9 
12 PLA 420.0 192.5 542.5 315.0 341.3 -7743.8 
14 PLA 752.5 988.8 857.5 603.8 757.8 -630.0 
17 PLA 630.0 936.3 840.0 656.3 612.5 9975.0 
26 PLA 1052.6 1232.9 1229.4 924.0 742.9 -8400.0 
29 PLA 1173.0 1185.6 1272.3 1161.1 883.8 -6789.4 
33 PLA 1037.8 1341.4 1261.8 1180.4 1092.0 17640.0 
35 PLA 1581.1 1409.6 1185.6 1074.5 840.0 -56503.1 
 
Study 3: Experiment 2 
Blood Glucose (mmol/L) 
 
 Time 
Rat # Treatment 0 17 27 37 47 60 AUC 
66 OB-CHO 6.7 12.3 17.9 23.2 23.1 26.6 669.4 
70 OB-CHO 4.3 13.5 13.2 12.9 13.9 14.0 471.8 
77 OB-CHO 5.2 17.1 16.4 15.3 15.9 15.9 565.8 
78 OB-CHO 4.5 18.0 15.6 15.6 14.6 15.4 590.2 
81 OB-CHO 5.4 11.9 12.1 12.2 12.5 12.7 352.9 
89 OB-CHO 5.1 12.1 10.5 10.8 12.4 12.1 337.0 
65 OB-AA-1 5.4 15.6 14.8 13.8 13.9 13.7 469.7 
67 OB-AA-1 5.5 11.0 8.6 8.1 7.8 7.8 173.6 
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71 OB-AA-1 4.9 13.1 10.5 10.3 10.8 11.0 324.6 
79 OB-AA-1 6.4 15.4 12.8 11.1 9.8 9.0 290.2 
83 OB-AA-1 5.1 10.2 8.9 9.0 8.6 8.5 206.3 
84 OB-AA-1 4.8 14.6 11.8 10.7 10.8 10.8 370.6 
91 OB-AA-1 6.3 12.2 10.0 10.1 10.3 9.6 221.5 
68 OB-PLA 6.9 7.8 7.5 7.2 7.8 7.4 33.6 
72 OB-PLA 4.7 5.4 5.6 5.3 5.9 6.0 48.9 
73 OB-PLA 5.3 5.8 6.2 6.3 6.5 6.6 46.6 
88 OB-PLA 5.1 6.1 5.6 5.8 5.7 5.4 31.5 
90 OB-PLA 5.2 7.3 7.2 6.8 6.7 6.6 91.0 
74 LN-CHO 4.4 8.2 7.4 7.4 7.8 7.7 169.5 
75 LN-CHO 4.4 6.1 8.9 9.0 9.6 9.2 202.6 
76 LN-CHO 4.1 10.0 8.6 8.3 9.3 9.4 263.1 
85 LN-CHO 4.6 10.4 10.1 10.3 9.9 8.7 276.9 
86 LN-CHO 3.8 7.8 6.8 6.5 7.2 7.2 171.5 
87 LN-CHO 4.4 9.1 8.1 7.5 6.9 6.0 170.2 
 
Study 3: Experiment 2 
Plasma Insulin (pmol/L) 
 
 Time 
Rat# Treatment 0 17 27 37 47 60 AUC 
66 OB-CHO 2068.5 2224.3 1180.4 1166.4 1296.8 1845.4 -26125.3 
70 OB-CHO 706.1 4320.8 650.1 341.3 653.6 1587.3 49712.3 
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77 OB-CHO 387.6 4202.6 1771.0 762.1 1112.1 1376.4 83839.9 
78 OB-CHO 827.8 5259.6 2032.6 952.9 1274.0 1034.3 79604.4 
81 OB-CHO 623.9 2044.0 664.1 700.0 857.5 553.9 22567.1 
89 OB-CHO 701.8 3698.6 1233.8 1036.0 1100.8 966.0 55426.4 
65 OB-AA-1 828.6 2544.5 857.5 1094.6 1317.8 1137.5 33745.7 
67 OB-AA-1 410.4 2954.0 1618.8 1488.4 982.6 516.3 64471.8 
71 OB-AA-1 846.1 2646.0 859.3 633.5 1190.0 525.0 24170.6 
79 OB-AA-1 1728.1 4071.4 987.0 679.0 1813.0 1219.8 11403.0 
83 OB-AA-1 644.9 6835.5 2337.1 1509.4 993.1 903.9 114829.3
84 OB-AA-1 945.0 4109.0 1830.5 947.6 1259.1 1636.3 59700.8 
91 OB-AA-1 1429.8 2483.3 1117.4 922.3 1043.0 2170.0 6387.5 
68 OB-PLA 995.8 1048.3 1280.1 1552.3 962.5 1078.9 9275.4 
72 OB-PLA 609.9 1355.4 1015.0 787.5 686.9 1265.3 21037.2 
73 OB-PLA 495.3 757.8 661.5 766.5 1125.3 787.5 17063.4 
88 OB-PLA 687.8 678.1 352.6 399.9 615.1 663.3 -7354.4 
90 OB-PLA 806.8 898.6 595.0 463.8 518.0 1190.0 -5136.7 
74 LN-CHO 10.5 209.1 89.3 94.5 100.6 111.1 5999.4 
75 LN-CHO 85.8 290.5 207.4 192.5 242.4 250.3 7918.3 
76 LN-CHO 44.6 483.0 167.1 199.5 326.4 237.1 13183.2 
85 LN-CHO 43.1 459.4 310.3 298.7 224.7 272.0 14426.2 
86 LN-CHO 43.1 459.4 204.2 145.4 280.9 183.2 11902.0 




Study 3: Experiment 2 
Skeletal Muscle Glucose Uptake (umol/100 g/min) 
 
Rat # Treatment RG WG 
66 OB-CHO 2.8 0.5 
70 OB-CHO 4.3 0.3 
77 OB-CHO 4.3 0.4 
78 OB-CHO 3.2 0.3 
81 OB-CHO 4.2 0.4 
89 OB-CHO 4.2 0.5 
65 OB-AA-1 3.9 0.4 
67 OB-AA-1 6.4 0.3 
71 OB-AA-1 5.0 0.4 
79 OB-AA-1 5.1 0.7 
83 OB-AA-1 5.6 0.3 
84 OB-AA-1 5.0 0.2 
91 OB-AA-1 5.1 0.4 
68 OB-PLA 0.4 0.3 
72 OB-PLA 0.3 0.3 
73 OB-PLA 0.9 0.2 
88 OB-PLA 1.0 0.1 
90 OB-PLA 1.0 0.2 
74 LN-CHO 5.9 0.3 
75 LN-CHO 5.9 0.3 
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76 LN-CHO 4.0 0.3 
85 LN-CHO 5.5 0.8 
86 LN-CHO 4.3 0.3 
87 LN-CHO 5.6 0.4 
 
Study 3: Experiment 2 
Akt/PKB (% of Standard) 
 
 Total Protein Thr-308 Phosphorylation 
Rat # Treatment RG WG RG WG 
66 OB-CHO 160.0 130.1 19.9 35.2 
70 OB-CHO 149.0 91.3 34.4 39.2 
77 OB-CHO 162.1 136.2 18.0 26.5 
78 OB-CHO 141.9 97.2 32.7 23.3 
81 OB-CHO 161.2 104.0 20.3 68.2 
89 OB-CHO 152.7 134.4 16.6 42.5 
65 OB-AA-1 178.1 127.1 33.5 36.4 
67 OB-AA-1 140.4 76.4 11.2 26.6 
71 OB-AA-1 136.2 107.1 30.7 29.3 
79 OB-AA-1 156.9 101.7 17.7 50.7 
83 OB-AA-1 151.0 130.1 16.6 22.6 
84 OB-AA-1 171.6 131.7 24.8 21.3 
91 OB-AA-1 155.8 112.8 38.2 50.8 
68 OB-PLA 180.2 89.6 24.6 27.7 
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72 OB-PLA 170.8 111.5 27.4 43.1 
73 OB-PLA 168.6 99.1 36.1 52.3 
88 OB-PLA 164.0 90.7 23.2 26.2 
90 OB-PLA 166.9 145.4 28.4 22.9 
74 LN-CHO 165.6 73.6 50.2 21.1 
75 LN-CHO 180.2 95.3 26.5 27.9 
76 LN-CHO 149.4 119.3 18.0 22.0 
85 LN-CHO 146.4 110.4 26.2 52.3 
86 LN-CHO 180.0 132.4 20.5 58.3 
87 LN-CHO 158.4 115.1 37.2 28.9 
 
Study 3: Experiment 2 
mTOR (% of Standard) 
 
 Total Protein Ser-2448 Phosphorylation 
Rat # Treatment RG WG RG WG 
66 OB-CHO 94.9 123.3 24.5 16.7 
70 OB-CHO 105.0 93.0 42.2 37.8 
77 OB-CHO 93.6 80.7 38.4 17.6 
78 OB-CHO 81.9 85.1 41.7 33.6 
81 OB-CHO 112.6 79.1 48.3 13.0 
89 OB-CHO 93.5 114.5 29.8 20.3 
65 OB-AA-1 104.1 91.9 39.6 30.7 
67 OB-AA-1 108.8 117.3 36.0 25.9 
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71 OB-AA-1 102.9 118.4 37.0 22.7 
79 OB-AA-1 112.6 100.1 44.5 18.4 
83 OB-AA-1 93.0 70.9 42.7 38.8 
84 OB-AA-1 112.8 105.1 70.7 13.9 
91 OB-AA-1 90.2 123.7 37.0 13.5 
68 OB-PLA 109.2 101.6 49.2 23.3 
72 OB-PLA 90.5 156.7 42.6 21.6 
73 OB-PLA 106.4 66.3 37.5 16.0 
88 OB-PLA 104.9 96.9 38.9 20.9 
90 OB-PLA 82.5 81.0 33.7 31.4 
74 LN-CHO 123.7 86.4 44.4 16.8 
75 LN-CHO 103.7 112.7 27.2 23.8 
76 LN-CHO 43.1 105.2 15.2 23.5 
85 LN-CHO 98.3 101.2 41.1 17.3 
86 LN-CHO 109.6 103.6 35.6 19.7 
87 LN-CHO 115.9 75.1 63.9 51.5 
 
Study 3: Experiment 2 
GS (% of Standard) 
 
 Total Protein Ser-641 Phosphorylation 
Rat # Treatment RG WG RG WG 
66 OB-CHO 140.5 86.9 200.1 151.2 
70 OB-CHO 132.8 68.0 144.5 51.3 
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77 OB-CHO 115.5 96.0 109.5 61.9 
78 OB-CHO 145.0 95.8 170.5 109.2 
81 OB-CHO 129.5 73.7 155.6 112.4 
89 OB-CHO 115.9 109.3 139.4 145.7 
65 OB-AA-1 117.7 58.0 154.0 73.6 
67 OB-AA-1 129.2 66.0 178.5 80.2 
71 OB-AA-1 123.3 69.0 158.0 111.2 
79 OB-AA-1 158.4 59.0 116.7 87.5 
83 OB-AA-1 141.9 125.5 177.2 116.2 
84 OB-AA-1 129.4 115.1 148.6 110.7 
91 OB-AA-1 92.9 56.6 62.0 61.1 
68 OB-PLA 159.8 59.4 155.1 87.9 
72 OB-PLA 145.4 85.7 102.6 73.7 
73 OB-PLA 111.7 107.8 212.8 119.6 
88 OB-PLA 116.2 80.1 126.2 132.1 
90 OB-PLA 114.8 103.9 53.6 126.3 
74 LN-CHO 138.1 88.0 196.0 122.6 
75 LN-CHO 111.8 63.1 121.7 83.5 
76 LN-CHO 112.6 80.0 130.5 118.9 
85 LN-CHO 117.6 79.4 183.6 106.6 
86 LN-CHO 129.0 103.3 141.2 121.2 




Study 3: Experiment 2 
AS160 (% of Standard) 
 
 Total Protein Thr-642 Phosphorylation 
Rat # Treatment RG WG RG WG 
66 OB-CHO 115.0 76.1 188.5 112.2 
70 OB-CHO 105.1 120.4 63.8 114.7 
77 OB-CHO 84.2 122.2 107.8 136.6 
78 OB-CHO 96.2 52.5 117.1 129.8 
81 OB-CHO 121.0 76.6 124.5 112.8 
89 OB-CHO 95.3 129.9 133.5 138.7 
65 OB-AA-1 93.0 109.9 165.3 141.8 
67 OB-AA-1 91.7 92.7 192.6 103.9 
71 OB-AA-1 83.2 107.4 135.3 149.9 
79 OB-AA-1 108.8 99.5 219.1 117.8 
83 OB-AA-1 112.9 82.3 93.3 102.8 
84 OB-AA-1 99.9 131.0 245.4 151.9 
91 OB-AA-1 99.5 125.1 120.1 152.4 
68 OB-PLA 89.0 100.6 87.2 90.6 
72 OB-PLA 104.2 83.3 108.0 95.4 
73 OB-PLA 109.5 65.5 64.6 78.1 
88 OB-PLA 124.1 129.3 59.8 100.4 
90 OB-PLA 104.5 97.5 64.7 210.3 
74 LN-CHO 115.1 73.3 128.2 136.8 
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75 LN-CHO 114.5 105.5 132.4 114.3 
76 LN-CHO 124.9 116.9 143.9 140.4 
85 LN-CHO 105.1 80.1 208.0 108.2 
86 LN-CHO 100.9 138.7 276.0 146.8 
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